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ABSTRACT 
With intensive and global usage, flame retardants (FRs) have played critical roles 
in the prevention of fires for decades. However, there are increasing concerns 
about the potential adverse effects of these chemicals due to the well documented 
environmental and human exposures to FRs. To date, relatively little is known 
about the molecular mechanisms of the potential toxic effects of human exposure 
to FRs. Toxicogenomic approaches utilizing transcriptomics, proteomics and 
metabolomics technologies have been demonstrated to provide unbiased insights 
into perturbations of molecular signatures, gene expression patterns, biological 
pathways and the networks of interactions between chemicals and organisms. In 
this study, microarray-based transcriptomics and direct injection mass spectrometry 
based metabolomics were employed to investigate the molecular responses of 
human lung cancer cells (A549) and human hepatoma cells (HepG2/C3A) exposed 
to a range of sub-lethal concentrations of hexabromocyclododecane (HBCD), tris 
(1, 3-dichloro-2-propyl) phosphate (TDCIPP) and a mixture of FRs at equivalent 
concentrations to those found in typical household dust. These represent of 
commonly used brominated FRs and phosphorus FRs. Combined with the 
quantification of HBCD levels in cells after exposure, the results suggest that 
following 24-hour HBCD exposure, no detectable acute toxicity was detected in the 
cell lines studied here at concentrations estimated to be achievable following 
exposure in humans. TDCIPP, however, induced defensive responses in gene 
expression (e.g. xenobiotic metabolism and ABC transporters) in HepG2/C3A cells 
following exposure to a sub-cytotoxic concentration for 24 hours. Functional 
pathways (e.g. ABC transporters) were disrupted after 72 hours in HepG2/C3A 
cells exposed to 100 μM TDCIPP, which corresponded to the transcriptional and 
metabolic changes at 24 hours. These results indicate that defensive changes to 
TDCIPP exposure precede the cytotoxic effects in HepG2/C3A cells. An 
exploratory investigation of the effects of mixtures of FRs, to mimic real-life human 
exposures, revealed no adverse effect on cell viability in HepG2/C3A cells treated 
with a surrogate of dust (a solvent extract of a dust standard reference material) 
and with mixtures of FRs (at equivalent concentrations to those found in dust 
samples). However, subsequent transcriptomic and non-targeted metabolomic 
analyses suggested that potential toxicity from dust exposure lies in components 
(e.g. polycyclic aromatic hydrocarbons) other than the FRs contained within. 
Overall, this work using the non-targeted capabilities of multi-omics approaches 
has revealed that at the concentrations investigated, and which are relevant to 
human exposures, significant molecular perturbations are not induced by exposure 
to  the FRs under study. The molecular responses identified in this work are 
beneficial for both understanding the potential mechanisms of effects of human 
exposure to FRs and for future risk assessment of these chemicals.   
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CHAPTER 1   Introduction 
  
2 
Fire is one of the most serious risks to life, property and the environment. It has been 
estimated that fires kill 10 to 20 people per million of the population every year in 
developed countries (ISO/TC92, 2014). In Europe alone, fire fatalities reach several 
thousand each year. In 2013-14, there were 322 fire-related deaths in Great Britain, of 
which 80% were dwelling fires (UK Department for Communities and Local 
Government, 2015).The direct and indirect costs of fire are estimated at around 1% of 
global GDP per year (The Geneva Association, 2014). To protect people‘s lives and 
properties from fires, fire safety standards and regulations have been introduced in 
many countries. In the UK, the Furniture and Furnishings (Fire Safety) Regulations 
1988 (amended 1989, 1993 and 2010) are designed to ensure that upholstery 
materials used for furniture supplied in the UK meet specified fire resistant ignitability 
standards 
(http://www.firesafe.org.uk/furniture-and-furnishings-fire-safety-regulations-19881989
-and-1993/). Similar standards (e.g. Furniture - Assessment of the ignitability of 
upholstered furniture) were also introduced by the European Committee for 
Standardization (http://www.bsef.com/fire-standards-and-regulations/). To comply 
with these standards and regulations, application of flame retardants (FRs) is an 
important means to reduce flammability and increase the fire resistance of a variety of 
materials and products. 
1.1 Flame retardants  
Flame retardants (FRs) are chemicals added into various consumer products 
including electronics, textiles, furniture and building materials to reduce their 
flammability and inhibit the spread of combustion after ignition. Four main classes of 
flame retardants are produced and used, comprising together more than 175 
3 
chemicals (Alaee et al., 2003;van Esch, 1997). These include: halogenated organic, 
organophosphorus, inorganic and nitrogen based flame retardants. They can be 
so-called additive compounds, meaning physically mixed within a base material, or 
reactive compounds, meaning covalently bonded to a material.  
Among these chemicals, halogenated organic flame retardants include chlorinated 
FRs (e.g. chlorinated paraffins) and brominated FRs (e.g. hexabromocyclododecane 
(HBCD), tetrabromobisphenol A (TBBPA) and polybrominated diphenyl ethers 
(PBDEs)). The class of organophosphorus FRs can be divided into three main 
subclasses: phosphate ester (e.g. triphenyl phosphate (TPP) and tricresyl phosphate 
(TCP)); phosphonates (e.g. dimethyl phosphonate (DMHP)); and phosphinates (e.g. 
aluminum diethyl phosphinate) (van der Veen and de Boer, 2012). Some flame 
retardants contain both phosphorus and halogen, such as 
tris(1,3-dichloro-2-propyl)phosphate (TDCIPP), tris(2- chloroethyl)phosphate (TCEP), 
Tris(2-chloroisopropyl) phosphate (TCIPP) and tetrekis(2-chlorethyl) 
dichloroisopentyldiphosphate (V6) and can also be recognized as OPFRs (van der 
Veen and de Boer, 2012). Aluminium hydroxide (ATH) and magnesium hydroxide 
(MDH) are the two most notable members of the class of inorganic FRs. In addition, 
melamine and its derivatives belong to the group of nitrogen based flame retardants 
(PINFA, 2015). 
Flame retardants can slow down or suppress the combustion process through 
chemical and/or physical actions in the gas or condensed phases, during a certain 
stage of this combustion process (i.e. during heating, decomposition, ignition or flame 
spread) (BSEF, 2012). The most effective chemical action of flame retardants to 
interfere with the combustion processes is to eliminate highly reactive radicals (i.e. 
4 
H· and OH· radicals) by hydrogen chloride or hydrogen bromide. Hydrogen chloride 
or hydrogen bromide are generated from halogenated flame retardants or metal 
halogen compounds from antimony trioxide in the gas phase. Flame retardants exert 
physical effects by cooling (endothermic degradation of FRs) or diluting combustible 
gases (i.e. formation of carbon dioxide and water), or by generating a char layer 
(shielding the material against oxygen and heat) with phosphorous and nitrogen 
compounds (www.flameretardants-online.com, 2015).  
It was estimated that the consumption of flame retardants in Europe was 465,000 
tonnes in 2006, of which brominated flame retardants have the highest market share 
by value (EFRA, 2007). 
1.1.1 Brominated flame retardants  
There are currently more than 75 different commercial BFRs available on the market 
(EFRA, 2007). Depending on the nature of the material, BFRs can be additive (such 
as PBDEs and HBCD) or reactive (such as TBBPA) (Alaee et al., 2003). BFRs are 
mainly applied to electronics and electrical devices (i.e. televisions and computer 
monitors) accounting for more than 50% of their usage, while other applications 
include insulation materials, carpets, furniture, and thermoplastics (e.g. high impact 
polystyrene (HIPS) and acrylonitrile-butadiene-styrene (ABS) resins) (EFRA, 2007; 
Rauert et al., 2014). Physicochemical properties and chemical structures of the most 
important BFRs are summarized in Table 1.1. These properties determine their 
environmental fate, persistence and bioaccumulation.  
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Table 1.1 Physicochemical properties of important brominated flame retardants 
( reviewed in Rauert, 2014).
 
Since some BFRs (i.e. PBDE and HBCD) have been shown to be persistent, 
bioaccumulative, (potentially) toxic to the environment and are capable of long-range 
atmospheric transport (Marvin et al., 2011), their production and usage has been 
restricted. For example, pentaBDE, the first commercialized BFR, was banned in the 
EU from 2004 and phased out in the USA from 2005 owing to concerns regarding its 
persistence and adverse effects (Dodson et al., 2012). HBCD, another widely used 
BFR, has been listed under the UNEP Stockholm Convention on persistent organic 
pollutants (POPs) in 2013, but with specific time-limited exemptions for production 
and use in extruded polystyrene (XPS) and expanded polystyrene (EPS) in buildings 
Compound penta-
bromodiphenyl
ether
Octa-
bromodiphenyl
ether
Deca-
bromodiphenyl
ether
Hexabromocyclododecane Tetrabrominated bisphenol‐A
Abbreviation
PentaBDE OctaBDE DecaBDE HBCD TBBPA
CAS number
32534-81-9 32536-52-0 1163-19-5 25637‐99‐4 79‐94‐7
Chemical 
structure
Molecular 
Formula C12H10‐xBrxO C12H10‐xBrxO C12Br10O C12H18Br6 C15H12Br4O2
Molecular Weight 
(g· mol
-1
) 
example: 564.7 
(BDE-99)
example: 801.4 
(BDE-203)
959.2 641.7 543.9
Melting point
-7 to -3°C 85 to 89 °C 290 to 306 °C 180-185 °C 178 °C
Water solubility 
(μg· L-1 at 25 °C) not soluble not soluble 20-30 8.6 insoluble
Octanol-water 
coefficient (Log 
KOW) 
6.57 to 6.97 6.29 ~10 5.63 to 5.81 4.5
Vapour pressure 
(Pa at 25°C) 
2.92 x 10
-5
 to
7.32 x 10
-5
1.20 x 10
-8
 to
2.26 x 10
-7
4.26 x 10 
-6
 to
4.62 x 10
-6 7.47 × 10
−10
8.47 × 10−9
Main
isomers/congene
rs in commercial 
product(s)
BDE‐47, BDE‐99, 
BDE‐100, 
BDE‐153
BDE‐183, BDE‐196, 
BDE‐197, BDE‐203
BDE‐209 α‐HBCD, β‐HBCD, γ‐HBCD n.a.
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(UN, 2013). The main applications of HBCD are addition to XPS and EPS foams used 
for thermal insulation in the building industry. Other uses of HBCD include upholstery 
textiles, furniture and electrical and electronic products (Covaci et al., 2006; Marvin et 
al., 2011). One of the primary applications of TBBPA is in the resin of printed circuit 
boards where it is used as reactive BFR which is less readily leached out from the 
products. As such TBBPA was regarded as no risk to human health in an EU risk 
assessment in 2005 (EU, 2006).  
1.1.2 Organophosphorus flame retardants  
In recent years, organophosphorus flame retardants (OPFRs) have become 
increasingly popular in the market and are often proposed as suitable alternatives to 
BFRs (Veen and Boer, 2012). OPFRs comprised 20% (91,000 tonnes) of the total 
consumption of flame retardants in 2006 in the EU (EFRA, 2007). The basic chemical 
structure of organophosphate (one subclass of OPFRs) is depicted in Figure 1.1 and 
the physicochemical properties of three chlorinated phosphorus flame retardants 
(which were investigated in this thesis) are summarized in Table 1.2. 
 
Figure 1.1 Basic chemical structure of organophosphate. Organophosphates are 
are derivatives of phosphoric acid. The various side chains (R1, R2 and R3) can be for 
example alkyl, aryl or haloalkyl either alone or in combination. 
OPFRs have a broad range of applications including addition to polyvinyl chloride 
(PVC) and polyurethane foam, resulting in satisfactory fire safety performance. For 
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example, TDCIPP is a high volume production OPFR which is added to flexible 
polyurethane foam in the automotive upholstery, foams for household furniture and 
other commercial products, i.e. beddings (van der Veen and de Boer, 2012). In terms 
of production volumes of OPFRs, TPHP, TDCIPP and TCIPP are the three most used 
PFRs (Brommer, 2014). 
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Table 1.2 Physicochemical properties of chlorinated phosphorus flame 
retardants ( reviewed in Brommer, 2014).
 
 
1.2 Human exposure to BFRs and OPFRs  
Due to the widespread use of FRs in various consumer products all over the world, 
especially the extensive applications of additive FRs which are easily released from 
Compound
Tris(2-chloroethyl)
phosphate
Tris(2-
chloroisopropyl)
phosphate
Tris(1,3-
dichloroisopropyl)
phosphate
Abbreviation
TCEP TCIPP TDCIPP
CAS number
115-96-8 13674-84-5 13674-87-8
Chemical 
structure
Molecular 
Formula C6H12Cl3O4P C9H18Cl3O4P C9H15Cl6O4P
Molecular Weight 
(g· mol-1) 285.49 327.57 430.91
Melting point
-35 °C -40 °C 27  °C
Boiling point
330 °C 
 >270 °C 236-237 °C at 5 mm Hg
Water solubility 
(mg· L
-1
 ) 7000 1200 7
Octanol-water 
coefficient (Log 
KOW) 
1.44 2.59 3.65
Vapour pressure 
(mm Hg at 25°C) 
6.13 x 10-2 2.02 x 10-5 7.36 x 10-8 
9 
products into the environment, FRs have been reported to occur ubiquitously in the 
environment, in wildlife and in humans (Alaee et al., 2003; Law et al., 2014; van der 
Veen and de Boer, 2012). The major routes of non-occupational human exposure to 
FRs (Figure 1.2) have been summarized as via ingestion of indoor dust, diet, 
inhalation of air, and dermal contact with dust/products containing FRs (Abdallah et 
al., 2015a). 
 
Figure 1.2 Major routes of human exposure to FRs ( Adapted from Abdallah et al., 
2015a). 
1.2.1 Human exposure to PBDEs 
Although dietary intake has been considered as one of the most significant exposure 
pathway for PBDEs in adults (Domingo, 2012), indoor dust ingestion and diet seem to 
be the predominant exposure routes both at work and at home in the UK and USA, 
with high consumption of PBDEs (Besis and Samara, 2012; Harrad et al., 2008, 2006, 
2004). Many studies have found that concentrations of PBDEs in air and dust were 
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higher in indoor environment than in outdoors (Besis and Samara, 2012). PBDE 
concentrations in house dust have also been reported to be significantly correlated 
with levels in adults‘ serum (Johnson et al., 2010) and in umbilical cord plasma 
(Frederiksen et al., 2010). Moreover, positively significant associations have been 
found between PBDE concentrations in first-time mothers‘ breast milk and domestic 
dust (r = 0.76, p = 0.003), as well as with the dietary consumption of dairy products 
and meat, which indicates that both house dust and diet are important sources for 
human exposure to PBDEs (Wu et al., 2007). It was reported that toddlers had a 
higher PBDE intake (49 ng/kg bw/day) than adults (7.7 ng/kg bw/day) because of a 
higher dust ingestion rate and lower body weight in toddlers (Lorber, 2008). 
1.2.2 Human exposure to HBCD 
Like PBDEs, human exposure to HBCDs can occur via multiple sources including diet, 
dust, air, and consumer products (Marvin et al., 2011). Although diet is a main 
exposure route in Europe and USA (Covaci et al., 2006; Schecter et al., 2012), indoor 
dust and air can be important contributors for exposure in both toddlers and adults 
(Abdallah et al., 2008a, 2008b; Marvin et al., 2011). Exposure to HBCDs via dust 
ingestion was estimated to contribute 24% of total exposure in adults and 63% in 
children in a comparison study of exposure to HBCD though indoor dust, diet and 
inhalation (Abdallah et al., 2008a). Human exposure to HBCD has been confirmed by 
its presence in breast milk, adipose tissue and blood (Marvin et al., 2011; Rawn et al., 
2014a). The levels of HBCD detected in human milk samples in Spain were up to 188 
ng/g lipid weight, with a median value of 27 ng/g (Eljarrat et al., 2009). The intake of 
HBCDs in breast-fed infants (0-6 months) was estimated up to 90 ng/kg bw/day 
based on a Canadian exposure estimate model which included uptake of HBCDs 
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from breast milk, dust and other environmental media (Environment Canada, 2011). A 
recent study (Rawn et al., 2014a) reported concentrations of HBCD in fetal liver 
(median 29 ng/g lipid) and placental tissues (median 49 ng/g lipid) collected between 
1998 and 2010 in Canada. Weiss et al. ( 2004) detected HBCD in both maternal and 
cord blood (average values of 1.1 ng/g and 1.7 ng/g lipid weight, respectively) in the 
Netherlands. That have also been report of concentration of HBCD in human serum 
was up to 856 ng/g lipid (Thomsen et al., 2007). 
1.2.3 Human exposure to OPFRs 
Although several studies reported levels of different types of OPFRs in the 
environment including indoor dust, air, surface water, drinking water, sediments and 
biota ( reviewed in van der Veen and de Boer, 2012), there is still a paucity of 
knowledge about human exposure to OPFRs (Abdallah and Covaci, 2014). For 
example, Carignan et al. ( 2013) found that the TDCIPP level in office dust samples 
from Boston, USA was up to 72 μg/g. The average concentration of TDCIPP in car 
dust in Germany was 130 μg/g (Brommer et al., 2012). These studies reported a high 
prevalence of TDCIPP in dust samples suggesting that dust could contribute as a 
source of human exposure to TDCIPP within indoor or enclosed environments 
(Abdallah and Covaci, 2014; Stapleton and Klosterhaus, 2009), especially for 
toddlers who may have more dust exposure due to frequent hand-mouth behaviour 
(Butt et al., 2014). Moreover, significant correlations have been found between the 
concentrations of diphenyl phosphate (DPHP) (1.1 ng/mL) and 
bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) (0.23 ng/mL) in childrens‘ urine and 
their precursor compounds (TPHP and TDCIPP, respectively) in indoor dust and air; 
while no significant associations between OPFRs metabolite concentrations in urine 
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and diet data were observed (Hoffman et al., 2015). Cumulative results suggest that 
indoor dust and air are important sources of TDCIPP (Cequier et al., 2015).Total 
intakes of TPHP and TDCIPP in children from indoor dust and air were 6.26 and 4.52 
ng/kg bw/day, respectively (Cequier et al., 2015, 2014). A few studies have also 
reported the levels of TDCIPP or its metabolites in humans. For example, the 
concentration of TDCIPP was reported up to 252 ng/g lipid in human adipose tissue 
samples (LeBel and Williams, 1986) and up to 162ng/g lipids in human breast milk 
(Kim et al., 2014). In addition, the concentration of BDCIPP (which is the primary 
metabolite of TDCIPP) in human urine was up to 25 ng/mL (Meeker et al., 2013) 
1.3 Toxicity of HBCD and OPFRs  
Human exposure to FRs is bound to occur due to their widespread usage and their 
physicochemical properties. While FRs reduce risk to human health by effective fire 
retardation, they might also increase risk to human health unless they exert low levels 
of toxicity.  
1.3.1 Toxicity of HBCD 
To respond to the environmental and human health concerns regarding exposure to 
HBCD, toxicity studies have investigated and reported potentially adverse effects of 
HBCD in animal models and human cell lines, including acute toxicity, endocrine and 
reproductive toxicity, neurotoxicity, and hepatotoxicity (reviewed in Marvin et al., 2011; 
Wikoff and Birnbaum, 2011). 
Generally, the acute toxicity of HBCD is very low, following oral, inhalation, or dermal 
exposures in rodents (reviewed in Wikoff and Birnbaum, 2011). For example, there 
was no increase in mortality could be observed after oral exposure, and the LD50 of 
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HBCD was estimated as to >6400 mg/kg bw in mice and >10000 mg/kg bw in 
rats(KEMI, 2002). 
Endocrine disruption (especially disruption of thyroid function) has been found as a 
consistent response to exposure to HBCD (Marvin et al., 2011) according to a number 
of in vivo and in vitro studies, including using rats (van der Ven et al., 2009, 2006), fish 
(Palace et al., 2010, 2008) and chicken (Crump et al., 2008). Significant increase of 
thyroid weight and decrease of circulating serum thyroxine (T4) levels were observed 
in female rats in 28-day repeated dietary exposure, with effect-specific no observed 
adverse effect levels (NOAELs) of 1.6 and 55.5 mg/kg bw/day, respectively (van der 
Ven et al., 2006).In vitro studies suggested that HBCD can bind to thyroid receptors 
(Schriks et al., 2007; Yamada-Okabe et al., 2005) affecting triidotyronine (T3) 
mediated cellular events (Schriks, et al., 2007;  Schriks, et al., 2006). Even at 
low-dose (10−4 μM), HBCD can suppress thyroid hormone receptor (TR) -mediated 
gene expression in cerebellar Purkinje cells (Kingsley Ibhazehiebo et al., 2011).  
In reproductive toxicity studies with rats, adverse effects were observed. These 
included decrease of testis weight, the induction of aromatase enzyme activity in 
ovaries and a decrease in the number of primordial follicles in ovaries, with a NOAEL 
of 10 mg/kg-day (Ema et al. 2008; van der Ven et al. 2009). HBCD has also been 
shown to be antagonistic to the progesterone receptor, androgen receptor, estrogen 
receptor and aryl hydrocarbon receptor in the chemically activated luciferase gene 
expression (CALUX) assay (Hamers et al., 2006).  
Significant changes in spontaneous behaviour, learning and memory were found after 
neonatal exposure of mice to HBCD (Eriksson et al., 2006), implying some degree of 
neurotoxicity. HBCD has also been shown to inhibit the uptake of dopamine in rat 
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brain synaptosomes in vitro (Mariussen and Fonnum, 2003) and to suppress the 
release of neurotransmitter(catecholamine) (Dingemans et al., 2009).Low micromolar 
concentrations of HBCD have been shown to give rise to neurotoxic effects in in vitro 
cultured neuronal cells (e.g. PC12 cells (Dingemans et al., 2009) and SH-SY5Y cells 
(Al-Mousa and Michelangeli, 2012)) by interfering with calcium (Ca2+) homeostasis 
and intracellular signalling pathways. One study focused on behaviour in humans; 
neurobehavioral function and serum levels of HBCD in a group of adolescents in 
Belgium were assessed. HBCD did not show consistent associations with 
performance in the neurobehavioral tests (Kiciński et al., 2012), which did not show 
agreement with previous results in model animals.  
Hepatotoxicity of HBCD has been reported in a wide range of studies, which showed 
that liver is one of the main target organs (Hakk et al., 2012; Marvin et al., 2011). Long 
term exposure to HBCD at a relatively high dose (30 mg/kg/day, 28 days) increased 
liver weight in female rats (van der Ven et al., 2006) and induced hepatic cytochrome 
P450 (CYP) enzyme activities (CYP2B1 and CYP3A1) in rats (Cantón et al., 2008; 
Germer et al., 2006). Other hepatic transcription (i.e. fatty acid desaturase 1, 
hydroxymethylglutaryl-CoA synthase, glutathione-S-transferase) in rats liver were 
also altered after exposure, which are relevant to lipid metabolism, cholesterol 
biosynthesis, and glutathione metabolism and conjugation pathways (Cantón et al., 
2008). Yanagisawa et al. ( 2014) also reported that HBCD can increase gene 
expression of peroxisome proliferator-activated receptor-γ in liver and decrease 
transcripts of glucose transporter 4 in adipose tissue in high fat diet-fed mice, which 
indicate that HBCD can contribute to disruption of lipid and glucose homeostasis. In 
juvenile rainbow trout (Oncorhynchus mykiss) (Ronisz et al., 2004) and Chinese rare 
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minnow (Gobiocypris rarus) (Zhang et al., 2008), HBCD inhibited CYPs enzyme 
activities in the liver after a 28-day exposure.  
In several in vitro studies, induction of cell apoptosis followed exposure to high 
concentrations of HBCD. This was seen in HepG2 cells (hepatocellular carcinoma 
cells) (An et al., 2014; Hu et al., 2009) and human L02 hepatocytes (An et al., 2013). 
Induction of apoptosis was suggested to result from increased production of reactive 
oxygen species (ROS). A slight increase in ROS was also observed after low 
concentration (10−7-10−1 μM) exposures in human L02 hepatocytes, while no acute 
toxic effect was reported (An et al., 2013; Zou et al., 2013).  
Collectively, there is limited information about molecular changes resulting from 
concentrations that are realistic for likely human exposures to HBCD. Therefore, 
further studies are needed in order to obtain a more comprehensive understanding of 
potential effects of HBCD exposure. 
1.3.2 Toxicity of TDCIPP 
Although less information is available on toxicity of OPFRs compared with BFRs, 
TDCIPP appears to be endocrine disruptive and neurotoxic in in vitro and in vivo 
studies. Meeker and Stapleton ( 2010) reported that altered thyroxine (T4) levels and 
decreased semen quality in men might be linked to exposure to TDCIPP. Other 
studies found that exposure to TDCIPP can change thyroid hormone concentrations 
in chicken (Gallus gallus) embryos (Farhat et al., 2013) and zebrafish (Danio rerio) 
(Wang et al., 2013) and alter sex hormone levels in human H295R cell lines and 
zebrafish (Liu et al., 2012). Dysregulation of gene expression related to thyroid 
hormone metabolism was found in zebrafish (Wang et al., 2013) and avian 
16 
hepatocytes (Crump et al., 2012). TDCIPP displays androgen receptor (AR), 
glucocorticoid receptor (GR) and pregnane X receptor (PXR) antagonistic activities in 
cell-based transactivation assays (Kojima et al., 2013).  
Concentration-dependent neurotoxicity of TDCIPP was observed in rat PC12 cells. 
For example, oxidative stress increased following 50 μM TDCIPP treatment (Dishaw 
et al., 2011), while dysregulation of gene and protein expression related to apoptosis, 
neurite growth and synapse formation, potentially disrupting neurodevelopment, were 
observed after exposure to TDCIPP (15 μM) (Ta et al., 2014). Moreover, exposure to 
TDCIPP (3 μM) can cause developmental toxicity in zebrafish larvae through altering 
gene expression relevant to regulating embryogenesis (Fu et al., 2013). 
Limited studies of the hepatic toxicity of TDCIPP were focussed on chicken 
embryonic hepatocytes or liver; in which phase I and II xenobiotic-metabolizing 
enzymes were elevated after TDCIPP exposure (Crump et al., 2012; Farhat et al., 
2014a).  
TDCIPP has also been listed as a carcinogen in the Proposition 65 list by the 
California Environmental Protection Agency (OEHHA, 2013). In contrast, it was 
classified as a safe compound for its intended application in a risk assessment report 
(European Union, 2008). The evidence for TDCIPP‘s carcinogenicity via a genotoxic 
mechanism(s) has been building (OEHHA, 2011). For example, positive evidence for 
genotoxicity was found in in vitro tests including mutagenicity in multiple strains of 
Salmonella (Gold et al., 1978), chromosomal aberrations and sister chromatid 
exchanges in mouse (Mus musculus) lymphoma cells (Brusick et al., 1979) and 
unscheduled DNA synthesis in rat (Rattus norvegicus) hepatocytes (Sederlund et al., 
1985), though negative results were also found in most in vivo genotoxicity studies 
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(OEHHA, 2011). As such, it has been suggested that the current available knowledge 
is yet sufficient to confirm that TDCIPP exposure can induce cancer in humans 
(ATSDR, 2012). However, in rats, exposure to TDCIPP can increase the rate of 
formation of tumours at multiple sites (i.e. liver, kidney and testes) (Freudenthal and 
Henrich, 2000).  
1.3.3 Toxicity of TCIPP and TCEP 
Compared to TDCIPP, there are fewer studies focusing on the toxicity of TCIPP and 
TCEP. In an risk assessment by EU, it was suggested that there was no adverse 
effects on male reproductive system in rats from a few available toxicity studies of 
TCIPP (European Chemicals Bureau, 2008a). However, TCEP exposure caused 
significant decrease of testicles weight in mice and adverse effects of sperm quality 
were reported in mice and rats (European Chemicals Bureau, 2008b). TCEP has also 
been listed as a carcinogen in the Proposition 65 list by the California Environmental 
Protection Agency (OEHHA, 2013). However, an ATSDR (The Agency for Toxic 
Substances and Disease Registry) report concluded that, like TDCIPP, limited 
information from available studies cannot confirm that TCEP exposure induce 
tumours in humans (ATSDR, 2012).  
From in vitro studies, there are mixed or inconsistent effects reported on endocrine 
disruption .While no mutagenic potential or estrogenic effects of TCIPP and TCEP 
were detected in Salmonella (Föllmann and Wober, 2006); Liu et al. reported ( 2012) 
that both TCIPP and TCEP can increase the concentrations of 17β-estradiol (E2) and 
testosterone (T) in H295R cells. In another study, TCEP showed notable 
antiestrogenic properties with lowest observed effect level (LOEL) at 1.0 × 10−5 M in a 
dual-luciferase reporter gene assay in Chinese hamster ovary cell line (CHO-K1 cells) 
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(Zhang et al., 2014). In addition, TCIPP displayed pregnane X receptor (PXR) 
agonistic activity, but no endocrine effect s of TCEP were observed in reporter gene 
assays of human nuclear receptors (Kojima et al., 2013). 
In short, although the toxic effects of some FRs have been reported, there remains a 
need to more fully understand the potential toxicities of FRs and their potentially toxic 
modes of action, especially considering the conflicting FR toxicity data reported in 
previous studies. Therefore, comprehensive investigations of the toxicity of FR's are 
necessary to determine any adverse effects and explain their underlying mechanisms, 
which eventually will be beneficial to understand the mode of actions of FRs and aid 
risk assessment of human exposures. 
1.4 In vitro models - A549 and HepG2/C3A cells 
The ‗3R‘ concept (replacement, reduction and refinement) has been widely accepted, 
due to the ethical, political and commercial pressure on the usage of animal models in 
toxicology studies(Kroeger, 2006). Compared to using animal models in vivo, in vitro 
analyses are a less costly and less time-consuming alternative option. These assays 
can be conducted in an identical genetic background using simple conditions and can 
overcome the drawbacks caused by the complexity of in vivo studies (Eisenbrand et 
al., 2002; Lilienblum et al., 2008). 
Since human exposure to FRs can occur via inhalation, the lung represents one of 
the main target organs. Therefore, in the current investigation we selected an 
adenocarcinomic human alveolar basal epithelial cell line (A549 cells) as an in vitro 
model to test the potential molecular effects of FRs on the lung. A549 cells have been 
widely used as an in vitro model for a type II pulmonary epithelial cell drug 
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metabolism and as a transfection host (Ahamed et al., 2011; Billet et al., 2008; 
Courcot et al., 2012; Komori et al., 2008; Seo et al., 2007). As it is derived from 
pulmonary tissues, the A549 cell line has functional xenobiotic metabolism and 
allowing extrapolation of results to the lung in vivo (Hukkanen et al., 2000; Vulimiri et 
al., 2009). 
The other in vitro model used in this study is a human hepatocellular carcinoma cell 
line (HepG2/C3A cells). This is a convenient alternative to primary human 
hepatocytes and has been shown to exhibit a degree of xenobiotic metabolic capacity 
(Gerets et al., 2012). HepG2 cells are regarded as a ―gold standard‖ in toxicology 
(Kang et al., 2010). The use of human liver cell lines for monitoring toxicological 
relevant stress related endpoints is a logical choice since the liver is the primary 
detoxification organ (Nobels et al., 2012).Moreover, the xenobiotic metabolizing 
capacities of HepG2 cell lines are comparable to that of primary cultures of human 
hepatocytes (Sevastyanova et al., 2007). The HepG2/C3A cell line is clonal derivative 
of HepG2 cell line which is a suitable in vitro model system for the study of polarized 
human hepatocytes.  
Both A549 cells and HepG2/C3A cells have been successfully employed in many 
toxicological studies to investigate transcriptional and/or metabolomic responses to 
various compounds (Bandele et al., 2012; Castorena-Torres et al., 2008; Gualtieri et 
al., 2012; Li et al., 2007; Mitsopoulos and Suntres, 2010; Nobels et al., 2012; 
Ruiz-Aracama et al., 2011; Shintu et al., 2012). However, very few applications of 
these cell lines were focusing on FRs toxicity. Hence, in the present study, they were 
employed as in vitro models to investigate the potential toxic effects of FRs. 
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1.5 Toxicogenomics - use of omics techniques in toxicology  
Toxicogenomics is a term to describe the investigation of the molecular responses to 
toxicants by analyzing genes, genetic polymorphisms, mRNA transcript expression, 
protein levels, or metabolite levels in cells, tissues or organisms (Foster et al., 2013). 
Combining toxicology with omics technologies (i.e. genomics, transcriptomics, 
proteomics, and metabolomics), toxicogenomics can provide unbiased insights into 
perturbations of molecular signatures, gene expression patterns, biological pathways 
and the networks of interactions between chemicals and organisms. Although 
conventional methods in toxicology can identify chemicals of potential concern, often 
they are unable to provide comprehensive mechanistic information on the underlying 
molecular responses that occur as a result of toxicant exposure (Chen et al., 2012; 
National Research Council (US), 2007) 
Using advanced technologies, toxicogenomics does not only focus on global gene 
expression patterns after exposure to toxicants through microarray or RNA-seq 
based transcriptomics, but also can look at the overall changes occurring at the 
protein level (proteomics) and the physiological output (metabolites) of biochemical 
processes in a living systems (metabolomics)(Hamadeh et al., 2002). This can 
provide great opportunities to generate hypotheses regarding the mechanisms of 
action of toxicants in a high-throughput fashion.  
There are, as yet, relatively few ‗omics studies of the potential toxicity of FRs. For 
example, hypothyroidism reported in rats following a 28-day high dose exposure (30 
and 100 mg HBCD/kg/day) of HBCD (Germer et al., 2006) was found to correlate well 
with gene expression changes in the cholesterol biosynthesis pathway in rats‘ liver, as 
revealed by transcriptomic analysis (Cantón et al., 2008). A proteomic study of 
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zebrafish (Danio rerio) liver cells found that protein metabolism decreased after 
72-hour exposure to 5 µM HBCD (Kling and Förlin, 2009). Few metabolomics studies 
of the effects of FRs have been reported using in vitro or in vivo systems. 
Metabolomics has already been applied to a wide range of toxicological studies, 
including in mechanistic toxicology (Nicholson et al., 2002) and ecotoxicology (Bundy 
et al., 2009). For example, DIMS based metabolomics has been applied successfully 
to investigate toxic effects of environmental chemicals to fish (Southam et al., 2011) 
and water flea (Daphnia magna) (Taylor et al., 2008).  
In the present study, transcriptomics and metabolomics were employed to investigate 
the molecular responses of human cell lines exposed to FRs so as to explore the 
potential mechanisms of the effects of FRs exposure in an overall view. The current 
primary technologies used in these two omics are summarized below. 
1.5.1 Transcriptomics  
Transcriptomics describes the global measurement of all species of transcripts, 
including mRNAs, non-coding RNAs and small RNAs in a biological system (Wang et 
al., 2009), which is essential to understand the molecular mechanisms of cellular 
responses to various treatments/conditions in cells or tissues at transcriptional level 
(Heijne et al., 2005). Transcriptomics has been widely employed in toxicogenomics 
studies and the application in accumulating research have suggested that 
transcriptional profiling of the exposure systems (in vivo and in vitro) is valuable for 
characterizing the mechanism of actions of toxicants and predicting toxicity of 
chemical compounds (Bandele, et al., 2012;  Castorena-Torres, et al., 2008;  
Gualtieri, et al., 2012;  Katsiadaki et al., 2010;  Li, et al., 2007;  Mitsopoulos and 
Suntres, 2010;  Santos et al., 2010;  Van Aggelen et al., 2010;  Williams et al., 
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2009). Currently, DNA microarray and RNA sequencing (RNA-seq) are two commonly 
used technologies in the market for analyzing the global transcriptional patterns. The 
typical analysis workflows of these two platforms are shown in Figure 1.3 (Fang et al., 
2012). 
 
Figure 1.3 The overview of analysis workflows of microarray and RNA-seq data 
(Adapted from Fang et al., 2012). 
1.5.1.1 DNA microarray  
A DNA microarray consist of a collection of oligonucleotide sequences immobilized in 
precise locations on a glass or a silicon chip in a high-density format which allows for 
the quantification of mRNAs from a biological sample under different conditions 
(Gabig and Wȩgrzyn, 2001). As mRNAs are the direct transcripts of genes, the 
changes of particular mRNAs indicate the specific gene pathways affected by toxicant 
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exposure (Schirmer et al., 2010). The basis of DNA microarray technology is nucleic 
acid hybridization with immobilized probes. Two primary microarray platforms are 
commonly used, cDNA microarrays, which utilize cloned probe molecules 
corresponding to characterized expressed sequences, and oligonucleotide 
microarrays, made of synthesized probes based on a priori knowledge on genome or 
transcriptome information (Gabig and Wȩgrzyn, 2001; Murphy, 2002). 
A typical microarray experiment involves multiple steps which are shown in Figure 1.4. 
The first step is sample preparation starting by total RNA isolation from biological 
samples. The extracted mRNAs are converted into complementary DNA (cDNA) in a 
reverse-transcriptase enzyme reaction. The procedure of complementary RNA 
(cRNA) synthesis and amplification is also used for oligonucleotide microarray 
experiments. Next, the cDNA or cRNA samples are labeled, often with fluorescent 
cyanine dyes (i.e. Cy3 and Cy5). Labelled cDNA or cRNA samples are hybridized with 
the immobilised target probes. After washing steps, the slides/chips are scanned and 
image acquisition is followed by feature extraction, employing specialist software. The 
last step is data processing and analysis including pre-processing, background 
correction and normalization and statistical analysis. 
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Figure1.4 Workflow of a cDNA microarray experiment (Adapted from 
http://en.wikipedia.org/wiki/DNA_microarray_experiment) 
1.5.1.2 RNA-seq 
RNA-Seq is a recently developed approach for transcriptome profiling utilizing 
deep-sequencing technologies (Wang et al., 2009), which could provide the most 
extensive evaluation, with a wide dynamic range and higher sensitivity. The typical 
RNA-seq experiment involves four main steps (Figure 1.5). First, total RNA is isolated 
from samples of interest. Then, a library of cDNA fragments is created after RNA 
fragmentation or DNA fragmentation, in which each cDNA is attached with adaptors at 
one or both ends. The third step is high-throughput sequencing step, which produces 
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one read in a single-end sequencing reaction, or two reads separated by an 
unsequenced fragment in paired-end reactions. The fourth step is data analysis, 
including alignment to reference genome/transcriptome and downstream data 
analyses such as differential expression analysis and functional interpretation 
(Corney, 2013; Wang et al., 2009). 
 
Figure 1.5 A typical RNA-Seq experiment (Adapted from Wang et al., 2009) 
While RNA-seq technology offers some advantages (e.g. increased specificity and 
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sensitivity, wider dynamic range and detection of novel transcripts), it also suffers 
from some challenges such as bias introduced in library preparation and high 
complexity of data analysis(Chu and Corey, 2012; Wang et al., 2009). The 
comparison of these two technologies in different aspects (Wang et al., 2009) is 
shown in Table 1.3. The oligonucleotide microarray technology was employed for 
analyzing the gene expression of human cell lines in this thesis, because of the 
nature of scientific questions of this project was focusing on comparison of gene 
expression pattern after exposure to FRs. In addition, the local availability of a 
well-established microarray platform for human gene expression analysis has also 
been considered. 
Table 1.3 Comparison of microarray and RNA-seq (Adapted from Wang et al., 
2009) 
 
1.5.2 Metabolomics 
Metabolomics is the study of comprehensive collections of metabolites of diverse 
cellular processes in a biological system (Ramirez et al., 2013). Since these 
metabolites (e.g. small peptides, lipids, amino acids, nucleic acids etc.) directly reflect 
Microarray RNA-Seq
Technology specifications 
Principle Hybridization High-throughput sequencing 
Resolution From several to 100 bp Single base 
Throughput High High
Reliance on genomic sequence Yes In some cases 
Background noise High Low
Application 
Simultaneously map transcribed regions and gene expression Yes Yes
Dynamic range to quantify gene expression level Up to a few-hundred fold >8,000-fold 
Ability to distinguish different isoforms Limited Yes
Ability to distinguish allelic expression Limited Yes
Practical issues 
Required amount of RNA High Low 
Data size and storage Small, cheap  large, expensive
Data analysis methods Standarized High complexity
Cost Relatively cheap Relatively high
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the biochemical processes of the system under investigation, metabolomics analysis 
provides insights into both the dynamic activities of particular metabolites and the 
alteration of biochemical pathways caused by nutrition and environmental stresses or 
exogenous compound insults (Ramirez et al., 2013). Unlike the genome, 
transcriptome and proteome, the chemical diversity of metabolome components 
make their comprehensive analysis difficult by using any single analytical method 
(Kuehnbaum and Britz-McKibbin, 2013). Generally, two analytical platforms dominate 
in metabolomics; these are nuclear magnetic resonance (NMR) spectroscopy, and 
mass spectrometry (MS) (Bouhifd et al., 2013; Dunn et al., 2011).  
1.5.2.1 NMR and MS based metabolomics 
NMR has several unique advantages, such as reproducibility, quantitative analysis 
and automation (Bouhifd et al., 2013; Viant and Sommer, 2012). NMR is 
non-destructive or even non-invasive, which make it possible to detect molecules in 
vivo (Bouhifd et al., 2013; Griffin and Kauppinen, 2007). The application of NMR 
based metabolomics has also been used widely in toxicological studies including 
metabolic biomarkers discovery ( reviewed in Coen et al., 2008). Proton NMR (1H 
NMR) spectroscopy is suitable to the investigation of toxic events, for example, a 
biofluid fingerprint that reflects a toxicant-induced response can be rapidly achieved 
without bias (Coen et al., 2008). However, the main challenge NMR suffers from is 
relatively lower sensitivity compared with MS (Lei et al., 2011). Over the past decade, 
MS has became a powerful tool in metabolomics researches because of its high 
sensitivity, selectivity and dynamic ranges (Robertson, 2005; Viant and Sommer, 
2012). Such advantages of MS allow MS-based metabolomics to be suitable for 
untargeted screening and discovering novel biomarkers or alterations in toxicity 
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pathways (Bouhifd et al., 2013). MS therefore met the requirements of the primary 
aim in this project (which is to explore the toxicity pathways perturbed by exposure to 
FRs). Therefore, a MS based-metabolomics approach was selected in this project. 
The two platforms for metabolomics application were compared by (Robertson, 2005) 
(Table 1.4).  
Table 1.4 Comparison of analysis by Nuclear Magnetic Resonance (NMR) 
versus Mass Spectrometry (MS) for metabolomics applications (Robertson, 
2005). 
 
The diversity of ion sources (e.g. electrospray ionization (ESI) and electron ionization 
(EI)) and mass analyzer (e.g. ion trap, triple quadrupole (QQQ), time-of-flight (TOF) 
and quadrupole-TOF (QTOF), Fourier transform ion cyclotron resonance (FT-ICR) 
and Orbitrap detectors) of mass spectrometers offers multiple analysis approaches 
for metabolomics (Viant and Sommer, 2012). Generally, the main methods in MS 
NMR MS
Logistics 
Capital cost no advantage
Maintenance advantage
Per sample cost no advantage
Footprint no advantage
Required technical skill advantage
Instrument ‘‘up‐time’’ advantage
Analytical considerations 
Sensitivity big advantage
Reproducibility (within lab) advantage
Reproducibility (across labs) big advantage
Quantitation big advantage
Average run speed no advantage
Sample preparation requirements advantage
Sample analysis automation advantage
Metabonomics 
Resolvable metabolites big advantage
Identification of unknowns advantage
Potential for sample biasd big advantage
Data analysis automation advantage
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based metabolomics analysis are direct injection (or direct infusion) mass 
spectrometry analysis (DIMS) and hyphenated MS (coupled with gas 
chromatography (GC), liquid chromatography (LC) or capillary electrophoresis (CE)) 
(Bouhifd et al., 2013). 
DIMS analysis of crude mixtures of metabolites provides a high throughput screening 
tool usually using high resolution mass spectrometers (i.e., Orbitrap, TOF and FT-ICR 
mass spectrometers)(Viant and Sommer, 2012). However, the limitations of DIMS 
analysis are ion suppression and MS peak identification. These limitations can be 
reduced by the chromatography coupled MS analyses (Lei et al., 2011). The benefits 
of chromatographic separation of metabolites prior to MS analyses are: (1) reducing 
ionization suppression in a complicated mixture, (2) improving separation of isobaric 
metabolites, (3) generating additional data (i.e. retention time) valuable for metabolite 
annotation, and (4) enhancing the accurate quantification of individual metabolites 
(Lei et al., 2011).The cost of these benefits in chromatography-coupled MS analysis 
is that they are time-consuming, thus resulting in lower throughput compared with 
DIMS analysis. 
In short, currently, no single analytical tool can meet all requirements in metabolomics 
which needs to accurately identify and quantify thousands of small molecules of 
interest in a high throughput way (Bouhifd et al., 2013). Hence, the selection of the 
most suitable analytical tool is generally a compromise between advantages and 
disadvantages of the available tools (Bouhifd et al., 2013). As illustrated in Figure 1.6, 
DIMS provides high sensitivity and high-throughput data, but suffers from the 
limitations of metabolite annotation (Taylor, 2010). 
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Figure 1.6 The trade-off between analytical platforms and the objectives of 
metabolomics Taken from (Taylor, 2010).  
1.5.2.2 DIMS based-metabolomics experiment 
The DIMS approach utilizing high resolution and high mass accuracy (<1 ppm) mass 
spectrometers is suitable for large-scale metabolic fingerprinting studies (Viant and 
Sommer, 2012). The work presented in this thesis used FT-ICR MS with ultrahigh 
resolution (>1,000,000 at 400 m/z), which matches the requirement of this project‘s 
primary aim to apply metabolomics to distinguishing the different molecular 
responses to FRs exposure and to identifying potential toxic effects and the 
underlying mechanisms of toxicity of FRs.  
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Figure 1.7 An overview of a pipeline of metabolomics experiment (Adapted from 
Brown et al., 2005).  
Similar to the pipeline illustrated in Figure 1.7, the main steps of DIMS-based 
metabolomics experiments also consist of (1) experimental design and data collection, 
(2) data pre-processing, (3) cleaned data for statistical analysis and (4) data to 
knowledge (i.e. metabolites annotation and pathway analysis). 
Southam et al.( 2007) developed a ―SIM-stitching‖ method for direct infusion FT-ICR 
mass spectrometry-based metabolomics. This method collects multiple overlapping 
selected ion monitoring (SIM) windows (using only 7 SIM windows each of m/z 100, 
overlapping by m/z 30, over the m/z range 70-590) in a short time analysis (2.25 mins 
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per sample)(Weber et al., 2011), which are then stitched together to generate a 
―SIM-stitched‖ spectrum with dynamic range (up to 16,000) and high mass accuracy 
(0.16 ppm).The detailed procedures of data processing (Figure 1.8) were also 
reported by (Kirwan et al., 2014), which includes a three-stage filters (TIC filter, 
replicate filter and sample filter), probabilistic quotient normalization (PQN) , missing 
value imputation using k-Nearest Neighbours (KNN) algorithm and generalised 
logarithm (Glog) transformation. 
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Figure 1.8 Data processing workflow for direct infusion FT-ICR mass 
spectrometry-based metabolomics dataset Taken from (Kirwan et al., 2014).  
After data processing, a DIMS dataset can be subjected to statistical analysis. For 
univariate analysis, t-tests or ANOVA are often employed. Since the size of 
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metabolomics datasets is considerably large, the multiple comparisons of variables 
will produce a large number of false positives (Robertson et al., 2007). Thus, the false 
discovery rate (FDR) is introduced for calculating corrected significance level 
(Benjamini and Hochberg, 1995). The MS peak will be considered to be changing 
significantly if the FDR adjusted p-value is smaller than the criteria (adjusted p<0.05). 
For multivariate analysis, unsupervised methods (e.g. principal component analysis 
(PCA)) or supervised methods (e.g. partial least squares discriminant analysis 
(PLS-DA)) can be applied. PCA has been widely used in analysis of various types of 
omic data, providing an overview of class separation, trends and outliers on the entire 
dataset (Bouhifd et al., 2013). PCA decomposes the data into scores and loadings, 
which indicate the relationship between samples and the correlations between the 
variables (MS peaks), respectively (Robertson, 2005). Principal components (PCs) 
represent degradation of variance in the data, where PC1 represent the greatest 
variance, followed by PC2 then PC3 and so on (Robertson 2005). The PC scores 
plots (i.e. PC1 versus PC2) are often displayed to show the similarities and 
differences between individual samples (Bouhifd et al., 2013; Robertson, 2005). 
The putative annotation of MS peaks can be achieved by searching against 
metabolites database, such as Kyoto Encyclopaedia of Genes and Genomes (KEGG), 
Human Metabolome Database (HMDB) and LIPIDMAPS. For example, DIMS peaks 
collected by FT-ICR MS can be allocated with putative empirical formulae and 
metabolite names by using the metabolite annotation package MI-Pack (Weber and 
Viant, 2010), which is based on single peak search (SPS) and transformation 
mapping (TM) algorithms. 
Pathway analysis allows us to decipher a list of putative metabolites which might be 
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linked to specific biochemical pathways or gene regulatory networks. However, such 
analysis can only be effective for known metabolic pathways (Bouhifd et al., 2013). 
Although pathway analysis of metabolomics data are still in their infancy, a few 
software packages have provided explorative tools to help generate hypothesis 
related to metabolic disruptions. For example, software available includes: IMPaLA 
(Kamburov et al., 2011), MPEA (Kankainen et al., 2011), MetaboAnalyst (Xia and 
Wishart, 2011; Xia et al., 2012) and MSEA (Persicke et al., 2012).  
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1.6 Research aims and objectives 
With intensive and global usage, flame retardants have performed an important role 
in preventing fires for decades; however, there are increasing concerns about the 
potentially adverse effects of these chemicals as studies documenting human 
exposure to FRs have become ubiquitous (Birnbaum and Staskal, 2004; Costa et al., 
2008; Sjodin et al., 2003).  
Therefore, the overall aim of this project was to expand our knowledge about the 
molecular mechanisms of the potentially toxic effects of FRs following human 
exposure, using in vitro models. The specific objectives are: 
1. To investigate the transcriptomic and metabolomic responses of A549 lung cancer 
cells and HepG2/C3A cells exposed to HBCD as a representative and commonly 
used brominated FR. 
2. To analyze the toxicogenomic responses to TDCIPP as a representative and 
commonly used organophosphorus FRs, at a series of concentrations in HepG2/C3A 
cells and A549 cells. 
3. To evaluate the potentially toxic effects of mixtures of FRs (HBCD, TDCIPP, TCIPP 
and TCEP) as well as indoor dust extracts at concentrations relevant to indoor 
environmental exposures to humans, using transcriptomic and metabolic approaches 
in HepG2/C3A cells.  
These objectives are addressed in Chapters 3, 4 and 5 respectively. 
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CHAPTER 2   Materials and methods  
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Generic methods and materials used in this thesis are presented in this chapter. The 
details of different FRs exposure experiments used only within a single chapter are 
described in chapters 3, 4 and 5, respectively. 
2.1 Chemicals and reagents 
All chemicals, including 1,2,5,6,9,10-hexabromocyclododecane (HBCD) (CAS 
Number: 3194-55-6, purity >95%), tris (1, 3-dichloro-2-propyl) phosphate (TDCIPP) 
(CAS Number: 13674-87-8, purity >97%), tris(2-chloroisopropyl) phosphate (TCIPP) 
(CAS Number: 13674-84-5, purity >95%) and tris(2-chloroethyl) phosphate (TCEP) 
(CAS Number: 115-96-8, purity >95%) were obtained from Sigma-Aldrich company 
Ltd. (Dorset, UK) unless otherwise stated. 
2.2 Cell culture 
A549 cells (adenocarcinomic human alveolar basal epithelial cells) were from our 
group‘s storage and cultured in DMEM medium (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (PAA, Cölbe, 
Germany), 100 U penicillin/mL and 100 μg streptomycin/mL (PAA, Cölbe, Germany), 
2 µM L-glutamine (PAA, Cölbe, Germany) and incubated in 37°C with humidified air 
containing 5% CO2. HepG2/C3A cells were generously provided by Prof. R. Blust 
from the University of Antwerp, Belgium. HepG2/C3A cells were cultured in Williams‘ 
E medium (Sigma-Aldrich, Dorset, UK) supplemented with 5% heat-inactivated FBS 
(PAA, Cölbe, Germany), 100 U penicillin/mL and 100 μg streptomycin/mL (PAA, 
Cölbe, Germany), 4 µM L-glutamine (PAA, Cölbe, Germany) and 0.4 µM sodium 
pyruvate (Sigma-Aldrich, Dorset, UK) and incubated in 37°C with humidified air 
containing 5% CO2. Cells were digested with 0.25% trypsin-EDTA and sub-cultured at 
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80% to 90% confluence. Exponentially growing cells were used for all assays.  
2.3 Cytotoxicity assays 
The cytotoxicity of FRs to A549 cells and HepG2/C3A cells were assessed using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, Cell 
Counting Kit-8 (CCK-8) assay or the adenylate kinase (AK) assay. 
2.3.1 MTT assay 
A549 cells or HepG2/C3A cells were seeded in 96-well plates and incubated at 37°C 
with a humidified atmosphere containing 5% CO2 for 24 hours. Then, cells were 
treated with FRs at a range of concentrations for 24 or 72 hours. Solvent controls (no 
FRs treatment) and blank controls (only medium) were also included, each with 6 
replicates. After 24 or 72 hours exposure, the culture media were removed and each 
well was washed with 100 µL phosphate buffered saline (PBS). 90 µL fresh media 
and 10 µL MTT solution (5mg/mL) were added to each well and mixed. The 96 well 
plates were then incubated at 37°C for an additional 3 hours. Culture supernatant 
was removed, 100 µL pure DMSO was added into each well and culture plates were 
gently rocked at low speed for 10 minutes to fully dissolve the blue crystals. 
Absorbance was measured at 530 nm (A530) using a plate reader (Tecan Spectrafluor 
Plus, Männedorf, Switzerland) against a DMSO blank. The percentage of cell viability 
was calculated at each concentration of flame retardant according to the following 
formula: cell viability (%) = (A530 Treatment group -A530Blank) / (A530 Solvent Control - 
A530Blank) × 100%. Dose-response curves were plotted and the half maximal 
effective concentration (EC50) values were then calculated by applying equation (1) 
in OriginPro8 (OriginLab, USA):  
40 
     
     
              
 
where A1 is the bottom asymptote, A2 is the top asymptote, p is the slope of the 
gradient, y is the viability as a percentage of control, and x is the nominal 
concentration of the test compound. 
2.3.2 CCK-8 assay 
The CCK-8 assay was also employed to evaluate the potential cytotoxicity of FRs 
using a commercial kit which is more convenient to use. According to the 
manufacturers‘ instructions (Dojindo Laboratories, Kumamoto, Japan), HepG2/C3A 
cells or A549 cells were cultured in a 96-well plate overnight and the cells were 
treated in six replicates with several concentrations of FRs in culture medium for 24 
hours or 72 hours. Then, 10 μL of CCK-8 solution was added into each well to treat 
the cells for 1 hour and the absorbance at 460 nm (A460) was measured using a plate 
reader (Tecan Spectrafluor Plus, Männedorf, Switzerland). Solvent control cells were 
considered as 100% viable. The viability of cells in the CCK-8 assays, in terms of 
EC50 values, was calculated using the same approach as for the MTT assay.  
2.3.3 AK assay 
The ToxiLight™ BioAssay kit (Lonza, Switzerland) was used, measuring the release 
of adenylate kinase from the damaged cells which can reflect the integrity of cell 
membrane. Following the manufacturers‘ instructions, after 24 or 72 hours treatments, 
20 μL of cell supernatants were transferred to a luminescence compatible 96 well 
plate, with 100 μL AK detection reagent for 10 mins. The 100% lysates of cells without 
treatment were used as total adenylate kinase control. 1-second integrated 
luminescence was measured using a Tecan M200 Pro Inﬁnite plate reader 
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(Männedorf, Switzerland). Ratio of AK release relative to total cell lysis was calculated 
using the direct luminometer light output (Relative Light Unit (RLUs)). The percentage 
of cytotoxicity was calculated at each treatment according to the following formula: 
Cytotoxicity (%) = Ratio of AK release at treatment group / Ratio of AK release at 
Solvent Control group × 100%. 
2.3.4 Cytotoxicity of HBCD to proliferating and confluent cells 
To compare the cytotoxicity of HBCD (60 μM) to proliferating cells and confluent cells, 
additional protein content assay (indicating the number of cells) while the CCK-8 
assay (reflecting the mitochondrial dehydrogenase activity) and AK assay (assessing 
the loss of cell integrity) were also employed. Specifically, HepG2/C3A cells were 
cultured in 96-well plates at different cell densities (1× 104 cells; 2× 104 cells; 4× 104 
cells and 6× 104 cells per well) which represent a gradient from proliferating cells to 
confluent cells. After an overnight acclimatisation, cells were treated with 60 μM 
HBCD or 10 μM DMBA (7,12-dimethylbenz[a]anthracene; positive control) in six 
replicates. Solvent control cells were treated with 0.5% DMSO (v/v). After a 24-hour 
exposure, the CCK-8 assays and AK assays were performed as above described on 
the proliferating (cultured at relatively low density) and confluent cells (cultured at 
relatively high density). 
For the total protein content assay, the BioRad DC Protein Assay (BioRad, USA) was 
employed. After treatment, cells were washed by PBS three times and lysed by RIPA 
buffer for 15 mins. The total protein content of cell lysates was determined the 
following manufacturer‘s instructions, in which absorbance at 645 nm (A645) to 
indicate the protein concentration was measured using a plate reader (Tecan 
Spectrafluor Plus, Männedorf, Switzerland).  
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Test results for each assay were expressed as a percentage of the untreated control 
± standard error (SE) or standard deviation (SD). Control groups were set as 100%. 
Differences between treated samples and the controls were evaluated using the 
statistical analysis package Minitab16. Statistically significant differences were set at 
p < 0.05. At least three independent experiments with six replicates for each group 
were conducted for each toxicity endpoint. 
2.4 Transcriptomics analysis 
2.4.1 RNA isolation  
Total RNA of cells harvested as described above were extracted using Qiagen‘s mini 
RNeasy Kit and QIAshredder (Qiagen, Crawley, UK) with subtle modification of 
manufacturer‘s instructions. Briefly, harvested cell pellets were centrifuged at 1,500 g 
(4,000rpm), 5 mins and the supernatant (methanol solution) were removed with 
Pasteur pipette as much as possible. Buffer RLT (350 μL per tube) were added to cell 
pellets in Eppendorf tube. The whole lysate was transferred directly into QIAshredder 
spin column and centrifuge at full speed for 2 mins. One volume (i.e. 350 μL) 70 % 
ethanol was added to lysate and was mixed well by pipetting. Then, totally 700 μL of 
sample including any precipitate, was transferred into RNeasy spin column. After 
centrifuge at 8,000 g (10,000 rpm) for 15 seconds, flow through was discarded. The 
DNase digestion step was added to yield the high quality of RNA samples as 
following steps: 350 μL Buffer RW1 was added to spin column and after centrifuged at 
8000 g (10,000 rpm) for 15 seconds to wash membrane, flow through was discarded. 
Then, 80 μL DNase I incubation mix (10 μL DNase I stock solution to 70 μL Buffer 
RDD) was directly added to spin column membrane and incubate at room 
temperature for 15 mins. After incubation, 350 μL Buffer RW1 was added to spin 
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column and centrifuged at 8,000 g (10,000 rpm) for 15 seconds. Then 500 μL Buffer 
RPE was added to spin column to wash membrane twice with centrifuge at 8,000 g 
(10,000 rpm) for 15 seconds or 2 mins respectively. Then a new eppendorf tube was 
placed into the spin column, and 30-50 μL RNase-free water was directly added to 
spin column membrane (incubate the RNeasy spin column on the bench for 10 mins 
with RNase-free water before centrifuging) to elute RNA with centrifuge at 8,000 g 
(10,000 rpm) for 1 minute. RNA was quantified with a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA), and the integrity of RNA was 
evaluated with a Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Only good quality RNA with RNA integrity numbers (RINs) greater than 7.5 were used 
for subsequent gene expression analyses or microarray experiments. 
2.4.2 Microarray analysis 
In the sub-project of HBCD study, six replicates of RNA samples from A549 cells 
(randomly selected from the total of eight replicates, to reduce costs) were used for 
each of the HBCD treated groups (2 nM (Very low), 20 nM (Low), 200 nM (Medium) 
and 2 µM (High)) while the solvent (DMSO) control group comprised of eight 
replicates. For RNA samples from HepG2/C3A cells, a total of 16 samples were 
subjected to microarray analyses, comprising six samples from the HBCD (4 µM) 
treated group, six from the solvent (DMSO) control group, and the remaining four 
from the DMBA (10 µM) positive control group.  
In the second sub-project of TDCIPP study, only HepG2/C3A cells and A549 cells 
exposed to 10 μM (Medium concentration) and 100 μM (High concentration) in the 
FBS-containing media for 24 hours were analysed (n=4). The solvent control groups 
in each treatment condition were treated with 0.5% DMSO (v/v) with the same 
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number of replicates for omics analyses. 
In the third sub-project of mixture of FRs study, HepG2/C3A cells were exposed to 
SRM2585 dust extract (equivalent to ca. 0.6mg dust per million cells), Mix 1, Mix 2, 
DMBA (2 μM), HBCD (4 μM) or 0.1% (v/v) DMSO as control for 72 hours with four 
replicates in each group. 
The procedures for microarray analysis were performed following the manufacturer's 
protocols (Agilent Technologies, Santa Clara, CA). Briefly, following synthesis of 
cRNA from 50 ng of total RNA per sample, the probe RNA was amplified and labelled 
with Cy3-CTP (Agilent One-Color RNA Spike-In Kit and QuickAmp Labelling kit, 
Agilent Technologies). The Cy3-labeled cRNA was then fragmented and hybridized to 
Agilent Human gene expression 8×60k microarray (Design ID: 028004 and 039494), 
at 65 °C for 17 hours. The hybridised microarrays were scanned with an Agilent 
G2565BA microarray scanner (Agilent Technologies, Santa Clara, CA) at OD535 for 
Cy3. Scanned images were processed according to manufacturer‘s instructions 
(Agilent Technologies, Santa Clara, CA) and the microarray results were extracted 
using Agilent Feature Extraction software (Agilent Technologies, Santa Clara, CA).  
Microarray data processing and analyses were performed within GeneSpring version 
GX7.3.1 and GX11 (Agilent Technologies, Santa Clara, CA) and MultiExperimental 
Viewer v4.9 (Saeed et al., 2003). In the sub-project of HBCD study,microarray data 
were first Quantile normalized using GeneSpring version GX11 , batch effects were 
corrected using ComBat (Johnson et al., 2007). In other sub-projects, Microarray data 
were first median normalized using GeneSpring version GX7.3. To visualise the 
similarities and differences in the gene expression profiles and to identify any 
significant trends, PCA was conducted using PLS_Toolbox Eigenvector Research, 
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Wenatchee, WA) in MatLab. ANOVA (or t-test) with a Tukey-Kramer‘s post-hoc test 
was conducted on the scores for the top three or four PCs from each model (FDR 
<10%).  
The log2 transformed normalised microarray dataset was subjected to Significance 
Analysis of Microarrays (SAM) (Tusher et al., 2001), embedded in MultiExperimental 
Viewer v4.9, to identify significant differential gene expression between groups. The 
delta parameter was adjusted to achieve a FDR <5% and this delta value were 
applied to determine significantly changed genes.  
Any significantly altered genes were then analysed using the Functional Annotation 
Clustering (FAC) tool contained in the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) (Huang et al., 2009) to determine the most relevant 
pathways and processes based on the Gene Ontology annotation function, with FDR 
<5% selected for the significant functions. Gene set enrichment analysis (GSEA) 
(Subramanian et al., 2005) was also applied to the above normalised microarray 
dataset to determine differentially expressed gene sets in FRs treated groups 
comparing to control. 
Microarray datasets are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress): E-MTAB-2173 (HBCD_1), E-MTAB-2174 (HBCD_2), 
E-MTAB-3323 (TDCIPP) and E-MTAB-3324 (mixture of FRs). 
2.4.3 Quantitative real time-PCR analysis 
Reverse transcription  real time-PCR were performed to quantify the mRNA levels of 
a selected set of genes in A549 or HepG2/C3A cells from different treatment group 
across this project. Firstly, 1 µg of DNase-treated total RNA was reverse transcribed 
to cDNA according to the manufacturer‘s protocol with a Tetro cDNA synthesis Kit 
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(Bioline, UK). Real-time PCR reactions were carried out in a 96-well reaction plate 
format on a Maxpro 3005 Detector (Agilent) using the SensiFAST SYBR Hi-ROX kit 
(Bioline, UK). The primers of selected genes (Table 2.1) were designed and bought 
from Sigma-Aldrich, UK. PCR reactions were performed in a total volume of 20 µL 
containing 500 nM of each primer and 1 µL of cDNA template. Thermal cycling was 
initiated with an initial incubation at 95 °C for 2 min. After that, 40 cycles of PCR were 
performed, with each PCR cycle consisting of a heating step at 95 °C for 15 s and an 
annealing/extension step at 60 °C for 30 s. As an endogenous control, the expression 
of the ACTB gene was measured in parallel. Negative controls were included in the 
same plate. A melting curve analysis was performed to ensure that single product 
was generated. Each biological sample was analysed in quadruplicate, and each 
dose group contained four biological replicates. Relative gene expression was 
analyzed using the 2-ΔΔCt quantification method (Livak and Schmittgen, 2001) and 
tested for significance using one-way ANOVA and Tukey‘s test (p <0.05)in Minitab16 
(Minitab Inc., State College, Pennsylvania, USA). 
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Table 2.1 Genes, primers, and Tm values used in the RT-PCR analysis 
 
2.5 Metabolomics analysis 
2.5.1 Extraction of metabolites 
2.5.1.1 Extraction of metabolites (cells harvested from T75 culture flask) 
After 24 hours exposure, A549 cells were rapidly washed with 10 mL PBS at room 
temperature twice. Then, 10 mL 60% methanol/40% water (pre-cooled on dry ice) 
was added into flask to quench cells. The residual was removed and the quenched 
flask was kept on the dry ice until harvest. After washing and quenching, 4.0 mL 100% 
methanol (pre-cooled on dry ice) was added into the flask. Cells were carefully 
scraped into methanol solution on dry ice and then transferred into a 5 mL cryovial 
(pre-cooled on dry ice), mixed well by pipetting several times and split in three parts 
(one for transcriptomic analyses, the second one for DIMS analysis and the third one 
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for NMR analysis (NMR data were not included in this study)). Specifically, 0.4 mL 
cell-methanol solution from a 5 mL cryovial was transferred into a 2 mL Eppendorf 
tube and centrifuged for 5 mins at 4000 rpm, -9°C and the supernatants were 
removed by Pasteur pipette. The cell pellets were then frozen at -80°C until extraction 
of RNA for transcriptomic analysis. The rest of cell-methanol solution (3.6 mL) went to 
freeze/thaw cycle (Liquid N2/Dry ice) three times before distributing into three 2 mL 
Eppendorfs (labelled A and B (1.6 mL per tube) for NMR analysis and labelled C (0.4 
mL per tube) for MS analysis separately). 
For extraction of metabolites, cell pellets in 400µL methanol/water solution were 
extracted by adjusting the solvent ratios to methanol/chloroform/water of 1:1:0.9 
(v/v/v). After vortexing and centrifuging the mixture had been separated into two 
phases (upper polar phase and lower non-polar phase). 300 µL aliquots of the polar 
phase were transferred into clean 1.5 mL Eppendorf tubes and then dried using a 
speed vac concentrator (Thermo Savant, Holbrook, NY) for 4 hr with a fixed temp of 
35 °C. All dried samples were then frozen at -80 °C until analysis. The non-polar 
aliquots were not used in this study. 
2.5.1.2 Extraction of metabolites (cells harvested from 6 well plate) 
After 24 hours or 72 hours exposure, cells cultured in the 6 well plates were quickly 
washed with 2 mL PBS twice before the 6-well plates were quenched on liquid 
nitrogen for 60 seconds. Then, 600 μL 80% methanol (pre-cooled on dry ice) was 
added into each well and the cells were scraped from the bottom of the wells while 
resting the plate on dry ice. Each cell pellet in the aqueous methanol solution 
(combining with additional 400 μL 80% methanol to wash the well) was transferred 
into a glass vial. The glass vial was pre-filled into 600 μL pre-cooled chloroform and 
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340 μL H2O. Then the well was washed with 400 μL 80% methanol (pre-cooled on dry 
ice) and all contents were transferred into the above-mentioned glass vial for the 
following metabolites extraction. After adjusting the ratio of 
methanol:chloroform:water (v/v/v) to 1:1:0.9, glass vials were vortexed for 30 s three 
times, at 30 s intervals. The glass vials were then cooled on dry ice for 10 mins before 
10 mins centrifugation at 1800 rcf at -9 °C. After vortexing and centrifuging, the 
mixture separated into two phases (upper polar phase and lower non-polar phase). 
Next, 300 µL aliquots of the polar phase were transferred into clean 1.5mL Eppendorf 
tubes and then dried in a speed vac concentrator (Thermo Savant, Holbrook, NY) for 
4 hours. 300 µL aliquots of the non-polar phase were transferred into clean 1.8mL 
glass vial and then were dried under a stream of nitrogen to minimise oxidation. All 
dried samples were then stored at -80°C until analysis. 
2.5.2 Direct infusion mass spectrometry analysis 
The dried polar extracts of cells were re-suspended in 75 μL 80:20 (v/v) 
methanol:water (HPLC grade) with 0.25% formic acid (for positive ion mode) or 20 
mM ammonium acetate (for negative ion mode), vortexed and centrifuged at 14000 
rpm, 4°C for 10 mins.(For the dried non-polar extracts of cells, it was re-suspended in 
with 2:1 (v/v) MeOH:chloroform with 5 mM ammonium acetate.) Each sample was 
loaded into three wells of a 96-well plate (10 µL per well) and then analysed (in 
triplicate) using direct infusion Fourier transform ion cyclotron resonance mass 
spectrometry in negative ion mode or positive ion mode (for polar metabolomics) and 
negative ion mode (for lipidomics) (LTQ FT Ultra, Thermo Fisher Scientific, Germany, 
coupled to a Triversa nanoelectrospray ion source, Advion Biosciences, Ithaca, NY, 
USA). Mass spectra were recorded utilizing the selected ion monitoring (SIM) 
stitching approach from m/z 70 to 590 (for polar metabolomics) or from m/z 100 to 
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2000 (for lipidomics) (Southam et al., 2007) and then processed using custom-written 
Matlab scripts as previously reported (Kirwan et al., 2014; Payne et al., 2009; 
Southam et al., 2007). In brief, time domain (‗transient‘) data were collected, Fourier 
transformed and internally mass calibrated. Only mass spectral peaks with a 
signal-to-noise ratio above 3.5 were retained. Mass spectra of the three technical 
replicates for each sample were filtered into a single peak list (with only those peaks 
present in ≥ 2 of the 3 spectra retained). Each filtered peak list (one per sample) was 
then further filtered to retain only those peaks that were present in 80% of all 
biological samples in the entire dataset, and missing values were imputed using the 
k-nearest neighbours (KNN) algorithm. The resulting matrices of peak intensity data 
(termed ―DIMS dataset‖) were normalised by the probabilistic quotient (PQN) method 
prior to statistical analyses. 
For univariate statistical analysis, one way ANOVA (or t-test) with 
Benjamini-Hochberg correction was conducted on the peaks in the normalised DIMS 
datasets to determine whether they changed intensity significantly between control 
and FRs or other treatment groups (at a false discovery rate (FDR) < 10% to correct 
for multiple hypothesis testing). For multivariate statistical analysis, the normalized 
DIMS datasets were generalized log transformed and principal component analysis 
performed using PLS_Toolbox (Eigenvector Research, Wenatchee, USA) in MatLab 
(version 7, the Math-Works, MA, USA). ANOVA (or t-test) with a Tukey-Kramer‘s 
post-hoc test was conducted on the PC scores for the top few principal components 
from each model (with an FDR of <10%) to evaluate the statistical significance of the 
treatments on the basis of the overall metabolic profiles.  
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2.5.3 Putative annotation and Pathway analysis 
For significantly changed DIMS peaks, putative empirical formulae and metabolite 
names were assigned by searching against the Human Metabolome Database 
(HMDB) and Kyoto Encyclopedia of Genes and Genomes (KEGG) and/or 
LIPIDMAPS database, using the metabolite annotation package MI-Pack (Weber and 
Viant, 2010) with an error window of 1 ppm. 
Putative annotated metabolite names of significant DIMS peaks from the above 
databases were combined together, generating a list of significantly changed DIMS 
peaks from polar metabolomics dataset with one or more putative metabolite names. 
A list of annotated metabolites names was then submitted into IMPaLA (Kamburov et 
al., 2011) in compound list format using Fisher‘s Exact test for pathway 
over-representation analysis. Putative annotation of significantly changed DIMS 
peaks from non-polar DIMS dataset was not subjected to pathway 
over-representation analysis due to the less reliable annotation results. 
2.6 Quantification of FRs in HepG2/C3A cells and in cell media  
(work conducted by Dr. Mohamed Abou-Elwafa Abdallah, University 
of Birmingham) 
2.6.1 Quantification of HBCD levels in HepG2/C3A cells and cell media after 
exposure 
To measure the cellular uptake of HBCD after exposure, their concentrations were 
measured in treated cells and media (both with and without fetal bovine serum) after 
24 hours using LC-MS/MS (Van den Eede et al., 2012). Briefly, 10 ng of each of 
13C-labelled α- and β-HBCDs and 25 ng 13C-labelled γ-HBCD (supplied in 10 µL 
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methanol) were added as internal (surrogate) standards while the samples were 
extracted from weighed cell pellets and cell media using liquid-liquid extraction with 
hexane:dichloromethane (DCM) (3:2) mixture. Chromatographic separation of the 
target analytes was achieved using a dual pump Shimadzu LC-20AB Prominence LC 
equipped with a SIL-20A autosampler, a DGU-20A3 vacuum degasser and an Agilent 
Pursuit XRS3 C18 reversed phase analytical column (150 mm × 2 mm i.d., 3 µm 
particle size). Mass spectrometric analysis was performed using a Sciex API 2000 
triple quadrupole mass spectrometer operated in negative electrospray ionisation 
mode.  
The concentrations of HBCD diastereomers in the samples were calculated 
according to the response factors of the respective 13C-labelled internal standard for 
each diastereomer. The recovery ratios were calculated from the total amount of α-, 
β- and γ-HBCDs (ΣHBCDs) in the cell pellets after exposure, divided by the nominal 
amount that was added into the exposure media. Average concentrations of ΣHBCDs 
detected in the cell media were also calculated where each treatment group included 
three biological replicates. 
2.6.2 Quantification of TDCIPP, TCIPP, TCEP and HBCD levels in HepG2/C3A 
cells and cell media 
To evaluate the cellular uptake of FRs after exposure, their concentrations were 
measured in treated cells and cell media after 24 hours or 72 hours using LC-MS/MS 
according to a previously reported method (Abdallah et al., 2015b). Briefly, 10 ng of 
each of 13C- α-, β-, γ-HBCDs and d15-TPhP (supplied in 10 µl methanol) were added 
as internal (surrogate) standards. Samples were extracted from weighted cell pellets 
and cell media using liquid-liquid extraction with hexane:ethylacetate (1:1) mixture. 
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Chromatographic analysis was conducted using a dual pump Shimadzu LC-20AB 
Prominence liquid chromatography equipped with SIL-20A autosampler, a DGU-20A3 
vacuum degasser and an AccucoreTM RP-MS column (100 x 2.1 cm, 2.6 µm, 
ThermoScientific, Bremen, Germany). Mass spectrometric analysis was performed 
using a Sciex API 4000 triple quadrupole mass spectrometer equipped with an 
electrospray ionization source and operated in MS/MS multiple reaction monitoring 
mode. Source and compound specific parameters were adjusted for each target FR 
(i.e. HBCDs, TCEP, TCIPP and TDCIPP) via direct infusion experiments (2 ng µL-1 
standard solution each, in methanol) using a built-in Harvard syringe pump at a flow 
rate of 10 µL min-1. 
The recovery ratios were calculated from the total amount of four individual FRs in the 
cell pellets after exposure, divided by the nominal amount that were added into the 
exposure media. Average concentrations of four FRs detected in the cell media were 
also calculated where each treatment group included three biological replicates. 
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CHAPTER 3   Transcriptomic and 
metabolomic approaches to 
investigate the molecular 
responses of human cell lines 
exposed to the flame retardant 
hexabromocyclododecane 
(HBCD)* 
 
 
*The content of this chapter has been submitted to Toxicology in vitro: Zhang, J., 
Williams, T.D., Abdallah Abou-Elwafa, M., Harrad, S., Chipman, J.K., Viant, M.R., 
2015. Transcriptomic and metabolomic approaches to investigate the molecular 
responses of human cell lines exposed to the flame retardant 
hexabromocyclododecane (HBCD).   
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3.1 Introduction 
Hexabromocyclododecane (HBCD) is one of the most widely used classes of 
brominated flame retardant (Covaci et al., 2006; Marvin et al., 2011). Like other 
additive flame retardants, HBCD is anticipated to migrate into the environment during 
various stages of their manufacture, use and disposal (Harrad et al., 2010). Studies 
have shown that HBCD is persistent, bioaccumulative and is capable of long-range 
atmospheric transport (Marvin et al., 2011). HBCD has been detected in various 
environmental media including indoor air and dust, which thus represent sources of 
human exposure (Roosens et al., 2009). Human exposure to HBCD has been 
confirmed by its presence in breast milk, adipose tissue and blood (Marvin et al., 2011; 
Rawn et al., 2014a). For instance, HBCD levels detected in human milk samples in 
Spain were up to 188 ng/g lipid weight, with a median value of 27 ng/g (Eljarrat et al., 
2009). A recent study (Rawn et al., 2014a) reported concentrations of HBCD in fetal 
liver (median 29 ng/g lipid) and placental tissues (median 49 ng/g lipid) collected 
between 1998 and 2010 in Canada. Weiss et al. (2004) detected HBCD in both 
maternal and cord blood (average values of 1.1 ng/g and 1.7 ng/g lipid weight, 
respectively) in the Netherlands. It has also been reported that the concentration of 
HBCD in human serum was up to 856 ng/g lipid (Thomsen et al., 2007). These 
studies confirm that human exposures are widespread across the globe.  
To respond to the environmental and human health concerns regarding exposure to 
HBCD, toxicity studies have investigated and reported potentially adverse effects of 
HBCD in animal models and human cell lines (Marvin et al., 2011). Disruption of 
thyroid function has been found in rats (van der Ven et al 2006; Ema et al 2008;), fish 
(Palace et al., 2010, 2008) and chicken (Crump et al., 2008) following exposure to 
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HBCD. Low micromolar concentrations of HBCD have been shown to give rise to 
neurotoxic effects in in vitro cultured neuronal cells (e.g. PC12 cells (Dingemans et al., 
2009) and SH-SY5Y cells (Al-Mousa and Michelangeli, 2012)) by interfering with 
calcium (Ca2+) homeostasis and intracellular signalling pathways. Hepatotoxicity of 
HBCD has been reported in a wide range of studies, which showed that liver is a 
major main target organ (Hakk et al., 2012; Marvin et al., 2011). Long term exposure 
to HBCD at a relatively high dose (30 mg/kg/day, 28 days) increased liver weight in 
female rats (van der Ven et al., 2006) and induced hepatic cytochrome P450 (CYP) 
enzyme activities (CYP2B1 and CYP3A1) in rats (Cantón et al., 2008; Germer et al., 
2006). In juvenile rainbow trout (Ronisz et al., 2004) and Chinese rare minnow 
(Zhang et al., 2008), HBCD inhibited activities of cytochrome P450s (CYPs) in the 
liver after 28-day exposure. The mRNA expression of CYPs (CYP2H1 and CYP3A37) 
were up-regulated in chicken (Gallus gallus) hepatocytes exposed to ≥ 1μM HBCD for 
24 and 36 hours (Crump et al., 2008). 
In several in vitro studies, induction of cell apoptosis by exposure to high 
concentrations of HBCD in HepG2 cells (An et al., 2014; Hu et al., 2009) and human 
L02 hepatocytes (An et al., 2013) has been suggested to result from increased 
production of reactive oxygen species (ROS). However, a slight increase in ROS has 
also been observed after low concentration (10−7−10−1 μM) exposures in human L02 
hepatocytes, while there was no acute toxic effect reported (An et al., 2013). More 
studies are necessary to better understand whether any molecular changes result 
from concentrations that are realistic to likely human exposures to HBCD.  
The aim of this chapter was to apply ‗omics approaches to investigate the potential 
molecular toxicity of HBCD under as realistic experimental conditions as possible with 
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in vitro cell line models, i.e. including serum within the cell culture media. A wide 
range of sub-lethal exposure concentrations of a commercial mixture of HBCD was 
investigated including levels comparable to those reported previously in human 
serum. Specifically, oligonucleotide microarray based transcriptomics and direct 
infusion mass spectrometry (DIMS) based metabolomics were applied to determine 
gene expression and metabolic profiles of A549 and HepG2/C3A cells exposed to 
HBCD, respectively. Used in combination, these ‗omics approaches can inform on 
both upstream regulatory processes as well as downstream functional molecular 
responses, providing insights into potential adverse effects of HBCD. 
3.2 Materials and Methods  
3.2.1 Chemicals and reagents 
All chemicals, including 1,2,5,6,9,10-hexabromocyclododecane (CAS Number: 
3194-55-6, purity >95%) were obtained from Sigma-Aldrich (Dorset, UK) unless 
otherwise stated. 
3.2.2 Cell culture 
The methods of A549 cells and HepG2/C3A cells culture were described in Section 
2.2. 
3.2.3 Cytotoxicity assays  
3.2.3.1 MTT assay 
The cytotoxicity of HBCD to A549 cells was assessed by the MTT assay. A549 cells 
were seeded in 96-well plates (5 × 103 cells per well) and incubated at 37°C with a 
humidified atmosphere containing 5% CO2 for 24 hours. Then, cells were treated with 
HBCD at various concentrations (0.1, 1, 5, 10, 25, 50 and 100 μM; with six replicates 
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at each concentration) for 24 hours. The percentage of viable A549 cells was 
calculated. Concentration-response curves were plotted and the half maximal 
effective concentration (EC50) values were then calculated. The procedure of MTT 
assay was described in Section 2.3.1. 
3.2.3.2 CCK-8 assay 
The cytotoxicity of HBCD to HepG2/C3A cells was evaluated by the CCK-8 assay 
using a commercial kit, according to the manufacturers‘ instructions (Dojindo 
Laboratories, Kumamoto, Japan). Briefly, HepG2/C3A cells (2× 104 cells per well) 
were cultured in a 96-well plate overnight and the cells were treated in six replicates 
with several concentrations (0.1, 1, 5, 10, 25, 50 and 75 μM) of HBCD in culture 
medium for 24 hours. The viability of cells in the CCK-8 assays, in terms of EC50 
values, was calculated using the same approach as that used for the MTT assay. The 
details of CCK-8 assay were available in Section 2.3.2. 
3.2.4 HBCD exposure experiments and sample preparation for metabolomics 
and transcriptomics 
3.2.4.1 A549 cells  
A549 cells were exposed to several HBCD concentrations: 2 nM ( nominal 
concentration in the media, termed Very low concentration group), 20 nM (termed 
Low concentration group), 200 nM (termed Medium concentration group) and 2 µM 
(termed High concentration group). In the control group, a concentration of 0.5% 
DMSO was used as a vehicle in the treated samples. Each concentration group 
included six or eight replicates. After 24-hour exposure, cells were rapidly quenched 
and harvested as described in. The extraction of metabolites employed liquid-liquid 
extraction approach with the ration of methanol/chloroform/water was 1:1:0.9 (v/v/v) 
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as described in Section 2.5.1.1.  
Total RNA of quenched cells was isolated using Qiagen‘s mini RNeasy Kit and 
QIAshredder (Qiagen, Crawley, UK) according to the manufacturer‘s protocol. RNA 
was quantified with a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Waltham, MA), and the integrity of RNA was verified with a 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). This was described in Section 2.4.1. 
3.2.4.2 HepG2/C3A cells  
Similar methodologies were used to culture, expose and harvest HepG2/C3A cells as 
above, with some subtle modifications to maximise the recovery of RNA and 
metabolites. Specifically, the HepG2/C3A cells were exposed to 4 µM HBCD or 10 µM 
7,12-dimethylbenz[a]anthracene (DMBA) for 24 hours; 10 µL DMSO as vehicle was 
added into the control samples (final concentration of DMSO was 0.5% (v/v) in all 
treatments). Each treatment group consisted of six replicates. Following the 
exposures, the cells were harvested and the metabolites (Section 2.5.1.2) and RNA 
(Section 2.4.1) were extracted in a similar manner to that described above.  
3.2.5 Direct infusion mass spectrometry (DIMS) analysis  
The dried polar extracts of cells were re-suspended in 150 μL 80:20 (v/v) 
methanol:water (HPLC grade) with 20 mM ammonium acetate, vortexed and 
centrifuged at 14000 rpm, 4°C for 10 mins. Each sample was loaded into three wells 
of a 96-well plate (10 µL per well) and then analysed (in triplicate) using direct infusion 
Fourier transform ion cyclotron resonance mass spectrometry in negative ion mode 
(LTQ FT Ultra, Thermo Fisher Scientific, Germany, coupled to a Triversa 
nanoelectrospray ion source, Advion Biosciences, Ithaca, NY, USA). Mass spectra 
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were recorded utilizing the selected ion monitoring (SIM) stitching approach from m/z 
70 to 590 (Southam et al., 2007) and then processed using custom-written Matlab 
scripts as previously reported (Southam et al 2007; Kirwan et al 2014). The procedure 
of data processing and statistical analysis of DIMS data were described as earlier in 
Section 2.5.2. 
3.2.6 Transcriptomic analysis  
For RNA samples from A549 cells, six replicates (randomly selected from the total of 
eight replicates, to reduce costs) were used for each of the HBCD treated groups (2 
nM (Very low), 20 nM (Low), 200 nM (Medium) and 2 µM (High)) while the solvent 
(DMSO) control group comprised of eight replicates. For RNA samples from 
HepG2/C3A cells, a total of 16 samples were subjected to microarray analyses, 
comprising six samples from the HBCD (4 µM) treated group, six from the solvent 
(DMSO) control group, and the remaining four from the DMBA (10 µM) positive 
control group.  
The procedures for microarray analysis were performed following the manufacturer's 
protocols (Agilent Technologies, Santa Clara, CA) and the detailed procedures were 
described in Section 2.4.2. Quantitative real time-PCR analysis (see Section 2.4.3) 
was performed to quantify the mRNA levels of a selected set of six genes in A549 or 
HepG2/C3A cells treated with HBCD or DMBA.  
3.2.7 Quantification of HBCD in A549 and HepG2/C3A cells and cell media 
(conducted by Dr. Mohamed Abou-Elwafa Abdallah, University of Birmingham) 
To measure the cellular uptake of HBCD after exposure, A549 and HepG2/C3A cells 
were exposed to 2 μM and 4 μM HBCD, respectively, in both FBS-containing and 
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FBS-free media. Following 24-hour exposures, HBCD levels were quantified in both 
the cell pellets and media using the LC-MS/MS method(Van den Eede et al., 2012). 
The details of procedures can be found in Section 2.6.1. Average concentrations of 
ΣHBCDs (total amount of α-, β- and γ-HBCDs) detected in the cell media were also 
calculated where each treatment group included three biological replicates. 
3.3 Results  
3.3.1 Cytotoxicity of HBCD to A549 cells and HepG2/C3A cells 
Concentration-dependent cytotoxicity of HBCD to A549 cells and HepG2/C3A cells 
after 24-hour treatments were observed (Figure 3.1). At relatively low concentration 
ranges from 0 to 10 μM, HBCD exhibited minimal cytotoxicity with the viability of 
HepG2/C3A cells remaining greater than 90%, while for the A549 cells the viability 
remained greater than 80%. The EC50 values of cytotoxicity of HBCD to A549 and 
HepG2/C3A cells were 27.4 μM and 63.0 μM, respectively, in the presence of serum 
in the exposure media. 
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Figure 3.1 Cytotoxic effects of HBCD to A549 cells and HepG2/C3A cells. Cell 
viability of A549 cells (A) and HepG2/C3A cells (B) was examined using the MTT assay and 
CCK-8 assay, respectively, after exposure to different concentrations (0-100 μM for A549 
cells; 0-75 μM for HepG2/C3A cells) of HBCD for 24 hours. Results are expressed as the 
percentage (mean ± SD, n=6) of cell viability compared to controls treated with the 
appropriate vehicle (DMSO). 
 
In order to explore potential molecular events in cells at sub-toxic concentrations, 2 
μM was selected as the highest concentration for exposure of A549 cells to HBCD, 
more than 10-fold lower concentration than the EC50 value. Three additional 
treatment groups were included, each 10-fold lower in concentration. The 
experimental design therefore consisted of exposing A549 cells to HBCD at 2 nM, 20 
nM, 200 nM and 2 μM, with the appropriate vehicle (DMSO) as a control group, so as 
to maximise the relevance of our findings to likely human exposure levels. Following a 
similar strategy for the HepG2/C3A cells, 4 μM was used as the exposure 
concentration for the ‗omics studies. DMBA at 10 μM was employed as a reference 
treatment (positive control) for the gene expression study. 
63 
3.3.2 Molecular responses of A549 cells exposed to HBCD 
3.3.2.1 Gene expression profiles of A549 cells exposed to HBCD 
Oligonucleotide microarrays were employed to evaluate gene expression profiles of 
A549 cells after 24-hour exposures to four concentrations of HBCD, as detailed 
above. There was no clear separation of gene expression profiles between different 
treatment groups in A549 cells in PCA scores plot (Figure 3.2 A).  
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Figure 3.2 PCA scores plots of microarray dataset (A) and DIMS dataset (B) in A549 cells exposed to HBCD for 24 hours. 
Legend: controls (blue), Very low concentration (2 nM) group (dark green), Low concentration (20 nM) group (green), Medium concentration 
(200nM) group (pink) and High concentration (2 μM) group (red). Biological replication comprised n=6 (microarray) and n=8 (DIMS) in HBCD 
treatment groups; n=8 in the control group. 
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The ANOVAs of the top four PC scores combined with a Tukey-Kramer's post hoc test 
(Table 3.1) also showed that there were no significant differences in the gene 
expression profiles between control and HBCD treated groups in A549 cells. 
Significance analysis of microarrays (SAM) found no significantly altered individual 
genes compared to controls, which is consistent with the results from the PCA of the 
gene expression dataset. Gene Set Enrichment Analyses also indicated there were 
no significantly enriched gene sets involving KEGG pathways in HBCD treated 
groups. 
Table 3.1 Summary of the principal component (PC) analyses of both the 
microarray and DIMS datasets of A549 cells and HepG2/C3A cells following 
exposure to HBCD. 
(Groups in A549 cells: Control, Very Low concentration, Low concentration, Medium 
concentration and High concentration; groups in HepG2/C3A cells: Control, HBCD and 
DMBA). The variance explained (%) by PCs 1-4 are listed together with p values from 
ANOVAs (or t-tests) of these PC scores across all treatments (values in bold indicate 
significance at a false discovery rate (FDR) <10%). 
Quantitative RT-PCR analysis of six genes of interest (CYP1A1 and CYP3A4: related 
to xenobiotic metabolism, CDK2: cell division/growth, EEF1A1: protein biosynthesis, 
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GSR: oxidative stress response, and GJB1: cell communication) revealed that only 
expression of CYP3A4 in A549 cells treated with 20 nM (Low concentration) and 200 
nM (Medium concentration) HBCD was slightly down-regulated (Figure 3.3 A), while 
no significant changes were observed in the microarray analysis after exposure to the 
different concentrations of HBCD for 24 hours. The expression levels of the other five 
genes were not significantly altered, in agreement with the results of the microarray 
analysis. 
 
Figure 3.3 qPCR analysis of mRNA expression of six selected genes in A549 
cells (A) and in HepG2/C3A cells (B) following HBCD or DMBA treatments. Data 
were obtained from quadruplicate PCR reactions of four biological replicates. Differences to 
the solvent control were tested by one-way ANOVA or t-test (*P <0.05). Results are presented 
as mean ± standard deviation. 
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3.3.2.2 Metabolic responses of A549 cells exposed to HBCD 
Polar metabolites extracted from HBCD-exposed A549 cells were analysed by direct 
infusion mass spectrometry based metabolomics. After spectral processing, the 
DIMS dataset comprised of a total of 1457 mass spectral peaks that were subjected 
to PCA to visualize the similarities and differences of the metabolic profiles between 
control and HBCD-treated groups. The PCA scores plot (Figure 3.2 B) showed no 
separation in the metabolic profiles measured from HBCD-treated and control groups 
for PC1 vs. PC2, an observation that was supported by ANOVA of the top four PC 
scores data and subsequent analysis using Tukey-Kramer's post hoc tests. These 
results (Table 3.1) indicate no separation along PC1, PC2 and PC4, though 
HBCD-treated and control samples separated along the PC3 axis (representing 4.8% 
of variance in DIMS dataset) (p =0.005). However, univariate statistical analyses of all 
1457 peaks revealed that none changed significantly in response to HBCD across all 
four concentration groups (FDR < 10%). 
3.3.3 Molecular responses of HepG2/C3A cells exposure to HBCD 
3.3.3.1 Gene expression profiles of HepG2/C3A cells exposed to HBCD 
Since no significant molecular changes had been discovered in A549 cells after 
exposure to the subtoxic HBCD concentration, HepG2/C3A cells, representing a 
system with a relatively higher xenobiotic metabolic activity, were exposed to 4 μM 
HBCD (less than 10% of EC50) and 10 μM DMBA (as a positive control to induce gene 
expression). DMBA is a polycyclic aromatic hydrocarbon with carcinogenic properties 
and a CYP1A1 -substrate. The PCA scores plot indicated no separation of the gene 
expression profiles between HBCD treated group and the control group, whereas the 
analyses distinguished marked differences between DMBA group and the rest groups 
68 
(Figure 3.4A).  
 
Figure 3.4 PCA scores plots of microarray dataset (A) and DIMS dataset (B) in 
HepG2/C3A cells exposed to 4 μM HBCD and 10 μM DMBA for 24 hours. Legend: 
controls (blue), 4 μM HBCD group (red) and 10 μM DMBA group (pink). Biological replication 
comprised n=6 (microarray) and n=6 (DIMS) in the control group and HBCD treatment groups; 
n=4 in 10 μM DMBA group (as positive control in microarray analysis). 
The statistical significance of the top four PC scores was verified by a t-test; no 
significant differences between the HBCD and control group existed, but the DMBA 
and control samples were significantly different along PC1 (representing 53.1% of the 
variance in the dataset, p=8.62x10-6). In addition, SAM of individual genes showed 
that there was no significant modulation of gene expression in the HBCD-treated 
group compared to the control group, while more than 300 probe sets changed in the 
DMBA treated group in HepG2/C3A cells (File 3.1, in Appendix).  
The functional annotation tool (DAVID) was employed to determine the most relevant 
pathway(s) or process(es) involved in these significantly dysregulated genes in the 
DMBA-treated group identified by SAM. The results (Table 3.2) suggest that p53 
signalling and apoptosis are the most significantly altered pathways in DMBA-treated 
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HepG2/C3A cells.  
Table 3.2 DAVID analysis of genes modulated in HepG2/C3A cells exposed to 
DMBA.
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GSEA showed similar results (Table 3.3) that cytokine-cytokine receptor interaction, 
p53 signalling pathway, apoptosis and metabolism of xenobiotics by CYPs are the top 
enriched gene sets in the DMBA group, while no significant enrichment of gene sets 
were identified in the HBCD-treated groups. In HepG2/C3A cells, the mRNA 
expression of six selected genes was analysed by quantitative RT- PCR. This 
revealed similar trends as measured by microarray; including a remarkable 
up-regulation of CYP1A1(175-fold, p<0.0001) and down-regulation of GJB1 (0.7-fold, 
p<0.0001) in the DMBA group, while there was no significantly altered expression of 
genes in cells treated with 4 μM HBCD, except a slightly increased expression of 
EEF1A1 (1.4-fold, p=0.004) (Figure 3.3B).  
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Table 3.3 Gene Set Enrichment Analysis of up-regulated gene sets in HepG2/C3A cells exposed to DMBA. 
 
22 gene sets (names in Bold) are significantly enriched at nominal p-value < 0.05. 24 gene sets are significantly enriched at FDR < 25%.  
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3.3.3.2 Metabolomics analysis of HepG2/C3A cells exposed to HBCD  
Polar metabolome of HepG2/C3A cells exposed to 4 μM HBCD were measured by 
DIMS. A total of 2128 mass spectral peaks were subjected to PCA and univariate 
analysis. No distinct separation was observed in the PCA scores plot (Figure 3.4 B) of 
which the top four PC scores were evaluated by t-test, confirming no significant 
differences (Table 3.1). Further t-tests on each of the 2128 individual peaks in the 
HBCD exposed group compared to the control group confirmed that there was no 
significant metabolic change in HepG2/C3A cells exposed to 4 μM HBCD for 24 hours. 
However, after extended HBCD exposure to72 hours, the subtle metabolic changes 
were found in DIMS dataset in which there were 85 (of total 3412) MS peaks 
significantly changed (Table 3.4) which is likely to be the results of extension of 
exposure time or the delayed effects of 24 hours exposure. 
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Table 3.4 Significant MS peaks in DIMS dataset from HepG2/C3A cells exposed to HBCD for 72hours. 
m/z Intensity Fold 
changes  
p value Adjusted 
p value 
Empirical 
formula 
Ion form Mass 
error 
(ppm) 
HMDB KEGG_COMPOUND 
124.00729 28262.31 0.38 1.01E-06 0.0011485 C2H7NO3S [M-H]- -0.8 Taurine Taurine 
127.05122 19331.709 0.61 0.0002001 0.0273072 C5H8N2O2 [M-H]- -0.64 5,6-Dihydrothymine', 5,6-Dihydrothymine', 
'alpha-Amino-gamma-cyanobutanoate', 
'gamma-Amino-gamma-cyanobutanoate 
166.99614 19835.911 0.69 0.000962 0.0455611 C5H6O5 [M+Na-2H]- -0.32 2-Oxoglutarate', 2-Oxoglutarate', 
'5-Hydroxy-2,4-dioxopentanoate', 
'Dehydro-D-arabinono-1,4-lactone', 
'Methyloxaloacetate', 'Oxaloacetate 4-methyl 
ester 
171.02744 43481.266 0.85 0.0008032 0.0434989 C5H10O5 [M+Na-2H]- -0.31 2-Deoxyribonic acid',     
'D-Ribose', 'D-Ribulose', 
'D-Xylose', 'D-Xylulose', 
'L-Arabinofuranose', 
'L-Arabinose',    
176.0564 7663.2379 0.56 0.001017 0.0456515 C4H7NO3 [M+Hac-H]- -0.27 'Acetylglycine', 
'L-2-Amino-3-oxobutanoic 
acid', 'L-Aspartate 
4-semialdehyde 
2-Amino-3-oxobutanoate',  
'L-2-Amino-3-oxobutanoic acid', 'L-Aspartate 
4-semialdehyde 
181.96597 3949.5365 0.55 0.0001011 0.0247906      
195.94999 6119.1374 0.74 0.0006189 0.0430959      
196.06033 2625.4167 1.02 0.0006726 0.0434989 C8H9N5 [M+Na-2H]- -0.68  
202.97286 13209.369 0.65 0.0001768 0.0262212 C4H7O6P [M+Na-2H]- 0.81  
206.01044 11861.708 0.33 5.53E-07 0.0011485      
212.06528 70909.693 0.53 0.0003918 0.036907      
213.06865 5627.8504 0.56 0.0006466 0.0432605 C11H14O2 [M+Cl]- -0.62 '5-Phenylvaleric acid', 1,1-Dimethylethyl benzoate', '1-Phenylpropyl 
acetate', '2-Phenylpropyl acetate', 
'3,5-Dimethoxyallylbenzene', '3-Phenylpropyl 
acetate', '4-t-Butylbenzoic acid', 
222.97972 7618.9158 1.35 5.53E-06 0.0037752      
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228.86057 24274.267 0.87 0.0007974 0.0434989      
230.85763 15876.586 0.96 0.0007948 0.0434989      
241.13622 11836.346 0.45 0.0009832 0.0455611      
243.97417 3979.8865 0.55 3.22E-06 0.0027488      
248.97804 5040.7756 0.59 0.0001043 0.0247906      
248.99906 15353.659 0.66 0.0011846 0.0475518      
250.02082 7117.1873 0.69 0.0010705 0.0462333      
252.90499 118476.97 0.86 0.0009056 0.0454414      
254.902 43332.246 0.86 0.0001118 0.0247906      
256.04359 25039.934 0.65 0.0011234 0.0475518      
269.00426 7401.5741 0.67 0.0011405 0.0475518 C12H10O3S [M+Cl]- -0.78  
269.97585 41616.794 0.84 0.000361 0.036907      
270.02362 13463.02 0.74 0.0004 0.036907 C8H16N3OPS [M+K-2H]- -0.59  
278.02553 17622.736 0.72 0.0003701 0.036907      
287.9864 100026.02 0.87 0.0004829 0.0398421      
294.06779 18674.228 0.4 0.0003731 0.036907 C10H15N3O5 [M+(37Cl)]- 0.57              5-Methylcytidine 
303.93145 13542.97 0.57 0.000742 0.0434989      
303.9604 23329.424 0.52 0.0007767 0.0434989      
305.07289 12985.946 0.62 0.0003938 0.036907      
307.94721 6798.1515 0.57 0.0001595 0.0249404      
309.96842 50017.327 0.77 0.0006335 0.043232      
336.90502 64825.242 0.95 0.0009553 0.0455611      
348.81943 49523.333 0.83 0.0001217 0.0247906      
350.8164 28170.606 0.83 0.0001235 0.0247906      
353.22759 9859.4717 0.7 0.0008259 0.0436666 C18H36O4 [M+(37Cl)]- -0.63 'MG(0:0/15:0/0:0)', 
'MG(15:0/0:0/0:0) 
'(9R,10R)-Dihydroxyoctadecanoic acid', 
'(9S,10S)-9,10-Dihydroxyoctadecanoate', 
358.013 5644.423 0.6 0.0007154 0.0434989      
358.95256 128404.21 0.66 0.0011591 0.0475518      
359.95573 8454.0662 0.71 0.0006016 0.0427646      
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395.24403 11680.977 0.47 0.0011733 0.0475518 C22H36O6 [M-H]- 0.29   
421.15545 33618.278 0.46 0.0004909 0.0398421      
437.30385 26265.913 0.49 0.0002997 0.036907 C27H44O3 [M+Na-2H]- 0.31 '23S,25-dihydroxyvitamin 
D3', 
'24,25-Dihydroxyvitamin 
D', 
'24R,25-Dihydroxyvitamin 
D3', '7 
alpha,24-Dihydroxy-4-chol
esten-3-one', 
'(25S)-5beta-Spirostan-3beta-ol',    
'1-alpha,24(R)-Dihydroxyvitamin D3',                   
'3beta-Hydroxy-5-cholestenoate', 
'4-Cholesten-7alpha,12alpha-diol-3-one', 
'5,6-24(S),25-Diepoxycholesterol',     
'7alpha,24-Dihydroxy-4-cholesten-3-one',  
438.30725 6840.7002 0.55 0.0001913 0.0271896      
439.30077 8120.3434 0.54 0.0003219 0.036907      
441.89656 12866.54 0.94 0.0009647 0.0455611      
445.91878 6475.9051 0.66 0.0003712 0.036907      
447.99842 3753.6685 0.86 0.0008644 0.0446863      
448.97661 6553.6893 2.02 0.0001471 0.0249404 C16H12O11S [M+(37Cl)]- 0.27   
450.00437 8486.3231 0.81 0.0009895 0.0455611      
453.98398 5791.1309 0.61 0.0010015 0.0455611      
457.98032 9909.2953 1.23 0.0005286 0.0401185      
460.20575 11499.996 0.46 0.0010671 0.0462333      
471.99569 87957.722 0.93 3.66E-05 0.0138904      
473.02089 13849.121 1.61 8.56E-07 0.0011485      
473.21805 598675.56 0.49 0.0007112 0.0434989 C26H34O8 [M-H]- -0.09   
473.99287 24843.642 0.95 0.0002493 0.0327196      
474.21511 6554.4147 0.57 0.0004002 0.036907      
474.22144 170314.69 0.5 0.0006826 0.0434989      
475.98259 34399.367 1.05 0.0001369 0.0249404      
477.97967 20608.562 1.12 0.0003051 0.036907      
479.22401 14651.462 0.43 0.0004166 0.0374101      
480.85739 13041.855 1.16 0.0010302 0.0456515      
485.94031 9478.8956 1.27 0.0008319 0.0436666      
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486.80237 44937.066 1.05 4.59E-05 0.0156771      
488.79947 59053.404 1.03 6.51E-05 0.0201971      
490.00212 58228.917 1.03 0.000698 0.0434989      
490.79667 30802.862 1.08 1.20E-05 0.0068249      
493.97226 11467.519 1.24 0.0005021 0.0398421      
501.85201 14352.645 1.27 0.0007619 0.0434989      
504.02192 6821.8271 0.82 3.66E-05 0.0138904      
504.90183 9945.2867 1.26 0.0004455 0.0389774      
511.17404 9645.0131 0.55 0.0004921 0.0398421 C26H34O8 [M+K-2H]- 0.12   
523.88112 33430.563 0.92 3.57E-05 0.0138904      
530.98007 5073.837 2.17 0.0009995 0.0455611      
533.96726 21740.72 1.05 0.0008839 0.0450127      
546.75824 45820.229 1.21 0.000733 0.0434989      
555.02414 9655.512 1.47 8.35E-05 0.0237542      
555.22117 11713.545 0.57 0.0005291 0.0401185      
555.99611 12532.507 0.81 0.00014 0.0249404      
557.9857 18065.501 0.96 0.0005515 0.0405234      
561.9805 8191.8178 1.1 0.0011624 0.0475518      
562.86044 9499.8975 1.04 0.0001608 0.0249404      
570.80277 56395.698 0.92 0.0005582 0.0405234      
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3.3.4 Uptake of HBCD into A549 and HepG2/C3A cells  
The recovery of HBCD from cell pellets and the concentrations of HBCD in the cell 
media were evaluated, with the objective to facilitate comparisons between the 
concentrations of HBCD in the present study and those reported in human tissue and 
biofluids.  
The results (Figure 3.5) show that when cultured in FBS-containing media, an average 
of 12.4% of the nominal amount of HBCD added to the exposure system was detected 
in A549 cell pellets, while in those cell pellets collected from the FBS-free media, 
approximately double the amount (20.9%) was measured in the cells. In HepG2/C3A 
cells, recoveries of HBCD from cell pellets exposed in FBS-containing or FBS free 
media were considerably higher, and similar, 50.7% and 48.1% respectively. This 
suggested that the capacity for HepG2/C3A cells to uptake HBCD was higher than for 
A549 cells. As shown in Table 3.5, the average concentrations of HBCD in A549 cell 
pellets were 15.9 and 27.5 ng mg-1 (wet weight) from FBS-containing exposure media 
and FBS-free media, respectively. However, the average concentrations of HBCD in 
HepG2/C3A cells from FBS-containing media and FBS-free media were 96.2 and 99.0 
ng mg-1 (wet weight) respectively, which were much higher than in A549 cells.  
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Figure 3.5 Recovery of HBCD from cell pellets in A549 cells and HepG2/C3A cells 
exposed to HBCD for 24 hours. A549 cells and HepG2/C3A cells were treated with 2 μM 
and 4 μM HBCD, respectively, in both serum (FBS)-containing media and serum-free media 
(without FBS). Recoveries are expressed as the percentage of detectable amount of HBCD 
from cell pellets and cell media after exposure, relative to the total nominal amount of HBCD 
added to the exposure media ± standard deviation (n=3). 
 
Table 3.5 Concentration of ΣHBCDs in cell pellets and cell media of A549 and 
HepG2/C3A cells after 24-hour exposure  
 
In addition to affecting uptake in A549 cells, the presence of FBS in the media also 
Cell types Types of 
Exposure 
Media
Nominal 
concentration of 
ΣHBCDs in 
exposure media
Average wet 
weight of cell 
pellets (mg)
Concentratio
n of SHBCDs 
in cell pellets 
(ng/mg )
Total amount of 
SHBCDs in cell 
pellets (ng)
Concentration of 
SHBCDs in cell 
media after 
exposure (ng/mL)
No FBS 2 μM (1283.4 ng/mL) 19.8 ± 3.3 27.5 ± 5.0 535.6 ± 71.2 46.9 ± 7.4
10% FBS 2 μM (1283.4 ng/mL) 19.8 ± 4.0 15.9 ± 1.7 319.2 ± 93.2 1133.7 ± 26.8
No FBS 4 μM (2566.8 ng/mL) 25.4 ± 3.1 99.0 ± 26.0 2470.8 ± 488.7 409.9 ± 77.8
5% FBS 4 μM (2566.8 ng/mL) 27.2 ± 2.8 96.2 ± 10.5 2601.7 ± 115.2 939.7 ± 124.3
A549
HepG2/C3A
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affected the post-exposure concentrations of HBCD in the cell media itself. In A549 
cells, following the 24-hour exposures, the concentration of HBCD in 10% 
FBS-containing media was 1133.7 ng/mL (Table 3.5), which is more than 20 times 
higher than HBCD measured in the FBS-free media. There was a similar difference in 
HepG2/C3A cell media (Table 3.5) where the concentration of HBCD in 5% 
FBS-containing media were considerably higher than in FBS-free media (939.7 ng/mL 
versus 409.9 ng/mL, respectively).  
3.4 Discussion 
The widespread use of HBCD has given rise to increasing health concerns following 
human exposure via various routes. Inhalation has been considered as one (albeit 
minor) pathway of human exposure to HBCD (Marvin et al., 2011). There is therefore a 
particular interest in investigating effects in lung cells as this organ has relatively high 
exposure and in liver cells that play a critical role in the detoxification (or activation) of 
xenobiotic chemicals and in which protective compensatory changes are often seen. 
A549 lung epithelial cells and HepG2/C3A liver cells were thus selected as in vitro 
models to investigate the potential toxic effects of HBCD in this study.  
The EC50 value of cytotoxicity of HBCD to HepG2/C3A cells in this study (63.0 μM) was 
similar to the value observed in HepG2 cells exposed to HBCD (ca. 50 μM)(Hu et al., 
2009) ), with both studies conducted containing serum in the exposure media. 
Furthermore, in the immortalised human hepatocyte L02 cell line, the EC50 for a 
24-hour exposure to HBCD was reported as ca. 60 μM (An et al., 2013). Hence, the 
EC50 value for this hepatic cell line treated with HBCD is consistent with previously 
published values, for the case of exposures conducted in the presence of serum which 
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more closely reflects the in vivo situation. 
However, in the absence of FBS in the exposure media, the EC50 values of HBCD was 
reported as being as low as ca. 3 μM in neuronal cell lines (Al-Mousa and Michelangeli, 
2012; Reistad et al., 2006). The discrepancy between these reported EC50 values 
might be explained by differences in the cell type or different levels of serum in the 
exposure media. The higher serum protein levels could result in a reduction in the free 
concentration of xenobiotic such as phenanthrene, a hydrophobic polycyclic aromatic 
hydrocarbon (PAH), accompanied by an increase in the EC50 (Kramer et al., 2012). 
Free concentrations of compounds are believed to be appropriate to characterise the 
toxic potency of a chemical in vitro which may be used for in vivo extrapolation (Gülden 
et al., 2013). In the present study, the concentrations of HBCD in cell pellets and cell 
media after exposure were quantified by LC-MS/MS. The lowest concentration of 
HBCD detected in A549 cell pellets after exposure was ca. 15 ng/mg cell pellet (wet 
weight) (Table 3.5), which is equal to 750,000 ng/g lipid (assuming 2% lipids in cell 
pellets which is similar to the lipid content in human liver (Rawn et al., 2014a)). This is 
several hundred times higher than the highest concentrations reported in human fetal 
liver (4,500 ng/g lipid, median value: 29 ng/g lipid) and placental tissue (5,600 ng/g lipid, 
median value: 49 ng/g lipid)(Rawn et al., 2014a). Thus, taking account of the EC50 
values of HBCD in cells (63 μM in HepG2/C3A cells in this study), the concentrations 
achieved in cells that cause cytotoxicity are vastly higher than those reported in human 
tissues. In addition, mitochondrial reductive activity (MTT assay) and the integrity of the 
cell membrane (AK assay) in proliferating cells were disrupted by 60 μM HBCD to a 
greater extent than in confluent cells (Figure 3.6 A and B). However, cell protein content 
was not significantly changed in the group exposed to 60 μM HBCD for 24 hours 
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compared to the control group in either proliferating cells or confluent cells (Figure 3.6 
C). This suggests that 60 μM HBCD has no significant effects on cell proliferation of 
HepG2/C3A cells but that proliferating cells were more susceptible to HBCD toxicity. 
 
Figure 3.6 Cytotoxic effects of proliferating and confluent HepG2/C3A cells 
exposed to 60 μM HBCD and 10 μM DMBA for 24 hours. HepG2/C3A cells at various 
seeding density (A: 10,000cells/well; B: 20,000cells/well; C: 40,000cells/well and D: 
60,000cells/well) were exposed to 60 μM HBCD or 10 μM DMBA for 24 hours. Mitochondrial 
enzyme activity and AK release of different density cells were measured by CCK-8 assay (a) 
and AK assay (b) (each bar represent at least three independent experiments).Total protein 
content was evaluated by BioRad DC Protein Assay (c) (each bar represents six replicates). 
Results of the CCK-8 assay, AK assay and protein assay were expressed as the percentage of 
the unexposed control ± standard error (SE). Solvent control values were set as 100%. 
Molecular responses in terms of transcriptomic and metabolic levels were also 
assessed. Particular attention was given to cytochrome P450 monooxygenases (CYPs) 
that play critical roles in biotransformation activities and the induction of which is a 
common response to organic toxicants (Danielson, 2002). Forty probe sets 
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(representing 35 mRNAs of CYPs) were detected in the A549 microarray dataset 
(Table 3.6), whereas 43 probe sets (representing 33 mRNAs of CYPs) in HepG2/C3A 
microarray dataset (Table 3.7). CYP1A1 and CYP3A4 are two particularly important 
members in phase I metabolism of aromatic hydrocarbons. The induction of CYP1A1 
mRNA expression has been used as an indicator of exposure to PAH 
(Castorena-Torres et al., 2008). In the present study, HBCD did not induce mRNA 
expression for either of these CYP genes in A549 cells or HepG2/C3A cells after a 
24-hour exposure in contrast to the marked induction of CYP1A1 (175-fold) observed 
in response to DMBA treatment in HepG2/C3A cells.  
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Table 3.6 Gene expression of CYPs in A549 cells exposed to HBCD for 24 hrs 
from microarray dataset. 
Gene Symbol Accession 
No. 
Control Very Low Low Medium High 
CYP11A1 transcript 
variant 1 
[NM_000781] 1.00±0.13 1.13±0.13 1.14±0.11 1.14±0.14 1.15±0.13 
CYP11B1 transcript 
variant 1 
[NM_000497] 1.00±0.51 0.86±0.20 1.14±0.62 1.00±0.27 0.99±0.31 
CYP11B2  [NM_000498] 1.00±0.15 0.99±0.12 0.97±0.19 1.25±0.34 1.11±0.39 
CYP17A1  [NM_000102] 1.00±0.10 1.08±0.06 1.09±0.06 1.00±0.08 1.12±0.12 
CYP19A1 transcript 
variant 2  
[NM_031226] 1.00±0.25 0.89±0.13 0.91±0.23 0.92±0.18 0.94±0.13 
CYP19A1 transcript 
variant 2  
[NM_031226] 1.00±0.64 0.67±0.15 0.62±0.21 1.43±1.58 0.61±0.11 
CYP21A2 transcript 
variant 1 
[NM_000500] 1.00±0.10 0.93±0.08 0.96±0.11 0.96±0.07 1.07±0.16 
CYP21A2 transcript 
variant 2  
[NM_0011285
90] 
1.00±0.13 1.08±0.16 1.05±0.12 1.08±0.09 1.09±0.16 
CYP24A1  [NM_000782] 1.00±0.09 0.94±0.19 0.99±0.08 0.89±0.21 1.00±0.08 
CYP26B1  [NM_019885] 1.00±0.12 0.98±0.08 0.90±0.16 1.20±0.17 1.05±0.13 
CYP27A1 [NM_000784] 1.00±0.24 1.02±0.34 0.99±0.22 1.00±0.28 1.13±0.55 
CYP27C1 
[NM_0010016
65] 
1.00±0.19 1.32±1.02 0.91±0.27 1.16±0.42 1.12±0.55 
CYP2A13  [NM_000766] 1.00±0.07 1.02±0.08 1.06±0.04 1.04±0.16 1.12±0.19 
CYP2A7 transcript 
variant 1  
[NM_000764] 1.00±0.19 0.96±0.26 0.99±0.23 0.89±0.24 1.11±0.53 
CYP2B6  [NM_000767] 1.00±0.06 1.05±0.15 1.01±0.07 0.96±0.13 1.01±0.10 
CYP2C18 transcript 
variant 1 
[NM_000772] 1.00±0.17 1.00±0.23 0.92±0.23 0.76±0.07 0.88±0.13 
CYP2C19 [NM_000769] 1.00±0.47 0.87±0.04 0.95±0.17 0.87±0.07 0.88±0.06 
CYP2C8 transcript 
variant 1 
[NM_000770] 1.00±0.51 0.91±0.24 0.85±0.11 0.87±0.06 0.81±0.07 
CYP2C9 [NM_000771] 1.00±0.17 0.96±0.30 0.89±0.20 0.88±0.27 0.94±0.18 
CYP2D6 transcript 
variant 1 
[NM_000106] 1.00±0.12 1.06±0.28 0.96±0.10 0.96±0.18 1.00±0.10 
CYP2D6 transcript 
variant 1 
[NM_000106] 1.00±0.12 1.04±0.14 1.16±0.14 1.03±0.11 1.07±0.09 
CYP2F1 [NM_000774] 1.00±0.21 0.95±0.08 1.17±0.22 1.07±0.43 1.27±0.40 
CYP39A1  [NM_016593] 1.00±0.45 0.75±0.12 0.77±0.22 0.78±0.18 0.64±0.14 
CYP3A4 transcript 
variant 1 
[NM_017460] 1.00±0.10 1.00±0.08 0.98±0.11 0.95±0.12 1.03±0.14 
CYP3A43 transcript 
variant 1 
[NM_022820] 1.00±0.18 1.20±0.39 0.91±0.24 0.89±0.11 1.11±0.38 
CYP3A5 transcript 
variant 2  
[NM_0011904
84] 
1.00±0.19 0.95±0.22 1.06±0.06 1.15±0.22 1.16±0.65 
CYP46A1  [NM_006668] 1.00±0.25 1.07±0.22 0.96±0.12 0.99±0.29 0.98±0.14 
CYP4A11  [NM_000778] 1.00±0.04 1.17±0.17 1.21±0.17 1.17±0.18 1.19±0.29 
CYP4A11 [NM_000778] 1.00±0.09 0.97±0.05 0.93±0.10 0.94±0.06 0.92±0.09 
CYP4A22  
[NM_0010109
69] 
1.00±0.18 1.16±0.13 1.12±0.13 1.21±0.18 0.98±0.20 
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CYP4B1 transcript 
variant 2 
[NM_000779] 1.00±0.37 2.44±2.15 1.48±1.32 2.50±2.38 2.50±2.69 
CYP4F11 transcript 
variant 1  
[NM_021187] 1.00±0.08 0.91±0.11 0.90±0.09 0.97±0.09 0.98±0.13 
CYP4F2  [NM_001082] 1.00±0.12 0.95±0.06 0.89±0.10 0.93±0.10 0.88±0.10 
CYP4F2  [NM_001082] 1.00±0.46 0.88±0.20 0.80±0.31 0.86±0.51 1.49±1.44 
CYP4F22  [NM_173483] 1.00±0.84 0.90±0.42 0.90±0.46 0.78±0.20 0.93±0.45 
CYP4V2  [NM_207352] 1.00±0.13 0.91±0.14 0.94±0.17 0.98±0.14 0.99±0.17 
CYP4Z1 [NM_178134] 1.00±0.86 7.52±10.50 1.50±1.99 0.31±0.06 0.67±0.91 
CYP4Z1   [NM_178134] 1.00±0.2 1.00±0.07 0.89±0.12 0.94±0.20 1.03±0.09 
CYP7A1  [NM_000780] 1.00±0.07 1.00±0.15 0.98±0.11 0.94±0.16 0.96±0.10 
CYP8B1  [NM_004391] 1.00±0.19 1.06±0.23 1.44±0.58 1.58±1.55 1.12±0.25 
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Table 3.7 Gene expression of CYPs in HepG2/C3A cells exposed to HBCD and 
DMBA for 24 hours from microarray dataset.  
Gene Symbol Accession No. Control HBCD DMBA 
CYP2A13 [AY513606] 1.00 ±0.08 0.89 ±0.42 1.16 ±0.13 
CYP1A1 [NM_000499] 1.00 ±0.27 0.78 ±0.27 26.26±3.10  
CYP1A2 [NM_000761] 1.00 ±0.07 0.88 ±0.40 2.14 ±0.09 
CYP11A1,transcript variant 1 [NM_000781] 1.00 ±0.05 0.92 ±0.44 0.99 ±0.08 
CYP17A1 [NM_000102] 1.00 ±0.10 0.85 ±0.38 0.98 ±0.11 
CYP19A1, transcript variant 2, [NM_031226] 1.00 ±0.05 0.86 ±0.41 1.16 ±0.07 
CYP19A1, transcript variant 2 [NM_031226] 1.00 ±0.12 0.81 ±0.36 0.91 ±0.04 
CYP2A13 [NM_000766] 1.00 ±0.08 0.86 ±0.41 0.94 ±0.08 
CYP2B6 [NM_000767] 1.00 ±0.07 0.98 ±0.45 1.62 ±0.08 
CYP2B6 [NM_000767] 1.00 ±0.03 0.88 ±0.43 1.07 ±0.05 
CYP2D6, transcript variant 1 [NM_000106] 1.00 ±0.10 0.86 ±0.38 0.92 ±0.08 
CYP2D6, transcript variant 1, [NM_000106] 1.00 ±0.13 0.91 ±0.41 0.95 ±0.18 
CYP2J2 [NM_000775] 1.00 ±0.10 0.88 ±0.39 1.10 ±0.08 
CYP2R1 [NM_024514] 1.00 ±0.10 0.81 ±0.36 1.14 ±0.07 
CYP2S1 [NM_030622] 1.00 ±0.12 0.93 ±0.39 1.29 ±0.15 
CYP2S1 [NM_030622] 1.00 ±0.07 0.93 ±0.43 1.37 ±0.10 
CYP2W1 [NM_017781] 1.00 ±0.06 0.81 ±0.37 0.87 ±0.07 
CYP20A1 [NM_177538] 1.00 ±0.06 0.84 ±0.39 1.00 ±0.17 
CYP20A1 [NM_177538] 1.00 ±0.04 0.84 ±0.39 0.96 ±0.08 
CYP21A2, transcript variant 1 [NM_000500] 1.00 ±0.05 0.85 ±0.39 2.09 ±0.17 
CYP21A2, transcript variant 2, [NM_001128590] 1.00 ±0.06 0.76 ±0.35 1.06 ±0.31 
CYP24A1,transcript variant 1, [NM_000782] 1.00 ±0.08 0.91 ±0.44 1.39 ±0.11 
CYP24A1,transcript variant 1, [NM_000782] 1.00 ±0.15 0.93 ±0.39 1.82 ±0.55 
CYP26A1, transcript variant 2, [NM_057157] 1.00 ±0.26 1.08 ±0.48 1.86 ±0.28 
CYP27A1 [NM_000784] 1.00 ±0.02 0.86 ±0.41 0.97 ±0.07 
CYP27B1 [NM_000785] 1.00 ±0.06 0.84 ±0.38 0.98 ±0.07 
CYP3A4, transcript variant 1 [NM_017460] 1.00 ±0.10 0.93 ±0.43 1.05 ±0.11 
CYP3A5, transcript variant 1 [NM_000777] 1.00 ±0.04 0.88 ±0.41 1.60 ±0.09 
CYP3A5, transcript variant 2 [NM_001190484] 1.00 ±0.22 1.01 ±0.43 1.66 ±0.22 
CYP3A7 [NM_000765] 1.00 ±0.06 0.93 ±0.43 1.37 ±0.07 
CYP3A7 [NM_000765] 1.00 ±0.09 0.89 ±0.40 1.42 ±0.07 
CYP4A11 [NM_000778] 1.00 ±0.10 0.92 ±0.43 1.16 ±0.07 
CYP4A11 [NM_000778] 1.00±0.12 0.76 ±0.33 0.80 ±0.10 
CYP4F11, transcript variant 1 [NM_021187] 1.00 ±0.09 0.89 ±0.40 1.58±0.11 
CYP4F11, transcript variant 1 [NM_021187] 1.00 ±0.10 0.90 ±0.41 1.44 ±0.26 
CYP4F12 [NM_023944] 1.00 ±0.10 0.80 ±0.35 1.15 ±0.14 
CYP4F2 [NM_001082] 1.00 ±2.14 0.16 ±0.06 0.14 ±0.03 
CYP4F2 [NM_001082] 1.00 ±0.09 0.82 ±0.36 1.44 ±0.07 
CYP4F3, transcript variant 1 [NM_000896] 1.00 ±0.08 0.83 ±0.37 1.43 ±0.11 
CYP4F8 [NM_007253] 1.00 ±0.05 0.81 ±0.38 1.13 ±0.05 
CYP4V2 [NM_207352] 1.00 ±0.09 0.80 ±0.37 0.98 ±0.15 
CYP51A1, transcript variant 1 [NM_000786] 1.00 ±0.04 0.83 ±0.39 0.84 ±0.05 
CYP8B1 [NM_004391] 1.00 ±0.07 0.89 ±0.41 0.91 ±0.03 
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Several studies have reported that CYP3A4 is not expressed in A549 cells (Courcot et 
al., 2012; Hukkanen et al., 2000). However, in a recent study, the expression of 
CYP3A4 was induced by 5 μM of the PAH benzo[a]pyrene (B[a]P) in A549 cells 
exposed for 14 hours, but not in HepG2 cells (Genies et al., 2013). Fery et al. (2009) 
also reported that HBCD failed to induce CYP3A enzyme activity in HepG2 cells, but a 
significant induction was observed in primary cultured rat hepatocytes. In this study, 
mRNA expression of CYP3A4 was detected in both A549 and HepG2/C3A cells, and 
this was slightly down-regulated after a 24-hour exposure to 20 nM and 200 nM HBCD 
in A549 cells while there were no significant changes in HepG2/C3A cells. These 
observations show a noticeable contrast between HBCD and DMBA in the induction of 
CYP expression.  
The effects observed with DMBA are markedly different from those following HBCD 
exposure despite the latter showing intracellular accumulation. The extensive 
modification of the transcriptome as seen with DMBA includes evidence of a significant 
stress response at sub-toxic concentrations. These responses include the changes in 
CYP expression as mentioned above plus a range of other responses in the expression 
of genes involved in (e.g. apoptosis, regulation of cell proliferation, etc.). Neither two 
cell types showed this stress response to HBCD. This might be interpreted as a failure 
to react in a compensatory mode for protective purposes since no such response is 
seen right up to the concentrations that exhibit a toxic effect in the MTT assay or CCK-8 
assay.  
Few detectable transcriptomic and metabolomic responses after 24 hours exposure 
might be due to missing the time window of some defensive or protective events. It has 
been reported that levels of CYP1A1 mRNA in A549 and HepG2 cells were modulated 
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by B[a]P at an early stage of exposure (less than 4 or 6 hours) but not beyond (Genies 
et al., 2013). Likewise, potential molecular responses after a relatively longer exposure 
may reflect potential chronic toxicity. van der Ven et al.(2006) reported that 28 days 
exposure to HBCD at a relatively high dose (30 mg/kg/day) increased liver weight in 
female rats and induced hepatic CYP enzyme activities (CYP2B1 and CYP3A1) in rats 
(Cantón et al., 2008; Germer et al., 2006). However, a 72-hour exposure at relative low 
concentration (2 to 200 nM) did not significantly change the survival rate and the 
malformation rate in zebrafish embryos (Wu et al., 2013). In the present study, 
additional DIMS analysis suggested possible metabolic changes (e.g. decrease of 
taurine) after 72hours exposure in HepG2/C3A cells exposed to 4 μM HBCD, which 
might be responsive to stress after longer exposure or the delayed effects of 24 hours 
exposure.  
3.5 Conclusions 
‗Omics approaches were used to determine the potential molecular changes in two cell 
lines after exposure to HBCD over a wide range of concentrations in the presence of 
serum. Few molecular changes were observed in the ‗omics data despite employing 
cellular concentrations of HBCD up to several hundred times higher than those 
reported in human tissues and concentrations that approached cytotoxic levels. In 
contrast to the findings for the PAH, there was little evidence of a compensatory stress 
response to HBCD such as elevation of CYP or antioxidant systems. This lack of 
compensatory response does not equate to a lack of protection since cytotoxicity 
(mitochondrial dysfunction and loss of cell integrity) was only observed in HepG2/C3A 
cells exposed to a high concentration of HBCD (60 μM), at which the cellular 
concentrations achieved exceeded, by several orders of magnitude, the tissue 
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concentrations observed in environmentally exposed organisms. 
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CHAPTER 4   Transcriptomic and 
metabolomic responses of human 
cell lines exposed to tris (1, 
3-dichloro-2-propyl) phosphate 
(TDCIPP)* 
 
 
 
*The content of this chapter has been accepted for publication in Journal of Applied 
Toxicology: Zhang, J., Williams, T.D., Chipman, J.K., Viant, M.R., 2015. Defensive and 
adverse energy-related molecular responses precede Tris (1, 3-dichloro-2-propyl) 
phosphate (TDCIPP) cytotoxicity. Journal of Applied Toxicology. DOI 10.1002/jat.3194.  
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4.1 Introduction 
Tris (1,3-dichloro-2-propyl) phosphate (TDCIPP) is a high volume production PFR 
which is added to flexible polyurethane foam in the automotive upholstery, foams for 
household furniture and other commercial products, i.e. beddings (van der Veen and 
de Boer, 2012). Stapleton et al. (2012) reported that TDCIPP is one of the most 
abundant PFRs in foam from residential couches in the United States, with an average 
concentration of 44.87mg/g.  
Similar to other additive FRs, TDCIPP is not chemically bound to the material it protects 
and can leach out from the products to the environment more easily than reactive FRs. 
TDCIPP has been detected in a wide range of environmental media, i.e. surface water, 
sediment, biota, air and dust (van der Veen and de Boer, 2012). For example, Carignan 
et al. ( 2013) found that the TDCIPP level in office dust samples from Boston, USA was 
up to 72 μg/g. The average concentration of TDCIPP in car dust in Germany was 130 
μg/g (Brommer et al., 2012). The high prevalence of TDCIPP in dust samples suggests 
that it could contribute as a source of human exposure to TDCIPP within indoor or 
enclosed environments ( Stapleton & Klosterhaus, 2009; van der Veen & de Boer, 
2012), especially for toddlers who may have more dust exposure due to frequent 
hand-mouth behaviour (Butt et al., 2014). The half-life of TDCIPP in humans is 
believed to be as short as several hours or a few days (Carignan et al., 2013). However, 
because of the long lifespan of commercial products that contain FRs, human 
exposure is likely to last for years, even decades (Betts, 2013). 
Although, in a risk assessment report, TDCIPP has been classified as a safe 
compound for its intended application (European Union, 2008), it has also been listed 
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as a carcinogen in the Proposition 65 list by the California Environmental Protection 
Agency (OEHHA, 2013). The evidence for TDCIPP‘s carcinogenicity via a genotoxic 
mechanism(s) has been building (OEHHA, 2011). For example, positive evidence for 
genotoxicity was found in in vitro tests including mutagenicity in multiple strains of 
Salmonella (Gold et al., 1978), chromosomal aberrations and sister chromatid 
exchanges in mouse (Mus musculus) lymphoma cells (Brusick et al., 1979) and weakly 
unscheduled DNA synthesis in rat (Rattus norvegicus) hepatocytes (Sederlund et al., 
1985), though negative results were also found in most in vivo genotoxicity studies 
(OEHHA, 2011). As such, it has been suggested that there is  insufficient information 
to date to determine whether or not TDCIPP induces cancer in humans (ATSDR, 2012). 
However, in rats, exposure to TDCIPP can increase the rate of formation of tumours at 
multiple sites (i.e. liver, kidney and testicles) (Freudenthal and Henrich, 2000).  
Recent in vitro and in vivo studies have suggested that TDCIPP is likely to be 
endocrine disrupting and neurotoxic. Meeker and Stapleton (2010) reported that 
altered thyroxine levels and decreased semen quality in men might be linked to 
exposure to TDCIPP. Other studies found that exposure to TDCIPP can change thyroid 
hormone concentrations in chicken (Gallus gallus) embryos (Farhat et al., 2013) and 
zebrafish (Danio rerio) (Wang et al., 2013) and alter sex hormone levels in human 
H295R cell lines and zebrafish (Liu et al., 2012). Dysregulation of gene expression 
related to thyroid hormone metabolism was found in zebrafish (Wang et al., 2013) and 
avian hepatocytes (Crump et al., 2012). TDCIPP displays androgen receptor (AR), 
glucocorticoid receptor (GR) and pregnane X receptor (PXR) antagonistic activities in 
cell-based transactivation assays (Kojima et al., 2013). Concentration-dependent 
neurotoxicity was observed in rat PC12 cells. For example, oxidative stress increased 
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following 50 μM TDCIPP treatment (Dishaw et al., 2011), while dysregulation of gene 
and protein expression related to apoptosis, neurite growth and synapse formation 
were observed after TDCIPP exposure which could disrupt neurodevelopment (Ta et 
al., 2014). Limited studies of the hepatic toxicity of TDCIPP were focussed on chicken 
embryonic hepatocytes or liver; in which phase I and II xenobiotic-metabolizing 
enzymes were elevated after TDCIPP exposure (Crump et al., 2012; Farhat et al., 
2014a).  
To assist in the assessment of effects following human exposure to TDCIPP, 
toxicogenomic responses of two human cell lines (HepG2/C3A and A549 cells) were 
investigated. Specifically, microarray based transcriptomics and direct infusion mass 
spectrometry (DIMS) based untargeted metabolomics were employed to explore the 
potential adverse effects of TDCIPP at sub-cytotoxic concentrations and to help 
elucidate the mechanisms of action of this PFR in these two human cell lines. 
Therefore, the aims of this chapter were (1) to examine the gene expression and 
metabolic profiles of these cell lines exposed to several concentrations of TDCIPP, and 
(2) to explore the molecular mechanisms of any toxicity in these human cell lines. 
4.2 Materials and Methods  
4.2.1 Chemicals and reagents 
All chemicals, including tris (1, 3-dichloro-2-propyl) phosphate (CAS Number: 
13674-87-8, purity >97%) were obtained from Sigma-Aldrich Chemical Company 
(Dorset, UK) unless otherwise stated. 
4.2.2 Cell culture 
HepG2/C3A cells were generously provided by Prof. R. Blust from the University of 
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Antwerp, Belgium. HepG2/C3A cells and A549 cells were cultured as described 
previously (Section 2.2).  
4.2.3 Cytotoxicity assay 
To assess the cytotoxicity of TDCIPP to HepG2/C3A cells and A549 cells, the CCK-8 
assay, which assesses mitochondrial reductive activity, was applied following the 
manufacturers‘ instructions (Dojindo Laboratories, Kumamoto, Japan) as described in 
Section 2.3.2. Briefly, HepG2/C3A cells (2× 104 cells per well) and A549 cells (1× 104 
cells per well) were seeded into 96-well plates overnight and the cells were treated in 
six replicates with various concentrations (1, 5, 10, 25, 50, 100, 200 and 500 μM) of 
TDCIPP in the media containing FBS for 24 hours or 72 hours. In parallel, a group of 
HepG2/C3A cells were exposed to the same concentrations of TDCIPP for 24 hours 
but in FBS-free media. The solvent control group were treated with 0.5% DMSO (v/v) 
and considered 100% viable. The cell viability was calculated at each concentration of 
TDCIPP. The half maximal effective concentration (EC50) values were calculated 
according to the plotted concentration-response curves.  
4.2.4 Design of exposure experiment 
HepG2/C3A cells and A549 cells were seeded into 6-well plates at cell density of 1×106 
and 8×105 cells/well respectively. After overnight acclimatisation, cells were exposed to 
different concentrations of TDCIPP (Low Concentration: 1 μM; Medium Concentration: 
10 μM and High Concentration: 100 μM) for 24 hours. In order to evaluate the effects of 
exposure time, 72-hour exposures were also conducted for HepG2/C3A cells using the 
same TDCIPP concentrations. In addition, a batch of HepG2/C3A cells was exposed to 
the same concentrations of TDCIPP for 24 hours employing FBS-free media.  
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For metabolomics analysis, eight biological replicates were used in each concentration 
group per treatment condition. For transcriptomics analysis, only HepG2/C3A cells and 
A549 cells exposed to 10 μM (Medium concentration) and 100 μM (High concentration) 
in the FBS-containing media for 24 hours were analysed (n=4). The solvent control 
groups in each treatment condition were treated with 0.5% DMSO (v/v) with the same 
number of replicates for omics analyses (Table 4.1).  
Table 4.1 Experimental design of TDCIPP exposure experiment. 
 
Numbers in this table indicate the biological replicates number in metabolomics analysis (n=8) 
and numbers in parentheses refer to the number of biological replicates in transcriptomics 
analysis (n=4). 
4.2.5 Transcriptomics analysis  
After 24 hours exposure, HepG2/C3A cells and A549 cells were harvested after rapid 
washing twice with PBS. Cell pellets were collected and quenched in liquid nitrogen for 
transcriptomics analysis. Total RNA of cells was extracted using Qiagen‘s mini RNeasy 
Kit and QIAshredder (Qiagen, Crawley, UK) as described in Section 2.4.1 
The procedures for microarray analysis were performed following the manufacturer's 
protocols as described in Section 2.4.2. Microarray datasets of this study are available 
from the ArrayExpress database under accession number: E-MTAB-3323. Quantitative 
Reverse Transcription PCR (qPCR) analysis was performed to quantify the mRNA 
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expression of six selected genes in HepG2/C3A or A549 cells exposed to TDCIPP as 
described in Section 2.4.3. 
4.2.6 Metabolomics analysis 
After 24 hours or 72 hours exposure, cells were harvested and metabolites were 
extracted as described earlier in Section 2.5.1.2. Briefly, cells were quickly washed with 
PBS twice before the 6-well plates were quenched on liquid nitrogen. Then, 
metabolites were extracted by liquid-liquid extraction method (methanol: chloroform: 
water (v/v/v) was 1:1:0.9). After centrifuge, polar phases were collected and dried until 
for direct infusion mass spectrometry (DIMS) analysis which was described in Section 
2.5.2 including statistical analysis of DIMS data. Putative annotation of significantly 
changed DIMS peaks were performed by using the metabolite annotation package 
MI-Pack (Weber and Viant, 2010) as described in 2.5.3.  
4.3 Results  
4.3.1 Cytotoxicity of TDCIPP to HepG2/C3A cells and A549 cells 
The cytotoxicity of TDCIPP to HepG2/C3A cells and A549 cells was evaluated using 
the CCK-8 assay. Concentration-response curves are shown in Figure 4.1. The EC50 
values of TDCIPP to HepG2/C3A cells and A549 cells cultured in the FBS-containing 
media were 167.9 μM and 193.1 μM, respectively. In serum-free media, the EC50 value 
in HepG2/C3A cells was 202.4 μM,. However, after an extended exposure of 72 hours, 
the EC50 value in HepG2/C3A cells (84.0 μM) declined noticeably compared to a 
24-hour exposure which indicates that the extended exposure enhances the 
cytotoxicity of TDCIPP. There were minimal cytotoxic effects at concentrations ranging 
from 1 to 100 μM in both cell lines exposed to TDCIPP for 24 hours, but after a 72-hour 
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exposure, 100 μM TDCIPP caused obvious cytotoxic effects with an onset at ca. 10 μM 
in HepG2/C3A cells. 
 
Figure 4.1 Cytotoxic effects of TDCIPP to HepG2/C3A cells and A549 cells. Cell 
viability of and HepG2/C3A and A549 cells  was examined by using CCK-8 assays after 
exposure to different concentrations (1, 5, 10, 25, 50, 100, 200 and 500 μM) of TDCIPP in 
FBS-containing media or FBS-free media for 24 or 72 hours, respectively. Results are 
expressed as the percentage of cell viability compared to controls treated with the appropriate 
vehicle (0.5% DMSO (v/v)). Data represent mean ± SD (n=6) (EC50 = 167.9 μM, 202.4 μM, 84.0 
μM and 193.1 μM)) (diamond represents HepG2/C3A_24hr-FBS; triangle represents 
HepG2/C3A_24hr +FBS; square box represents HepG2/C3A_72hr+FBS; circle represents 
A549_24hr+FBS.) 
Using these concentration-response curves (Figure 4.1) and EC50 values, several 
concentrations were selected for the omics studies. These included Low (1μM) and 
Medium (10μM), which represent sub-cytotoxic concentrations in the present study, 
and a High concentration (100μM) at which cytotoxic effects were known to occur by 72 
hour. 
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4.3.2 Omics effects of TDCIPP on HepG2/C3A and A549 cells  
4.3.2.1 Transcriptomic responses of HepG2/C3A and A549 cells exposed to 
TDCIPP for 24 hours 
Oligonucleotide microarrays were employed to investigate the gene expression profiles 
of HepG2/C3A and A549 cells exposed to 10 μM (Medium Concentration) and 100 μM 
(High Concentration) TDCIPP for 24 hours. PCA analysis of these microarray datasets 
(Figure 4.2) showed a distinct difference between the High concentration group and all 
other groups in both cell lines.  
 
Figure 4.2 PCA scores plot of all genes of HepG2/C3A and A549 cells exposed to 
TDCIPP for 24 hours (n=4). Legend: circles represent HepG2/C3A cells treated with 
TDCIPP for 24 hours with FBS in the exposure media, squares represent A549 cells treated 
with TDCIPP for 24 hours in the presence of FBS, red represents the High concentration group, 
pink the Medium concentration group, and blue are the control group. 
Similarly, the results of univariate analyses showed there were 5320 probes altered 
significantly at High concentration in HepG2/C3A cells and 2803 probes at High 
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concentration in A549 cells (File 4.1, in Appendix). However, there were no significant 
changes in individual gene expression in the Medium concentration group for either 
HepG2/C3A or A549 cells. DAVID analysis showed that the significantly differentially 
expressed genes in High concentration groups in HepG2/C3A cells were related to 
regulation of transcription, mitochondrion, lipid metabolism and amino acid metabolism 
related pathways (File 4.2, in Appendix). In A549 cells, DAVID analysis of significantly 
modulated genes revealed up regulation of apoptosis and down regulation of cell cycle 
related pathways (File 4.2, in Appendix) after exposure to High concentration TDCIPP. 
Gene Set Enrichment Analysis was then employed to explore any potential changes of 
gene sets where the subtle changes of individual genes may not be significant in 
classic univariate statistical analysis. Interestingly, the results of GSEA (Table 4.2) 
revealed that genes involved in oxidative phosphorylation and cell cycle pathways were 
down-regulated subtly in the Medium concentration group in HepG2/C3A cells, and to a 
greater extent in High concentration groups, while the Medium concentration group of 
A549 cells shared similar results. However, xenobiotic metabolism related pathways 
(e.g. drug metabolism cytochrome P450 and ABC transporters) were up-regulated in 
the Medium concentration group of HepG2/C3A cells, but down-regulated in the High 
concentration group. Similar results were found in A549 cells, but these were not 
statistically significant in the High concentration group. 
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Table 4.2 Normalized Enrichment Scores of significant pathways in HepG2/C3A cells and A549 cells exposed to TDCIPP for 
24 hours. 
Normalized enrichment scores (NES) of significantly changed gene sets/KEGG pathways (FDR <0.05) from both HepG2/C3A and A549 cell 
lines exposed to TDCIPP. Red colour donates enrichment amongst up-regulated genes, and green colour donates enrichment amongst 
down-regulated genes, NS denotes no significant change. (Detailed results of GSEA including FDR q-values are available in File 4.3, in 
Appendix.)
Medium High Medium High Medium High Medium High
KEGG_ABC_TRANSPORTERS 1.550 NS 2.039 NS KEGG_RNA_POLYMERASE -1.521 NS -1.927 NS
KEGG_RETINOL_METABOLISM 1.843 NS NS NS KEGG_RNA_DEGRADATION -1.644 NS NS NS
KEGG_LINOLEIC_ACID_METABOLISM 1.705 NS NS NS KEGG_SELENOAMINO_ACID_METABOLISM -1.517 NS NS NS
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 1.647 -1.796 NS NS KEGG_N_GLYCAN_BIOSYNTHESIS -1.516 NS NS NS
KEGG_TASTE_TRANSDUCTION 1.569 NS NS NS KEGG_PEROXISOME NS -2.136 NS NS
KEGG_ERBB_SIGNALING_PATHWAY NS 1.916 NS NS KEGG_PROPANOATE_METABOLISM NS -2.130 NS NS
KEGG_LYSOSOME NS NS 2.029 NS KEGG_BETA_ALANINE_METABOLISM NS -2.038 NS NS
KEGG_STEROID_BIOSYNTHESIS NS -2.124 2.227 NS KEGG_FATTY_ACID_METABOLISM NS -1.992 NS NS
KEGG_RIBOSOME -1.719 1.838 -1.813 NS KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATIONNS -1.973 NS NS
KEGG_DNA_REPLICATION -1.898 -2.318 -2.020 -2.867 KEGG_BUTANOATE_METABOLISM NS -1.948 NS NS
KEGG_PARKINSONS_DISEASE -1.866 -2.499 -1.729 -1.990 KEGG_GLUTATHIONE_METABOLISM NS -1.932 NS NS
KEGG_SPLICEOSOME -1.768 -1.640 -2.152 -2.624 KEGG_CARDIAC_MUSCLE_CONTRACTION NS -1.918 NS NS
KEGG_MISMATCH_REPAIR -1.806 -1.718 -1.667 -2.240 KEGG_PENTOSE_PHOSPHATE_PATHWAY NS -1.911 NS NS
KEGG_CELL_CYCLE -1.680 -1.652 -1.917 -2.475 KEGG_PYRUVATE_METABOLISM NS -1.904 NS NS
KEGG_PROTEASOME -1.998 -1.911 -1.831 NS KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDSNS -1.874 NS NS
KEGG_HUNTINGTONS_DISEASE -1.761 -2.019 -1.820 NS KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISMNS -1.804 NS NS
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS -1.578 -2.213 -2.547 NS KEGG_O_GLYCAN_BIOSYNTHESIS NS -1.737 NS NS
KEGG_OXIDATIVE_PHOSPHORYLATION -1.774 -2.504 NS -1.812 KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATENS -1.626 NS NS
KEGG_BASE_EXCISION_REPAIR -1.542 -1.568 NS -2.027 KEGG_ARGININE_AND_PROLINE_METABOLISM NS -1.552 NS NS
KEGG_PYRIMIDINE_METABOLISM -1.625 NS -2.027 -2.046 KEGG_HISTIDINE_METABOLISM NS -1.548 NS NS
KEGG_NUCLEOTIDE_EXCISION_REPAIR -1.694 NS -1.670 -1.799 KEGG_CITRATE_CYCLE_TCA_CYCLE NS -1.536 NS NS
KEGG_ALZHEIMERS_DISEASE -1.724 -2.206 NS NS KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION NS NS -1.655 NS
KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS-1.537 -1.670 NS NS KEGG_HOMOLOGOUS_RECOMBINATION NS NS NS -2.111
KEGG_GLYCOLYSIS_GLUCONEOGENESIS NS -2.223 NS -1.722 KEGG_OOCYTE_MEIOSIS NS NS NS -1.952
KEGG_PURINE_METABOLISM NS -1.536 NS -1.723 KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATIONNS NS NS -1.895
HepG2/C3A A549Pathways Pathways HepG2/C3A A549
100 
 
Since the gene expression profiles of both cell types showed concentration-response 
trends, we tested several genes in the Medium concentration group, which might 
represent the marginal effects on gene expression, by using qPCR. As shown in 
Table 4.3, the fold change of selected genes (CYP1A1: phase I xenobiotic 
metabolism; ABCC2: multi-drug transporter; ATP5J2, NQO1 and NDUFB3: oxidative 
phosphorylation; MT1L: stress response) from Medium concentration groups were 
similar to those found by microarray analysis. In HepG2/C3A cells, the expression of 
CYP1A1 gene showed an up-regulated trend (1.5-fold, but not significant in qPCR 
analysis) in the Medium concentration group, with a remarkable 38-fold up-regulation 
in the High concentration group. The expression of the ABCC2 gene was statistically 
significantly slightly increased (1.3-fold in qPCR analysis) in the Medium 
concentration group and statistically significantly induced in the High concentration 
group (2.6-fold) in HepG2/C3A cells. None of the three selected genes (ATP5J2, 
NQO1 and NDUFB3) involved in the oxidative phosphorylation pathway were 
significantly changed in the Medium concentration group in either qPCR or microarray 
analysis except for a slight increase of gene expression of NQO1 (1.2-fold in qPCR 
analysis) in A549 cells. However, significant down-regulation of these genes was 
observed in the High concentration group in both cell lines. MT1L was 21-fold 
up-regulated in the High concentration group of HepG2/C3A cells, while in the 
Medium concentration group there was no significant change detected by qPCR 
analysis. In A549 cells, a slight (non-significant) increase was observed for the High 
concentration group and there was no significant change in Medium concentration 
group by either qPCR or microarray analysis. 
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Table 4.3 Fold changes of selected genes in HepG2/C3A and A549 cells exposed to 10 μM TDCIPP for 24 hours. 
 
In qPCR analysis, fold changes (mean ± SD) with p-values less than 0.05 by t-test (in Minitab 16) were considered as significant, while 
significance of fold changes in microarray analysis were tested by t-tests with corrected p-values using Benjamini-Hochberg method in 
Genespring (Agilent). Bold p-values or corrected p-values were less than 0.05.  
Fold change p-value Fold change
corrected p-
value
Fold change
corrected p-
value
Fold change p-value Fold change
corrected p-
value
Fold change
corrected p-
value
CYP1A1 1.47 ± 0.30 0.052 1.48 ± 0.75 0.622 37.58 ± 12.74 0.000 1.21 ± 1.04 0.714 1.15 ± 0.50 0.874 1.65 ± 0.67 0.426
ABCC2 1.30 ± 0.17 0.032 1.27 ± 0.18 0.581 2.58 ± 0.42 0.001 1.01 ± 0.25 0.926 1.16 ± 0.27 0.905 0.94 ± 0.19 0.648
ATP5J2 1.02 ± 0.37 0.903 0.89 ± 0.05 0.581 0.41 ± 0.04 0.000 1.14 ± 0.11 0.091 0.88 ± 0.25 0.893 0.55 ± 0.08 0.038
NQO1 0.92 ± 0.20 0.494 1.09 ± 0.14 0.73 0.56 ± 0.08 0.002 1.18 ± 0.05 0.004 0.99 ± 0.27 0.97 0.58 ± 0.18 0.032
NDUFB3 0.98 ± 0.36 0.933 0.88 ± 0.05 0.581 0.31 ± 0.04 0.000 1.22 ± 0.16 0.066 0.87 ± 0.23 0.889 0.38 ± 0.06 0.015
MT1L 0.88 ± 0.29 0.459 0.93 ± 0.14 0.76 20.50 ± 3.02 0.000 1.49 ± 0.63 0.217 1.01 ± 0.68 0.943 1.27 ± 0.34 0.487
Medium concentration Medium concentration High concentrationGenes
HepG2/C3A A549
qPCR Microarray qPCR Microarray
Medium concentration Medium concentration High concentration
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4.3.2.2 Metabolomic responses of HepG2/C3A and A549 cells exposed to 
TDCIPP for 24 hours  
PCA showed that the polar metabolome of HepG2/C3A cells in the High 
concentration group was separated remarkably from the rest of the groups (Figure 
4.3).  
 
Figure 4.3 PCA scores plots of the polar metabolome of HepG2/C3A cells (A) 
and A549 cells (B) exposed to TDCIPP (n=8). Legend: red represents the High 
concentration group, pink the Medium concentration group, green the Low concentration 
group, and blue are controls.  
ANOVA (and subsequent Tukey-Kramer's post hoc tests) of the top four PC scores 
confirmed that this group was significantly different along both PC1 and PC2 
(representing 35.0% and 16.1% of the variance within the DIMS dataset, respectively) 
(Table 4.4). 
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Table 4.4 Summary of principal component (PC) analyses of microarray and 
DIMS datasets of A549 cells and HepG2/C3A cells exposed to TDCIPP. 
 
(Groups in each dataset as described in section 4.2.4: Control, Low concentration, Medium 
concentration and High concentration). The variance explained (%) by PCs 1-4 are listed 
together with p values from ANOVAs of these PC scores across all treatments (values in bold 
indicate significance at a false discovery rate (FDR) <10%). 
More than 2000 DIMS peaks were determined to change significantly in the High 
concentration group (corrected p-value < 0.05) by t-test (File 4.4, in Appendix). In the 
Medium concentration group, only 66 DIMS peaks changed significantly compared to 
the control group, of which 41 DIMS peaks were also significantly altered in the High 
concentration group. Only one DIMS peak was significantly changed in the Low 
concentration group. 
Putative annotation of these significantly changed DIMS peaks was performed in 
MI-Pack by searching against the HMDB and KEGG databases. These results were 
then subjected to pathway over-representation analysis in IMPaLA, which indicated 
the dysregulation of several metabolic pathways related to ABC transporters, 
metabolism of amino acids and derivatives (i.e. arginine and proline metabolism, 
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cysteine and methionine metabolism, glycine and serine metabolism) and glutathione 
conjugation in the High concentration group (File 4.5, in Appendix). 
Similarly, the High concentration group of A549 cells also showed distinct differences 
from all other groups in the PCA scores plot (Figure 3B). The significance tests of the 
PC scores confirmed that groups differed along PC1 (Table 4.4). There were more 
than 1000 significantly changed DIMS peaks in the High concentration group 
compared with the control (File 4.4, in Appendix). Although there were fewer 
significantly changed DIMS peaks in the High concentration group of A549 cells 
compared to that discovered for the High concentration group in HepG2/C3A cells, 
the pathway analysis of significant DIMS peaks with putatively annotated metabolite 
names showed similar disturbed metabolic pathways, which included ABC 
transporters, metabolism of amino acids and derivatives, and glutathione conjugation 
(File 4.5, in Appendix). 
4.3.2.3 Metabolomic responses of HepG2/C3A exposed to TDCIPP for 72 hours 
To evaluate the effects of increased exposure time on the toxicity of TDCIPP, the 
metabolome of HepG2/C3A cells treated with TDCIPP (1, 10 and 100 μM) for 72 
hours were analysed. Following these extended exposures, the metabolic profiles of 
HepG2/C3A cells in the High concentration group was altered drastically compared 
with the controls (Figure 4.4), and the statistical significance of the top four PC scores 
were all verified by ANOVA and Tukey-Kramer's post hoc tests (Table 4.4). 
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Figure 4.4 PCA scores plot of the polar metabolome of HepG2/C3A cells 
exposed to TDCIPP for 24 hours and 72 hours (n=8). Legend: circles represent the 
24-hour exposure, triangles represent the 72-hour exposure, red represents the High 
concentration group, pink the Medium concentration group, green the Low concentration 
group, and blue are controls. 
Further analyses revealed that more than 4000 DIMS peaks were significantly 
changed in the High concentration group after 72-hour exposures, double that of the 
High concentration group after 24-hour exposures (File 4.4, in Appendix). However, 
there were no significantly changed DIMS peaks in the Medium concentration group 
or the Low concentration groups, similar to the 24-hour exposures. Additional 
significant metabolic pathways (e.g. metabolism of nucleotides, glyoxylate and 
dicarboxylate metabolism, and fructose and mannose metabolism) were identified in 
the High concentration group after 72-hour exposures, but both 24-hour and 72-hour 
exposures shared some common pathways, e.g. ABC transporters, arginine and 
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proline metabolism, cysteine and methionine metabolism, glycine and serine 
metabolism, and glutathione conjugation (File 4.5, in Appendix). 
4.4 Discussion  
Although TDCIPP has been widely applied as an alternative flame retardant since 
PBDEs have been phased out from global FRs market, its molecular mechanisms of 
toxicity have not been extensively characterised. In the present study, unbiased 
transcriptomic and metabolomic approaches were employed to explore potential 
adverse effects and to help understand the mechanisms of action resulting from 
exposure to TDCIPP in two human cell lines (HepG2/C3A and A549 cells). 
Concentration-dependent cytotoxicity of TDCIPP was observed in both cell lines 
(Figure 4.1). With FBS in the exposure media, the 24-hour EC50 of TDCIPP in 
HepG2/C3A cells was 167.9 μM, which is similar to the cytotoxicity found in 
HepG2/C3A cells exposed in FBS-free media (EC50 = 202.4 μM). Furthermore, DIMS 
analysis also showed similar metabolic profiles of HepG2/C3A cells treated with 
TDCIPP for 24 hours in FBS-containing media or FBS-free media (Figure 4.5). This 
indicates that FBS in the exposure media minimally affected the potency of TDCIPP 
to HepG2/C3A cells. 
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Figure 4.5 PCA scores plot of DIMS data of polar extracts of HepG2/C3A cells 
exposed to TDCIPP in FBS containing media or FBS-free media (n=8). Legend: 
closed round represent as HepG2/C3A cells treated with TDCIPP for 24 hours with FBS in 
the exposure media, while open round represent as HepG2/C3A cells treated with TDCIPP 
for 24hours without FBS in the exposure media; red represents the High concentration group, 
pink the Medium concentration group, green the Low concentration group and blues are the 
control group. 
 
According to the concentration-response curve for TDCIPP, 10 μM TDCIPP did not 
cause substantial cytotoxicity in either cell line after a 24-hour exposure, but 
transcriptional changes were observed that indicated a defensive response in 
HepG2/C3A cells including an up-regulation of genes involved in xenobiotic 
metabolism (i.e. cytochrome P450 and ABC transporters). Although the induction of 
CYP1A1 gene expression in the Medium concentration group in HepG2/C3A cells 
was not statistically significant (1.5-fold, p=0.052), the tendency towards an 
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up-regulation was confirmed in the High concentration group with a 38-fold induction. 
CYP1A1 is a member of the cytochrome p450 superfamily; it plays a key role in 
primary xenobiotic metabolism and can be induced by polycyclic aromatic 
hydrocarbons (PAHs) (Ma and Lu, 2007). It has been reported that a CYP1A1 gene 
orthologue was also induced in zebrafish embryos/larvae exposed to 4.64 μM 
TDCIPP (Liu et al., 2013), but suppression of CYP1A4, which is avian orthologue of 
human CYP1A1, was also observed in chicken embryonic hepatocytes (Farhat et al., 
2014b). ABCC2 is a member of the ATP-binding cassette transporters that play 
important roles in protection against xenobiotics by excreting phase II products out of 
cells in phase III of xenobiotic metabolism (Szakács et al., 2008). The up-regulation of 
ABCC2 mRNA in HepG2/C3A cells exposed to 10 μM TDCIPP was confirmed by 
qPCR analysis. GSEA of microarray data also suggested that the ABC transporters 
as a group were up-regulated in cells exposed to Medium concentration TDCIPP, 
which may be part of the cell‘s protective response. 
The genes associated energy metabolism pathways (i.e. oxidative phosphorylation) 
were down-regulated in HepG2/C3A cells exposed to 10 μM TDCIPP; this effect was 
concentration dependent with more significantly down-regulated individual genes 
involved in the oxidative phosphorylation pathway detected after exposure to 100 μM 
TDCIPP. For example, the expressions of ATP5J2, NQO1 and NDUFB3 genes were 
not significantly changed at 10 μM TDCIPP exposure in HepG2/C3A cells but were 
statistically significant in the High concentration group (Table 4.3). The disruption of 
oxidative phosphorylation may implicate mitochondrial dysfunction at 100 μM 
TDCIPP exposure, which may link to the cytotoxic effects in HepG2/C3A cells. It has 
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been reported that tetrabromobisphenol A (TBBPA), another flame retardant, could 
elicit cytotoxicity through mitochondrial dysfunction linked to oxidative 
phosphorylation at an early stage, and subsequently lipid peroxidation, in rat 
hepatocytes (Nakagawa et al., 2007). Here, down-regulated transcriptional 
responses relevant to peroxisome and lipid metabolism were also found in 
HepG2/C3A cells exposed to 100 μM TDCIPP, but not in the 10 μM group. 
Furthermore, pathways involved in cell proliferation (e.g. DNA replication, cell cycle) 
(Files 4.2 and 4.3, in Appendix) were also down regulated in transcriptomic analysis 
of HepG2/C3A cells treated with 10 or 100 μM, which may also contribute to the 
observed cytotoxicity. 
In the High concentration group, more adverse transcriptional responses of 
HepG2/C3A cells were observed (Files 4.2 and 4.3, in Appendix), e.g. pathways 
relevant to energy metabolism (oxidative phosphorylation, glycolysis/ 
gluconeogenesis, TCA cycle), xenobiotic activity (drug metabolism cytochrome P450, 
and glutathione metabolism) and cell cycle were down regulated while up-regulation 
of apoptosis pathway transcripts was also found. These transcriptional changes in the 
High concentration group suggest cellular damage subsequently resulting in 
cytotoxicity. TDCIPP has been reported as a potential carcinogen possibly through a 
genotoxic mechanism (OEHHA, 2011). In this study we found that DNA repair gene 
expression was generally repressed (File 4.1, in Appendix), whereas certain 
DNA-damage responsive transcripts (e.g. DDIT3 and DDIT4) were induced. If 
TDCIPP indeed reduces base excision and mismatch DNA repair capacity this could 
indirectly enhance susceptibility to mutation. 
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Consistent with the transcriptional changes at 100 μM exposure, metabolomics 
analysis (File 4.5, in Appendix) also demonstrated that pathways related to ABC 
transporters and xenobiotic activity (represented by the glutathione conjugation 
pathway) were disturbed at the metabolic level. However, the metabolomics results 
did not provide any further support to the transcriptional changes observed at 10 μM 
TDCIPP exposure. Notably, several DIMS peaks were putatively annotated to be 
reduced glutathione (GSH) (File 4.4, in Appendix), which is a key cellular antioxidant 
and used in phase II conjugation reactions in xenobiotic metabolism. Glutathione 
concentration was increased (but not statistically significantly) in the Low and Medium 
concentration groups, but significantly decreased in the High concentration group in 
HepG2/C3A cells. This might imply a defensive response via glutathione oxidation or 
conjugation in Low and Medium concentration groups, which was overwhelmed in the 
High concentration group. 
The adverse metabolic responses of HepG2/C3A cells after a 24-hour exposure to 
100 μM TDCIPP were also observed after 72-hour exposures, with additional 
significantly changed DIMS peaks. This may be the result of the cytotoxic effects in 
HepG2/C3A cells after a 72-hour exposure to 100μM TDCIPP. In addition, the shifting 
of the concentration-response curve from 24-hour to 72-hour exposures (Figure 4.1), 
thereby decreasing the EC50 value (at 72 hours) to 84.0 μM, confirms the impact of 
exposure time on HepG2/C3A cytotoxicity.  
There are still some limitations in interpreting the molecular responses to TDCIPP in 
this study. First, the HepG2/C3A cell lines were selected as an in vitro model for 
hepatotoxicity, since these cells have been shown to provide many characteristics of 
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primary hepatocytes and have been valuable in previous studies(Jairaj et al., 2003; 
Kawata et al., 2009; Khalaf et al., 2009; Lu et al., 2000; Tian et al., 2008). However, 
various aspects of xenobiotic metabolising activity of HepG2/C3A cells are still limited 
compared to human primary culture hepatocytes (Gerets et al., 2012; Hart et al., 
2010). It remains possible that a response in primary cells in vivo may not be fully 
recapitulated in cancer- derived cells due to different responsiveness of a particular 
biological pathway. Therefore, the extrapolation of current results to different cell 
types in vivo should be cautious. 
Moreover, the lowest nominal observed effect concentration in this study is 10 μM (ca. 
4300 ng/mL). This is an unlikely concentration can be achieved in humans via normal 
exposure routes. A few available studies reported that the level of TDCIPP in human 
body is approximate at ng/g lipid levels which is several orders of magnitude lower 
than concentrations used in the present study. For example, up to 252 ng/g lipid was 
detected in human adipose tissue samples (LeBel and Williams, 1986) and up to 162 
ng/g lipid was reported in human breast milk (Kim et al., 2014) while the average 
concentration of BDCIPP (which is the primary metabolite of TDCIPP) in human urine 
was 0.12 ng/mL(Meeker et al., 2013).) There is a  need is to gain more information 
on human exposure to TDCIPP, thus enabling a more robust risk assessment. 
In addition, only polar metabolic profiles of the two cell lines were analysed using 
DIMS-based metabolomics. The non-polar part of the intracellular metabolome was 
not analysed and potentially could contribute novel insights into the lipidomic 
changes.  
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4.5 Conclusions 
In summary, we have demonstrated concentration-dependent cytotoxicity of TDCIPP 
in HepG2/C3A and A549 cells after 24- or 72-hours exposures. Stress responses that 
reflect a defensive response (e.g. xenobiotic metabolism and ABC transporters) were 
observed at a transcriptional level following exposure to a sub-cytotoxic concentration 
of TDCIPP for 24 hours. The down-regulation of energy metabolism-related 
transcription (oxidative phosphorylation) was apparent at 10 μM, but more severe at a 
higher concentration (100μM) exposure, accompanied by the suppression of 
pathways relevant to cell proliferation (e.g. cell cycle, DNA replication). Functional 
metabolic pathways (e.g. ABC transporters and metabolism of nucleotides) were 
disrupted after 72 hours in HepG2/C3A cells exposed to 100 μM TDCIPP that 
corresponded to the transcriptional and metabolic changes at 24 hours. Taken 
together, defensive changes to stress and energy-related responses preceded the 
cytotoxic effects of TDCIPP in HepG2/C3A cells. 
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CHAPTER 5   Toxicogenomic 
responses of HepG2/C3A cells 
exposed to environmental levels of 
flame retardants and indoor dust 
extracts* 
 
 
 
*The content of this chapter has been submitted to Chemosphere: Zhang, J., 
Abdallah Abou-Elwafa, M., Williams, T.D., Harrad, S., Chipman, J.K., Viant, M.R., 
2015. Gene expression and metabolic responses of HepG2/C3A cells exposed to 
flame retardants and dust extracts at concentrations relevant to indoor environmental 
exposures.  
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5.1 Introduction 
Since additive FRs are not covalently bound to the treated materials, they can leach 
out of consumers products over time, particularly to the indoor environment. Studies 
have suggested that indoor dust is a sink for different types of FRs released from 
consumer products (Harrad et al., 2010; Rauert et al., 2014), where they are present 
as a complex mixture with other indoor contaminants (Butte and Heinzow, 2002). For 
example, the concentration of TDCIPP can reach up to 72 μg/g in office dust 
(Carignan et al., 2013) and HBCD was found in house dust in the USA at levels up to 
130 μg/g (Stapleton et al., 2008).  
The ingestion of indoor dust is one of primary routes for human exposure to mixed 
FRs while others include through diet, inhalation of air and direct dermal contact with 
dust or consumer products (Abdallah et al., 2015a; Harrad et al., 2010). Consequently, 
there are increasing concerns about the effects of human exposure to FRs, especially 
since different types of FRs have been detected in human serum and tissues 
(Darnerud, 2003; Frederiksen et al., 2009; Kim et al., 2014; Pulkrabová et al., 2009; 
Rawn et al., 2014a, 2014b; van der Veen and de Boer, 2012). 
Toxicological studies have demonstrated that many FRs can be neurotoxic, and 
endocrine disruptive, both in vitro and in vivo. For example, PBDEs are neurotoxic to 
rat neuronal cells by altering the release of neurotransmitters and disturbing Ca2+ 
homeostasis (Dingemans et al., 2008), while PBDEs have been shown to alter serum 
thyroxine (T4) levels in pregnant women (Stapleton et al., 2011; Zota et al., 2011). It 
has also been shown that TBBPA can mimic estrogen to bind and inhibit a key 
hormone-metabolizing enzyme, human estrogen sulfotransferase (SULT1E1) 
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(Gosavi et al., 2013). Hepatoxicity of FRs has also been described. Chronic exposure 
to HBCD at 30 mg/kg/day (for 28 days) increased liver weight in female rats (van der 
Ven et al., 2006) and induced hepatic cytochrome P450 (CYP) enzyme activities 
(CYP2B1 and CYP3A1) in these animals (Cantón et al., 2008; Germer et al., 2006). 
Besides the neurotoxic (Dishaw et al., 2011) and endocrine disruptive (Dishaw et al., 
2014) properties of a number of OPFRs, some of them (e.g. TCEP, TCIPP and 
TDCIPP) have been suggested to possess carcinogenic potential (ATSDR, 2012; 
OEHHA, 2011; van der Veen and de Boer, 2012). 
However, under realistic indoor conditions, humans are exposed to a complex mixture 
of chemicals including FRs. Toxicity screening of chemical mixtures might reflect the 
effects of exposure more accurately by including the potential interactions (i.e. 
additive, synergistic or antagonistic) of individual components in the complex 
formulation (Bandele et al., 2012). Suzuki et al. (2013) reported that indoor dust 
extracts containing various FRs were agonistic to estrogen receptor α (ERα) and 
antagonistic to the androgen receptor (AR) and progesterone receptor (PR). These 
effects correlated with the levels of FRs in dust and were similar to the 
endocrine-disrupting potencies of some individual FRs. In another study, rats were 
exposed to a complex brominated FR mixture mimicking the relative individual levels 
of the flame retardants in house dust. This affected liver and thyroid physiology in 
adult male rats (Ernest et al., 2012) and increased abnormalities of bone 
development in fetal rats, which are novel phenotypes that have not been reported in 
previous studies of the effects of individual brominated FR congeners (Berger et al., 
2014). Altered gene expression patterns of MCF-7 cells have been reported after 
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exposure to an urban dust standard reference material (SRM) 1649a, which is a 
complex mixture containing PAHs (Mahadevan et al., 2005). 
However, most studies to date have characterised the toxicity of FRs using doses that 
are unlikely to be achieved through human exposure. Furthermore, the majority of 
investigations have targeted specific molecular or cellular responses. Here, to 
discover the acute responses of human cells to concentrations of FRs that attempt to 
simulate indoor exposure scenarios, hepatoma cells were exposed to FR mixtures 
and molecular changes were investigated using an array of non-targeted approaches 
including transcriptomics, metabolomics and lipidomics. 
HepG2/C3A cells were used as the in vitro model; they have previously been 
successfully employed in heptatoxicity testing, for example by evaluating the 
cytotoxic and metabolic effects of a commercial oil dispersant mixture (Bandele et al., 
2012). Furthermore, a solvent extract of SRM 2585 was used as a surrogate dust 
sample, representing the environmental mixture, in which we characterised four FRs 
(TCEP, TCIPP, TDCIPP and HBCD) (Abdallah et al., 2015b). SRM 2585 is an indoor 
dust reference material developed recently by the National Institute of Standards and 
Technology (NIST) for determination of concentrations for organic contaminants 
including flame retardants, polychlorinated biphenyls (PCBs), polycyclic aromatic 
hydrocarbons (PAHs) and organochlorine pesticides in house dust and similar 
matrices (Poster et al., 2007; Stapleton et al., 2006; Wise et al., 2006). We also 
employed a mixture of four FRs, namely TCEP, TCIPP, TDCIPP and HBCD each at 
the same concentration as in the dust extract, and a second mixture with 100-fold 
greater concentrations. The 100-fold concentrated mixture provided us a worst case 
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scenario for our hazard assessment. Oligonucleotide microarray based 
transcriptomics and direct infusion mass spectrometry (DIMS) based metabolomics 
and lipidomics were then applied to assess the molecular responses of HepG2/C3A 
cells exposed to the FR mixtures and dust extract. The aims of this chapter were (1) 
to evaluate the cytotoxic effects of mixture of four FRs and a dust extract to 
HepG2/C3A cells; (2) to determine changes in the gene expression, metabolic and 
lipid profiles of HepG2/C3A cells after the exposures; and (3) to search for any FR 
mixture-specific molecular responses in HepG2/C3A cells. 
5.2 Materials and Methods  
5.2.1 Chemicals and reagents 
All chemicals were obtained from Sigma-Aldrich Chemical Company (UK) unless 
otherwise stated. 
5.2.2 Cell culture 
HepG2/C3A cells culture were described as in Section 2.2.  
5.2.3 Design of Exposure experiment 
Since hepatocytes are vital to the liver‘s detoxification role in humans, HepG2/C3A 
cells were employed as an in vitro model to test the toxicity of FRs. Dust ingestion is 
one of the primary routes of exposure to chemical contaminants. Relating 
environmental levels to concentrations achievable intracellularly represents a 
significant challenge. We have taken a conservative approach (from a hazard 
assessment perspective) that assumes total uptake of the ingested material, all of 
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which is processed by the liver. Since this is an overestimate of hepatocyte exposure, 
we have also measured cellular uptake levels which can be compared directly to 
reported tissue levels. The average amount of ingested dust is ca. 100-200 mg per 
day (Johnson-Restrepo and Kannan, 2009) for toddlers (ca. 12 kg), who are 
estimated to have ca. 350 million hepatocytes (Sohlenius-Sternbeck, 2006). In this 
study, therefore, the concentrations of FRs in the exposure system (ca. 0.6 mg dust 
per million hepatocytes) were designed on the basis of an average uptake of dust in 
toddlers. A solvent extract of the indoor dust reference material SRM2585 (NIST, USA) 
was used as a surrogate dust sample to mimic human exposure to all chemicals from 
dust. Four FRs (TCEP, TCIPP, TDCIPP and HBCD) were measured in the dust 
extract allowing preparation of a mixture (Mix 1) that reflected the concentrations of 
the four FRs in the dust extract, and a second mixture (Mix 2) of the same FRs at 100 
times higher concentrations. DMBA (7,12-dimethylbenz[a]anthracene) (2 μM), a 
polyaromatic hydrocarbon (PAH) was used as a positive control, while 0.1 % (v/v) 
DMSO was used as a vehicle for all exposures and as the vehicle control. An 
additional group treated with 4 μM HBCD was also included in this design to compare 
the effect of an individual FR (Table 5.1).  
HepG2/C3A cells were seeded into 96 well or 6 well plates at 2×104 or 4×105 
cells/well respectively. After overnight acclimatization, cells were exposed to 
SRM2585 dust extract (equivalent to ca. 0.6mg dust per million cells), Mix 1, Mix 2, 
DMBA (2 μM), HBCD (4 μM) or 0.1% (v/v) DMSO as control. For cytotoxicity tests and 
quantification of FRs, cells were exposed for 24 or 72 hours; for omics study, the 
exposure time was 72 hours. 
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Table 5.1 Experimental design of mixture of FRs and dust extracts exposure 
study.  
 
5.2.4 Cytotoxicity assays 
To evaluate the cytotoxicity of dust extracts and mixture of FRs to HepG2/C3A cells, 
the CCK-8 assay and AK assay were employed to assess mitochondrial 
dehydrogenase activity and loss of cell integrity, respectively. Briefly, HepG2/C3A 
cells were exposed to dust extracts, mixture of FRs, DMBA and HBCD (Table 5.1) for 
24 or 72 hours. The detailed procedure of CCK-8 assay and AK assays were as 
described in Section 2.3.2 and 2.3.3, respectively. 
Groups Description Concentration of quantified 
chemicals 
No. of 
replicates for 
transcriptomics
No. of 
replicates for 
metabolomics
Control 0.1% DMSO as solvent control. - 4 5
TCEP: 1.57 nM ( 0.45 ng/mL);
TCIPP: 1.49 nM ( 0.49 ng/mL); 
TDCIPP: 2.67 nM ( 1.15 ng/mL);
HBCD: 0.153 nM ( 0.099 ng/mL).
(other chemicals were not 
characterized in this study.)
TCEP: 1.57 nM;
TCIPP: 1.49 nM;
TDCIPP: 2.67 nM;
HBCD: 0.153 nM.
TCEP: 157 nM ( 45.00 ng/mL);
TCIPP: 149 nM ( 48.75 ng/mL); 
TDCIPP: 267 nM ( 115.00 ng/mL);
HBCD: 15.3 nM ( 9.85 ng/mL).
DMBA Positive control DMBA: 2 μM (512.7 ng/mL) 4 5
HBCD
Quality control, a FR at the same 
concentration as in Chapter 3.
HBCD: 4 μM ( 2566.8 ng/mL) 4 5
Mix 2
Mixture of four FRs at 100 times 
higher concentrations as in the 
Mix 1 group.
4 5
Dust 
Extract
One million cells were exposed 
to solvent extract equivalent to 
ca. 0.6 mg dust.
4 5
Mix 1
Mixture of four FRs at the same 
concentrations as quantified in 
the dust extract.
4 5
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5.2.5 Transcriptomics analysis 
After 72 hours exposure, HepG2/C3A cells were harvested after two brief PBS 
washes. Cell pellets were collected and flash frozen in liquid nitrogen for further RNA 
extraction. Each treatment group included four biological replicates. The total RNA 
isolation and microarray analysis were also described as in Section 2.4.1 and 2.4.2.  
Microarray datasets are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number：E-MTAB-3324. 
5.2.6 Metabolomics analysis 
5.2.6.1 Extraction of Metabolites 
After 72 hours exposure, HepG2/C3A cells were harvested and metabolites were 
extracted as previously described in Section 2.5.1.2. Briefly, cells were quickly 
washed with PBS twice before the 6-well plates were quenched on liquid nitrogen. 
Then, metabolites were extracted by liquid-liquid extraction method (methanol: 
chloroform: water (v/v/v) ratio was 1:1:0.9). After vortexing and centrifuge, the mixture 
separated into two phases (upper polar phase and lower non-polar phase). 300 µL 
aliquots of the polar phase were transferred into clean 1.5mL Eppendorf tubes and 
then dried in a speed vac concentrator (Thermo Savant, Holbrook, NY) for 4 hr. 300 
µL aliquots of the non-polar phase were transferred into clean 1.8mL glass vial and 
then were dried under a stream of nitrogen to minimise oxidation. All dried samples 
were then stored at -80°C until analysis. 
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5.2.6.2 DIMS analysis and data processing 
The DIMS analysis method was similar to that reported previously in Section 2.5.2. 
Briefly, the dried polar extracts of cells were re-suspended in 75 μL 80:20 (v/v) 
methanol:water (HPLC grade) with 0.25% formic acid (for positive ion mode). For the 
dried non-polar extracts of cells, it was re-suspended in with 2:1 (v/v) 
MeOH:chloroform with 5 mM ammonium acetate. After centrifugation at 22000 rcf, 
4°C for 10 min, 10 µL supernatant of each sample was loaded into one well in a 
384-well plate and then analysed (in triplicate) using direct infusion Fourier transform 
ion cyclotron resonance mass spectrometry in positive ion mode (for polar 
metabolomics) or negative ion mode (for lipidomics) (LTQ FT Ultra, Thermo Fisher 
Scientific, Germany, coupled with a Triversa nanoelectrospray ion source, Advion 
Biosciences, Ithaca, NY, USA). Mass spectra were recorded utilizing the selected ion 
monitoring (SIM) stitching approach from m/z 70 to 590 (for polar metabolomics) or 
from m/z 100 to 2000 (for lipidomics) (Southam et al., 2007) and then processed 
using custom-written Matlab scripts as previously reported (Kirwan et al., 2014; 
Southam et al., 2007). Univariate and multivariate statistical analysis of DIMS 
datasets are described in Section 2.5.2.  
5.2.6.3 MS peaks annotation and pathway analysis 
For significantly changed DIMS peaks, putative empirical formulae and metabolite 
names were assigned by searching against HMDB, KEGG and LIPIDMAPS database 
in the metabolite identification package (MI-Pack) (Weber and Viant, 2010). And the 
details are in Section 2.5.3. Putative annotation of significantly changed DIMS peaks 
from non-polar DIMS dataset was not subjected to pathway over-representation 
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analysis due to the less reliable annotation results. 
5.2.7 Quantification of FRs in HepG2/C3A cells and cell media  
(conducted by Dr. Mohamed Abou-Elwafa Abdallah, University of Birmingham) 
To evaluate the cellular uptake of FRs after exposure, their concentrations were 
measured in treated cells and cell media after 24 or 72 hours using LC-MS/MS 
according to a previously reported method (Abdallah et al., 2015b). The detailed 
procedure is available in the Section 2.6.2. 
5.3 Results  
5.3.1 Cytotoxicity of dust extracts and mixture of FRs to HepG2/C3A cells 
To evaluate the cytotoxicity of the dust extract and mixtures of FRs to HepG2/C3A 
cells, the CCK-8 assay and AK assay were employed after 24- and 72-hour 
treatments. As shown in Figure 5.1, there was no significant cytotoxic effect in any 
treatment group compared to the control group after 24 hours, although a slight 
decrease (not statistically significant) of cell viability was observed in the 2 μM DMBA 
group. After a 72-hour exposure, there was still no obvious toxic effect in any group 
except the DMBA group. Specifically, in the 2 μM DMBA group (positive control), there 
was a significant decrease of average cell viability (48.6%) and remarkable increase 
of AK release due to the loss of cellular integrity after 72 hours. The AK release of 
cells in the 4 μM HBCD group declined slightly after 72 hours (81.8%) compared to 
the control group. 
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Figure 5.1 Cytotoxicity assays of HepG2/C3A cells exposed to dust extract, 
mixture of FRs, DMBA and HBCD. Cell viability of HepG2/C3A cells were evaluated 
using CCK-8 assay (A) and AK assay (B) after exposed to dust extract, Mix 1, Mix 2,  2 μM 
DMBA and 4 μM HBCD for 24 hours or 72 hours. Results are expressed as the percentage of 
cell viability or AK release compared to solvent controls treated with the appropriate vehicle 
(DMSO). Data represent mean ± SEM from at least three independent experiments. Two 
asterisks indicate a p-value of less than 0.01 in t-test. 
5.3.2 Transcriptomic analysis  
The oligonucleotide microarrays were employed to evaluate gene expression profiles 
of HepG2/C3A cells after 72-hour exposures to a dust extract and mixtures of FRs, as 
detailed above. The PCA scores plot (Figure 5.2 A) showed that there was a clear 
separation of gene expression patterns between the DMBA group (positive control) 
and the other treatment groups, while there was no obvious separation between the 
Dust extract group, the FR mixture groups and the control group (Figure 5.2 B).  
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Figure 5.2 PCA scores plots of the gene expression of HepG2/C3A cells (A) and 
(B, which excludes DMBA group) following 72-hour treatments (n=4). Legend: 
Blue represents solvent control, red is dust extract, green is Mix 1 of flame retardants, brown 
is Mix 2 of flame retardants, pink is 4 μM HBCD control and black is 2 μM DMBA group 
control. 
The statistical significance of the top six PC scores was verified by ANOVAs s 
combined with a Tukey-Kramer's post hoc test (Table 5.2). The results showed that 
PC 1 (representing 55.5% of the variance in the whole microarray dataset) was 
significant (p=7.20 x10-21). However, when the DMBA group was excluded from the 
dataset, only PC 3 and PC 5 were significant, which represented 9.70% (p=0.029) 
and 6.22% (p=0.007) variance of the modified dataset, respectively. 
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Table 5.2 Summary of principal component (PC) analyses of both microarray 
and MS datasets of HepG2/C3A cells after 72 hours treatment 
(Groups in each dataset as described in section 5.2.3). The variance explained (%) by PCs 
1-6 are listed together with p values from ANOVAs of these PC scores across all treatments 
(values in bold indicate significance at a false discovery rate (FDR) <10%). 
Significance analysis of microarrays (SAM) in MeV was employed to identify the 
significant differentially expressed genes between the treatment groups and controls. 
The results (File 5.1, in Appendix) showed that 49 probe sets were up-regulated in the 
Dust extract group compared to the control group (Figure 5.3 A), among which 
several genes (e.g. CYP1A1, CYP1A2, GSTP1 and UGT1A6) were related to the 
metabolism of xenobiotics by cytochrome 450, revealed by DAVID analysis (File 5.2, 
in Appendix). There was no significantly changed gene expression in either Mix 1 or 
Mix 2 groups compared to the control group (Figure 5.3 A).  
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Figure 5.3 Univariate statistics analysis of significantly changed transcripts in 
HepG2/C3A cells following 72-hour treatments (n=4). (A) Number of significantly 
changed probes between various treatment groups. (B) The Venn diagram indicates the 
number of significantly up-regulated probes (all compared with control) in the DMBA group, 
dust group and HBCD group. 
In the 4 μM HBCD group, 81 probe sets were significantly changed compared to the 
control group (File 5.1, in Appendix). 4 μM HBCD exposure resulted in transcriptional 
induction of a group of metallothionein genes (MT1A, MT1B, MT1E, MT1L, MT1H 
and MT1X) while the expression of glutathione S-transferase gene (GSTP1) was 
down-regulated. More than 4000 probe sets (File 5.1, in Appendix) were significantly 
altered in the DMBA group compared to controls. DMBA responsive transcripts were 
related to apoptosis/cell death pathways and suppressed cell proliferation pathways 
(e.g. cell cycle, cell division) as well as xenobiotic metabolism (e.g. CYP1A1) (File 5.2, 
in Appendix). Interestingly, 26 probe sets (File 5.1, in Appendix) were up-regulated in 
the Dust extract group compared to the Mix 1 group. These changes are likely to be in 
response to the many other components of this complex mixture, not the four FRs 
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that were investigated here. DAVID analysis also suggested that the metabolism of 
xenobiotics by cytochrome 450 was the most significantly enriched pathway in 
response to the dust extract. However, no significantly expressed genes were found 
in the comparison of the Mix1 and Mix 2 groups. 
The results of GSEA (Table 5.3) were similar to DAVID analysis. Pathways related to 
metabolism of xenobiotics by cytochrome P450 were also found to be increased, 
while ribosomal transcripts were down-regulated in the Dust extract group. There was 
no significant enrichment of gene sets in either Mix1 or Mix2 groups compared to the 
controls. In the 4μM HBCD group, pathways relevant to ribosome and steroid 
biosynthesis were decreased, and gap junction transcripts were up-regulated. In the 
positive control group, 2μM DMBA caused extensive changes including significant 
elevation of apoptosis/cell death related pathways and down-regulation of cell 
proliferation related pathways (e.g. cell cycle, DNA replication).
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Table 5.3 GSEA of gene expression of HepG2/C3A cells from different treatment groups for 72 hours. 
 
NAME SIZE NES
NOM 
p-val
FDR 
q-val
NAME SIZE NES
NOM 
p-val
FDR 
q-val
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 36 2.169 0.000 0.000 KEGG_RIBOSOME 87 -2.868 0.000 0.000
KEGG_TRYPTOPHAN_METABOLISM 31 2.073 0.000 0.001 KEGG_OLFACTORY_TRANSDUCTION 39 -2.435 0.000 0.000
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHRO
ME_P450
37 2.072 0.000 0.000 KEGG_MATURITY_ONSET_DIABETES_OF_THE_Y
OUNG
19 -1.935 0.001 0.005
KEGG_PROTEASOME 41 2.025 0.000 0.001 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 96 -1.782 0.000 0.020
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATI
ON
41 1.882 0.000 0.010
KEGG_TYROSINE_METABOLISM 29 1.875 0.001 0.009
KEGG_HISTIDINE_METABOLISM 22 1.847 0.000 0.013
KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM 17 1.824 0.002 0.015
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 49 1.774 0.001 0.024
KEGG_PYRUVATE_METABOLISM 34 1.744 0.002 0.033
KEGG_FATTY_ACID_METABOLISM 35 1.735 0.002 0.034
KEGG_DORSO_VENTRAL_AXIS_FORMATION 15 1.720 0.011 0.037
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION
52 1.715 0.001 0.036
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 47 1.706 0.002 0.038
KEGG_BUTANOATE_METABOLISM 26 1.696 0.006 0.039
KEGG_PROPANOATE_METABOLISM 30 1.689 0.005 0.040
KEGG_BETA_ALANINE_METABOLISM 17 1.685 0.011 0.039
KEGG_GLIOMA 50 1.676 0.003 0.041
KEGG_SELENOAMINO_ACID_METABOLISM 23 1.658 0.016 0.048
Mix1 NA NA NA NA NA NA NA NA NA NA
Mix2 NA NA NA NA NA NA NA NA NA NA
KEGG_GAP_JUNCTION 57 1.934 0.000 0.031 KEGG_RIBOSOME 87 -1.882 0.000 0.020
KEGG_STEROID_HORMONE_BIOSYNTHESIS 24 -1.903 0.000 0.031
KEGG_STEROID_BIOSYNTHESIS 15 -1.762 0.012 0.038
KEGG_OLFACTORY_TRANSDUCTION 39 -1.774 0.005 0.046
HBCD
Up-regulated pathways Down-regulated pathways
Dust extract
TREATMENT 
GROUPS
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KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION
52 2.012 0.000 0.003 KEGG_DNA_REPLICATION 36 -2.646 0.000 0.000
KEGG_APOPTOSIS 70 1.966 0.000 0.004 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 96 -2.560 0.000 0.000
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 113 2.035 0.000 0.005 KEGG_CELL_CYCLE 115 -2.513 0.000 0.000
KEGG_ENDOCYTOSIS 150 1.920 0.000 0.007 KEGG_RIBOSOME 87 -2.362 0.000 0.000
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 62 1.835 0.000 0.015 KEGG_SPLICEOSOME 124 -2.270 0.000 0.000
KEGG_TYPE_I_DIABETES_MELLITUS 24 1.821 0.002 0.015 KEGG_MISMATCH_REPAIR 23 -2.134 0.000 0.000
KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS 39 1.844 0.000 0.015 KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 40 -1.944 0.001 0.002
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 48 1.800 0.000 0.018 KEGG_PYRIMIDINE_METABOLISM 88 -1.915 0.000 0.002
KEGG_CHEMOKINE_SIGNALING_PATHWAY 106 1.776 0.000 0.021 KEGG_PURINE_METABOLISM 117 -1.924 0.000 0.002
KEGG_P53_SIGNALING_PATHWAY 60 1.717 0.001 0.037 KEGG_HOMOLOGOUS_RECOMBINATION 28 -1.947 0.000 0.002
KEGG_HEMATOPOIETIC_CELL_LINEAGE 39 1.676 0.008 0.047 KEGG_OOCYTE_MEIOSIS 91 -1.960 0.000 0.002
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PROD
UCTION
22 1.660 0.009 0.050 KEGG_BASE_EXCISION_REPAIR 33 -1.837 0.002 0.005
KEGG_LYSINE_DEGRADATION 41 -1.819 0.001 0.005
KEGG_PROGESTERONE_MEDIATED_OOCYTE_M
ATURATION
64 -1.823 0.001 0.005
KEGG_RNA_DEGRADATION 55 -1.790 0.002 0.006
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEG
RADATION
41 -1.711 0.007 0.013
KEGG_ONE_CARBON_POOL_BY_FOLATE 15 -1.690 0.005 0.015
KEGG_NUCLEOTIDE_EXCISION_REPAIR 43 -1.675 0.005 0.017
KEGG_CITRATE_CYCLE_TCA_CYCLE 29 -1.646 0.008 0.021
KEGG_NITROGEN_METABOLISM 16 -1.628 0.022 0.023
KEGG_PENTOSE_PHOSPHATE_PATHWAY 22 -1.601 0.017 0.027
KEGG_RNA_POLYMERASE 28 -1.595 0.021 0.027
KEGG_PROPANOATE_METABOLISM 30 -1.537 0.032 0.042
DMBA
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5.3.3 Metabolomic analysis  
Polar and non-polar metabolites of HepG2/C3A cells from different treatment groups 
were analysed by DIMS based metabolomics. The polar and non-polar DIMS 
datasets included 2943 and 489 mass spectral peaks after data processing, 
respectively. To visualise the similarities and differences of the metabolic profiles 
between control and treatment groups, these data were subjected to PCA. 
The PCA scores plot (Figure 5.4 A) showed the polar metabolic profiles of 
DMBA-exposed cells separated clearly from the other treatment groups and the 
controls. The PCA plot of non-polar metabolic profiles, shown in Figure 5.4 B, 
suggested that both the HBCD group and the DMBA group are distinct from the other 
treatment groups. The ANOVAs (combined with a Tukey-Kramer's post hoc test) of 
the top six PC scores showed PC 1 and PC 2 in the polar DIMS analysis were 
significant (Table 5.2). In the non-polar DIMS analysis, PC 1, PC 2, PC 5 and PC 6 
were significant in the top six PC scores. 
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Figure 5.4 PCA scores plots of the DIMS datasets of polar (A) and non polar (B) 
extracts of HepG2/C3A cells following 72-hour treatments (n=5). Legend: Open 
squares represent polar samples, while open circles represent non-polar samples. Blue 
represents solvent control, red is dust extract, green is Mix 1, brown is Mix 2, pink is 4 μM 
HBCD control group and black is 2 μM DMBA control group.) 
 
Univariate statistical analyses were conducted on the DIMS datasets (File 5.3, in 
Appendix and Figure 5.5). In the polar DIMS dataset, 994 peaks (of a total of 2943 
peaks) in the DMBA group significantly changed intensity compared to controls, while 
only five peaks changed in response to HBCD treatment compared to controls. The 
other treatment groups had no significantly changed peaks relative to controls. 
However, in the non-polar DIMS dataset, 50.7% of the peaks (248 outof 489 peaks) in 
the DMBA group significantly changed compared to controls. There were also 186 
peaks (38.0%) that significantly changed in the HBCD group. Meanwhile, only 4 
peaks (of 489 in total) changed significantly between the Dust extract group and the 
controls. 
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Figure 5.5 Number of significantly changed DIMS peaks between various 
treatment groups in the polar and non-polar DIMS datasets of HepG2/C3A cells 
following 72-hour treatments (n=5). 
Putative annotation of these significantly changing peaks (File 5.3, in Appendix) was 
performed in MI-Pack by searching against HMDB, KEGG and LIPIDMAPS 
databases. The assigned metabolite names of these putatively annotated peaks in 
the polar DIMS dataset were subjected to pathway over-representation analysis in 
IMPaLA. Pathway analysis (Table 5.4) suggested the dysregulation of metabolic 
pathways related to metabolism of amino acids and derivatives (i.e. arginine and 
proline metabolism, glycine and serine metabolism) and glutathione conjugation in 
the DMBA group. Only one of the significantly changing peaks in the polar DIMS 
dataset of the HBCD group was putatively annotated as taurine. 
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Table 5.4 Pathway over-representation analysis of putative annotation of significant MS peaks from polar metabolomics 
dataset in the DMBA group  
Pathway name Pathway source Number of 
overlapping 
metabolites
Number of all 
pathway 
metabolites
P value Q value
Transport of inorganic cations-anions and amino acids-oligopeptides Wikipathways 18 32 2.47E-16 5.88E-14
Central carbon metabolism in cancer - Homo sapiens (human) KEGG 19 37 3.47E-16 7.28E-14
Protein digestion and absorption - Homo sapiens (human) KEGG 19 47 8.90E-14 1.67E-11
Glycine_ serine and threonine metabolism - Homo sapiens (human) KEGG 18 50 4.35E-12 7.06E-10
Aminoacyl-tRNA biosynthesis - Homo sapiens (human) KEGG 18 52 9.44E-12 1.47E-09
Metabolism of amino acids and derivatives Wikipathways 33 187 2.74E-11 3.76E-09
Mineral absorption - Homo sapiens (human) KEGG 13 29 1.76E-10 2.32E-08
tRNA Aminoacylation Wikipathways 18 65 6.29E-10 8.02E-08
Phase II conjugation Wikipathways 23 115 2.82E-09 3.15E-07
Lysine degradation - Homo sapiens (human) KEGG 15 52 9.63E-09 1.01E-06
Cyanoamino acid metabolism - Homo sapiens (human) KEGG 14 45 1.03E-08 1.05E-06
Arginine and proline metabolism - Homo sapiens (human) KEGG 19 91 3.47E-08 3.31E-06
Valine_ leucine and isoleucine biosynthesis - Homo sapiens (human) KEGG 10 23 3.52E-08 3.31E-06
Glucose Homeostasis Wikipathways 9 21 2.05E-07 9.50E-06
Cysteine and methionine metabolism - Homo sapiens (human) KEGG 13 57 1.90E-06 7.22E-05
ABC transporters - Homo sapiens (human) KEGG 19 123 4.66E-06 0.000173
Urea cycle and metabolism of amino groups Wikipathways 9 30 6.82E-06 0.000251
Ascorbate and aldarate metabolism - Homo sapiens (human) KEGG 11 47 9.20E-06 0.000335
Tyrosine metabolism - Homo sapiens (human) KEGG 14 77 1.30E-05 0.00047
Alanine_ aspartate and glutamate metabolism - Homo sapiens (human) KEGG 8 28 3.36E-05 0.00103
Biogenic Amine Synthesis Wikipathways 6 17 9.05E-05 0.00236
Phenylalanine metabolism - Homo sapiens (human) KEGG 12 72 0.000132 0.00322
D-Glutamine and D-glutamate metabolism - Homo sapiens (human) KEGG 5 12 0.000146 0.0035
Trans-sulfuration and one carbon metabolism Wikipathways 6 20 0.000251 0.00598
Valine_ leucine and isoleucine degradation - Homo sapiens (human) KEGG 8 40 0.000504 0.011
Amino acid conjugation of benzoic acid Wikipathways 4 9 0.000537 0.0116
Propanoate metabolism - Homo sapiens (human) KEGG 8 44 0.000983 0.02
Amino acid conjugation Wikipathways 3 5 0.00101 0.0205
Phenylalanine_ tyrosine and tryptophan biosynthesis - Homo sapiens (human) KEGG 7 35 0.00113 0.0227
Glutathione metabolism Wikipathways 5 18 0.00125 0.0241
Glyoxylate and dicarboxylate metabolism - Homo sapiens (human) KEGG 9 58 0.00157 0.0279
Pantothenate and CoA biosynthesis - Homo sapiens (human) KEGG 6 28 0.00177 0.0304
Metabolism of water-soluble vitamins and cofactors Wikipathways 12 96 0.00194 0.033
Neurotransmitter uptake and Metabolism In Glial Cells Wikipathways 3 6 0.00196 0.033
Dopamine metabolism Wikipathways 6 31 0.00306 0.045
Effects of Nitric Oxide Wikipathways 3 7 0.0033 0.0476
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5.3.4 Quantification of FRs in HepG2/C3A cells after exposure 
To evaluate the cellular uptake of FRs following exposure, their concentrations were 
measured in treated cells and cell media after 24 hours and 72 hours (Table 5.5). The 
detection of these four FRs in cells and the decreased concentrations in cell media 
show that these FRs can be taken up into HepG2/C3A cells. Compared with the 
nominal concentrations, the concentrations of the three PFRs in cell media after 
exposure declined significantly for the Dust extract group and Mix 1 group but not for 
the Mix 2 group, in which they were even higher than the nominal concentrations 
before exposure. Considering that the concentrations of these three PFRs in the Mix 
2 group was 100 times higher than in the Mix 1 group, this suggests that the uptake 
rate of these three PFRs to HepG2/C3A cells did not increase proportionally. However, 
the uptake rate of HBCD did increase accordingly when the nominal concentration of 
HBCD increased, as the concentration of HBCD in cell pellets increased and in cell 
media decreased proportionally after exposure. This discrepancy may be explained 
by the hydrophilic feature of the three PFRs (with log Kow values of TCEP, TCIPP and 
TDCIPP equal to 1.47, 2.59 and 3.27) and the relatively high lipophilicity of HBCD 
(log Kow of 7.92). There was minimal change between the concentrations of the four 
FRs in cell pellets after a 24-hour exposure compared to a 72-hour exposure. 
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Table 5.5 Concentration of FRs in cell pellets and cell media in HepG2/C3A cells after 72 hours exposure.  
 
Concentration 
in cell pellets 
(ng/mg)
Concentration 
in cell media 
(ng/mL)
Concentration  
in cell pellets 
(ng/mg)
Concentration  
in cell media 
(ng/mL)
Concentration  
in cell pellets 
(ng/mg)
Concentration 
in cell media 
(ng/mL)
Concentration 
in cell pellets 
(ng/mg)
Concentration in 
cell media (ng/mL)
Control 10.73 ± 1.17 ND ND ND ND ND ND ND ND
Dust 11.67 ± 1.07 0.045 ± 0.006 0.312 ± 0.019 0.038 ± 0.005 0.247 ± 0.023 0.061 ± 0.001 0.633 ± 0.056 0.008 ± 0.001 0.042 ± 0.003
Mix1 15.70 ± 3.24 0.031 ± 0.006 0.320 ± 0.019 0.027 ± 0.003 0.252 ± 0.029 0.054 ± 0.012 0.762 ± 0.014 0.006 ± 0.001 0.039 ± 0.004
Mix2 14.33 ± 3.35 2.112 ± 0.685 45.717 ± 1.982 1.639 ± 0.375 41.233 ± 2.886 1.702 ± 0.644 138.943 ± 4.773 0.671 ± 0.163 3.987 ± 0.269
HBCD (4 μM) 17.23 ± 7.44 NA NA NA NA NA NA 160.59 ± 86.58 1071.48 ± 111.43
Control 13.33 ± 1.67 ND ND ND ND ND ND ND ND
Dust 13.67 ± 0.86 0.038 ± 0.004 0.302 ± 0.012 0.032 ± 0.002 0.240 ± 0.018 0.052 ± 0.003 0.642 ± 0.070 0.007 ± 0.000 0.043 ± 0.002
Mix1 11.87 ± 0.86 0.045 ± 0.003 0.307 ± 0.017 0.036 ± 0.000 0.236 ± 0.032 0.061 ± 0.006 0.628 ± 0.056 0.008 ± 0.001 0.036 ± 0.004
Mix2 13.37 ± 1.11 1.918 ± 0.203 48.355 ± 2.334 1.839 ± 0.204 42.597 ± 2.254 1.605 ± 0.213 145.417 ± 6.398 0.684 ± 0.044 4.154 ± 0.247
HBCD (4 μM) 13.23 ± 1.29 NA NA NA NA NA NA 185.98 ± 14.58 964.95 ± 27.30
ND: not detected; NA: not analyzed.
HBCD
24 hours
72 hours
TCEP TCIPP TDCIPPExposure 
time
Treatment 
groups
Wet weight 
of cell pellets 
(mg)
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5.4 Discussion 
To date, there is a paucity of studies about the effects of human exposure to 
mixture of flame retardants. This explorative investigation aimed to evaluate the 
cytotoxic effects and molecular responses of human hepatoma cells 
(HepG2/C3A) to mixture of FRs at concentrations relevant to environmental 
exposure. Since ingestion of dust is one of the primary routes of human 
exposure to FRs (Abdallah and Harrad, 2009), a solvent extract of an indoor 
dust reference SRM2585 was employed as a surrogate dust sample. SRM2585 
is an indoor dust reference material developed for determination of 
concentrations for organic contaminants including flame retardants, PCBs, PAHs 
and organochlorine pesticides in house dust (Wise et al., 2006). The certified 
or/and reference concentrations of PCBs and PAHs have been reported 
previously (Poster et al., 2007; Stapleton et al., 2006; Wise et al., 2006). In our 
study we quantified several FRs (TCEP, TCIPP, TDCIPP and HBCD) within the 
solvent extract of SRM2585 (Abdallah et al., 2015b). To mimic environmental 
reality, we studied the effects of the FRs at concentrations estimated on the 
basis of  average uptake of dust by toddlers (ca. 0.6 mg dust per million 
hepatocytes), which is comparable with a previous publication (Riechelmann et 
al., 2007).  
The concentration of HBCD detected in HepG2/C3A cell pellets in the Dust 
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extract group and Mix 1 group, after exposure, was ca. 0.006 - 0.008 ng/mg cell 
pellet (wet weight) (Table 5.5), which is equivalent to 300 - 400 ng/g lipid 
(assuming 2% of cells are lipids, similar to that reported for human liver (Rawn et 
al., 2014a)). This is approximately ten times higher than the average 
concentrations of HBCD reported in human fetal liver (median of 29 ng/g lipid) 
and placental tissue (median of 49 ng/g lipid), but ten times lower than the 
highest concentrations reported in these human tissues (4,500 ng/g lipid in liver; 
5,600 ng/g lipid in placenta; Rawn et al., 2014a). Although the potential to 
bioaccumulate organophosphate FRs such as TDCIPP and TCIPP was 
suggested to be low in rodents (due to rapid metabolism; European Union, 
2008a, 2008b), concentrations of TDCIPP have been reported up to 252 ng/g 
lipid in human adipose tissue (LeBel and Williams, 1986) and up to 162 ng/g 
lipids in human breast milk (Kim et al., 2014). In addition, the concentration of 
BDCIPP (which is the primary metabolite of TDCIPP) in human urine has been 
reported as high as 25 ng/mL (Meeker et al., 2013). In this study, the 
concentrations of TDCIPP in HepG2/C3A cell pellets in the Dust extract group 
and Mix 1 group were estimated at ca. 2600-3050 ng/g lipid (ca. 0.052 -0.061 
ng/mg cell pellets (Table 5.5)), which is approximately ten times higher than the 
levels in human adipose tissue. Taken together, these values suggest the 
exposure concentrations of FRs in the present study are relevant to those found 
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in humans. 
Cytotoxicity tests indicated that there was no significant change of cell viability or 
cell integrity after 24- and 72-hour exposures of HepG2/C3A cells to the 
environmentally-relevant mixture of FRs or dust extract. However, comparative 
analyses of transcriptomic and metabolic responses suggest that the mixture of 
the four FRs studied here, representing environmental exposure levels, were 
less toxic than the dust extract containing similar concentrations of FRs. For 
example, the up-regulated genes in the cells exposed to the dust extract were 
related to the metabolism of xenobiotics by cytochrome P450. As these were not 
induced by Mix 1 or Mix 2 of the FRs, other compounds from the dust extract 
must be responsible. The well known molecular responses to PAH (e.g. 
benzo[a]pyrene (B[a]P)) and PCB exposures occur primarily via aryl 
hydrocarbon receptor (AHR) binding and subsequently induction of transcription 
of mRNA encoding the drug-metabolizing cytochrome P450 enzymes such as 
CYP1A1 and CYP1A2 (Hennig et al., 2002; Jungnickel et al., 2014). In the 
present study, a series of xenobiotic responsive genes (e.g. CYP1A1, CYP1A2, 
CYP3A5, UGT1A6, ALDH3A1) were induced by 2μM DMBA that was used as a 
positive control. Combined, the up-regulation of xenobiotic metabolism related 
genes (e.g. CYP1A1, CYP1A2 and CYP2B6) in the dust extract group suggests 
induction by PAHs, PCBs or dioxin like compounds, not FRs. 
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Uncertainty factors are often employed in chemical risk assessment when there 
is lack of toxicity information of chemicals (Kalberlah et al., 2003). Conversely, 
Mix 2 was used to test the potential toxicity of the FR mixture at 100 times the 
concentrations estimated to be achievable from environmental exposure. 
However, even this relatively higher concentration of FRs did not induce any 
changes in gene expression. This lack of response was also supported by the 
metabolomics analyses which showed no significant changes at the metabolic 
level after HepG2/C3A cells were exposed to Mix 1 or Mix 2. 
Although there were no significantly changed molecular responses to the 
mixture of four FRs, multiple and univariate statistical analyses of the non-polar 
DIMS dataset showed statistically significant changes in the lipid profiles of 
HepG2/C3A cells exposed to 4 μM HBCD. A detailed interpretation of the 
dysregulation of metabolism at this relatively high concentration of HBCD (4 μM) 
would require robust identification of DIMS peaks in the lipidomics dataset which 
is not currently achievable. In Chapter 3, 4 μM HBCD did not induce any gene 
expression changes after a 24-hour exposure in HepG2/C3A cells. Here, after 
extended exposure to 72 hours, 81 probe sets were found to change significantly, 
including the up-regulation of several metallothionein genes (MT1A, MT1B, 
MT1E, MT1L, MT1H and MT1X). Metallothionein is a family of intracellular 
cysteine-rich proteins with metal-binding activity, while it has also been 
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associated with oxidative stress (Coyle et al., 2002). MTs can be induced not 
only by a variety of heavy metals but also by xenobiotics (Coyle et al., 2002). For 
example, 100 μM TDCIPP also induced the MT1L gene in HepG2/C3A cells 
inChapter 4. 
In a parallel study, the quantification of the potential metabolites of these four 
FRs in HepG2/C3A cells using LC-MS/MS method (Abdallah et al., 2015b) 
suggested that the FRs were metabolised. Several hydroxylated and 
debrominated metabolites of HBCD (i.e. di-hydroxylated and mono-hydroxylated 
HBCD, mono-hydroxylated pentabromocyclododecene (PBCD) and 
mono-hydroxylated tetrabromocyclododecadiene (TBCD)) were identified in 
HepG2/C3A cells after a 24-hour exposure, while glucuronic acid-conjugated 
HBCDs were also observed. Therefore, the metabolism of HBCDs in 
HpeG2/C3A cells was proposed as in Figure 5.6 based on the available 
identification of metabolites of HBCD. Similarly, hydroxylated, oxidised and 
glutathione-conjugated metabolites of chlorinated PFRs have also been 
detected in HepG2 cells or human liver microsomes (Abdallah et al., 2015b; Van 
den Eede et al., 2013). For example, as shown in Figure 5.7, oxidation and 
glutathione conjugation are proposed as metabolic pathways of TDCIPP in 
human hepatocytes according to the identification of several metabolites of 
TDCIPP after exposure. 
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Figure 5.6 Proposed metabolic profile of biotransformation of HBCDs by 
human HepG2/C3A cells (Adapted from Abdallah et al., 2015b). 
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Figure 5.7 Representation of metabolic profile of TDCIPP by human 
hepatocytes (Adapted from Abdallah et al., 2015b; Van den Eede et al., 2013).  
Although these metabolites of FRs detected in cells might contribute to the 
potential toxic effects of FRs in cells, the DIMS based untargeted metabolomics 
data showed few significantly changed peaks corresponding to such xenobiotic 
processes in the Dust extract group, Mix 1 and Mix 2 groups. In the 2 μM DMBA 
and 4 μM HBCD groups, untargeted metabolomics revealed dysregulation of 
metabolic pathways related to the metabolism of amino acids and derivatives (i.e. 
arginine and proline metabolism, glycine and serine metabolism) and glutathione 
conjugation which require further confirmation by a targeted approach (e.g. 
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LC-MS/MS). 
5.5 Conclusions 
In summary, toxicogenomic responses of human hepatoma cells exposed to a 
mixture of flame retardants were investigated at concentrations mimicking those 
maximally achievable following human exposure in real-life scenarios. Although 
there were no cytotoxic effects in HepG2/C3A cells following exposures to a dust 
extract and to mixture of FRs (at the same FR concentrations as detected in the 
dust), transcriptomics analysis revealed significant changes in gene expression 
associated with the metabolism of xenobiotics in the Dust extract group but not 
in the FRs mixture groups. Moreover, few significant changes were detected by 
untargeted metabolomics and lipidomics analyses following exposure to a dust 
extract and mixture of FRs, though a relatively high concentration of HBCD (4 
μM) was discovered to disrupt the lipid profile of HepG2/C3A cells. Given the 
dust extract contained compounds that elicited a molecular response, in contrast 
to the lack of effect induced by the FR mixtures (Mix 1 group), we can conclude 
that concern for the potential toxicity of dust should focus on compounds other 
than the four flame retardants studied here. 
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CHAPTER 6   Conclusions and 
Future work 
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The potential for human exposure to FRs has given rise to increasing health 
concerns, yet there is relatively limited knowledge about their possible adverse 
effects and the underlying molecular mechanisms that may mediate any impacts 
on health. Therefore, at the start of this research, the overall aim (Section 1.6) 
was to investigate the potential toxic effects of human exposure to FRs in in vitro 
systems using non-targeted (unbiased) transcriptomic and metabolomic 
approaches. To address such aim, the molecular responses of A549 and 
HepG2/C3A cells exposed to HBCD (Chapter 3) and TDCIPP (Chapter 4) were 
studied using microarray based transcriptomics and DIMS based metabolomics. 
HBCD represents one of the widely used BFRs, while TDCIPP is one of the 
commonly used PFRs. Then, in Chapter 5, the potential effects of a mixture of 
FRs at concentrations relevant to indoor environmental exposures were also 
assessed using transcriptomics and metabolomics.  
6.1 Molecular responses of A549 and HepG2/C3A cells exposed 
to HBCD 
The work of Chapter 3 represented the first use of unbiased transcriptomic and 
metabolomic approaches to investigate the potential molecular changes in 
human cell lines which could lead to toxicity of HBCD under concentrations 
relevant to human exposure conditions. A concentration-dependent cytotoxic 
effect of HBCD to A549 and HepG2/C3A cells was observed with EC50 values of 
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27.4 μM and 63.0 μM, respectively. Following a 24-hour exposure to HBCD at 
several sub-lethal concentrations (2, 20, 200 and 2000 nM), both 
microarray-based transcriptomics and DIMS-based untargeted metabolomics 
revealed few molecular changes occurred in A549 cells. Similarly, no significant 
transcriptional or metabolic changes in HepG2/C3A cells were detected after 
exposure for 24 hours. However, in Chapter 5, after an extended exposure time 
to 72 hours, 4 μM HBCD caused significant changes to the lipid profile and 
induced expression of some xenobiotic-related genes including several 
metallothionein genes (MT1A, MT1B, MT1E, MT1L, MT1H and MT1X) in 
HepG2/C3A cells. Quantification of the level of HBCD in the A549 and 
HepG2/C3A cells exposed to 2 or 4 μM HBCD respectively suggested that the 
HBCDs were present at several orders of magnitude higher concentration 
compared to those reported to occur in human tissues. Thus, it can be 
concluded that HBCD exhibits no detectable acute toxicity in A549 cells, 
representative of a major cell type of the lung, and HepG2/C3A cells, 
representing a cell type that shows some xenobiotic metabolic capacity, studied 
here at the concentrations known to be achievable following exposure in 
humans. Since the metabolomics analysis in Chapter 3 was focusing on the 
polar metabolome only, future work on lipidomic analysis (of the non polar 
metabolome) would be beneficial for a more comprehensive understanding of 
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the effects of HBCD exposure. The treatments with HBCD in this study used a 
technical mixture of HBCDs, which is composed of the three main diastereomers 
denoted as alpha (α-HBCD), beta (β-HBCD) and gamma (γ-HBCD). Thus, the 
effects of HBCD measured in the current study represent the overall effects of 
HBCDs rather than that of individual isomers. In the future study of toxicity of 
HBCD, the detailed specific effect of individual HBCD isomers need to be 
investigated to fully understand the potential mechanisms of toxicity of HBCD.  
6.2 Defensive and adverse energy-related molecular responses 
precede TDCIPP cytotoxicity  
In Chapter 4, as one of the widely used OPFRs, the effect of TDCIPP was 
investigated in human cell lines. Similar combined transcriptomic and 
metabolomic approaches were employed to investigate the molecular responses 
of two human cell lines (HepG2/C3A and A549) exposed to different 
concentrations of TDCIPP. Firstly, the concentration-dependent cytotoxicity of 
TDCIPP was determined by CCK-8 assays with EC50 values of 167.9 μM for 
HepG2/C3A cells and 193.1 μM for A549 cells after 24-hour exposures. Next, 
comparative analyses of transcriptional and metabolic profiles of the two cell 
lines were performed after exposure to 1, 10 and 100 μM TDCIPP for 24 and 72 
hours. Stress responses (e.g. xenobiotic metabolism and ABC transporter 
pathways) were observed at the transcriptional level following a 24-hour 
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exposure to a sub-cytotoxic concentration (10 μM). Transcription of an energy 
metabolism-related pathway (oxidative phosphorylation) was down-regulated 
more severely at 100 μM TDCIPP exposure, accompanied by the suppression of 
pathways relevant to cell proliferation (e.g. cell cycle, DNA replication), while no 
significant cytotoxic effects were observed.  
Metabolomics analysis revealed that several metabolic pathways related to ABC 
transporters, metabolism of amino acids and derivatives (i.e. arginine and 
proline metabolism, cysteine and methionine metabolism, glycine and serine 
metabolism) and glutathione conjugation were dysregulated in both HepG2/C3A 
and A549 cells exposed to 100 μM TDCIPP for 24 hours. Similar functional 
metabolic changes (but to a greater extent) were also observed after 72 hours in 
HepG2/C3A cells exposed to 100 μM TDCIPP that corresponded to changes 
detected at the transcriptional level after 24 hours. Taken together, defensive 
responses to TDCIPP exposure and energy-related changes both precede the 
cytotoxic effects of TDCIPP in HepG2/C3A cells. 
Since only polar metabolic profiles of the two cell lines were analysed using 
DIMS-based metabolomics, the understanding of the molecular responses to 
TDCIPP in this study just reflect part of the whole metabolic system. In addition, 
annotation of DIMS data remains a considerable challenge in metabolomics, and 
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consequently only a fraction of the significantly changing DIMS peaks have been 
assigned putative metabolite names. Therefore, future analyses of the non-polar 
part of the intracellular metabolome as well as a more advanced MS peak 
annotation platform might contribute novel insights into the lipidomic changes, 
providing a more comprehensive metabolic profile. Quantification of TDCIPP in 
the treatments can also provide a clue about the bioaccessibility of such 
chemical. A further need is to gain more information on the likely cellular 
concentrations of TDCIPP that can be achieved through human exposure, which 
will enable a more accurate risk assessment. 
6.3 Mixture of FRs at environmental level are less toxic than 
indoor dust extract  
While most studies (including those shown in Chapters 3 and 4 in this thesis) 
have attempted to investigate the potential adverse effects of individual FRs, the 
real-life scenario of human exposure to FRs comprises the exposure to mixtures 
of FR chemicals from multiple resources. Chapter 5 was aimed at exploring the 
potential effects of human exposure to a mixture of FRs from indoor dust. A 
solvent extract of an indoor dust standard reference material SRM2585 was 
employed as a surrogate dust sample, while an artificial mixture of four FRs 
(TCEP, TCIPP, TDCIPP and HBCD) was used to mimic the FR mixture in the 
dust. HepG2/C3A cells were exposed to such a mixture for 24 or 72 hours. The 
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quantification of four individual FRs after exposure suggested that the exposure 
concentrations of FRs in the present study are relevant to FR levels in humans. 
Cytotoxicity screening tests (CCK-8 assays and AK assays) indicated there were 
no significant changes of cell viability or cell integrity after 24 or 72 hours 
exposure of HepG2/C3A cells to the mixtures of FRs or dust extract. Microarray 
analysis revealed changes in gene expression associated with the metabolism 
of xenobiotics (e.g. CYP1A1, CYP1A2, CYP2B6) in the dust extract group but 
not in the FR mixture groups after 72 hours exposure. Few metabolic or lipidomic 
changes were detected in the mixture of the FRs group and the dust extract 
group. Given the dust extract contained components that elicited a biological 
response in contrast to the negative effect of the mixture of FRs group (Mix 1 
group), it appears that the greatest concern around potential toxicity from dust 
exposure lies in components other than the FRs contained within, e.g. PAH, 
PCBs. Although combined omics approaches revealed the different molecular 
responses to a mixture of FRs or dust extract in HepG2/C3A cells which classic 
toxicological tests did not, further validation experiments (e.g. qPCR or targeted 
tandem MS analysis of significantly changed features) might be helpful to 
confirm such subtle changes at transcriptional and metabolic levels.  
6.4 Future work 
The work presented in this thesis contributes valuable knowledge to understand 
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the potential effects of human exposure to FRs. However, there are still gaps in 
knowledge which should be investigated in future work so as to overcome the 
current issues to achieve a more comprehensive understanding of FRs toxicity.  
First, while A549 and HepG2/C3A cells used in this study have also been widely 
employed in various toxicological studies, they are not expected to fully 
recapitulate whole organism physiology. Therefore, to investigate other aspects 
of FRs toxicity (e.g. endocrine mediated effects or neurotoxicity), other types of 
cells (e.g. human adrenocarcinoma cells such as H295R cells, MCF-7 cells and 
human neuronal cell line such as SH-SY5Y cells ) could be used for assessing 
site specific FR toxicity. Furthermore, using primary cultured cells or in vivo 
models for the studies of FRs toxicity can also be valuable to illustrate the 
mechanisms of potential effects of exposure to FRs and the risk assessment of 
such FRs. 
Second, the untargeted DIMS-based metabolomics approach employed in this 
study suffers from the technological limitation of limited annotation of the MS 
peaks. Combining new computational tools and the application of hyphenated 
techniques such as LC-MS or tandem MS in metabolomics could generate more 
reliable metabolite annotation or identification though the capabilities of these 
techniques still need to be improved to increase their sensitivity and sample 
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high-throughput. Targeted metabolomics using LC-MS/MS could be beneficial to 
obtain more accurate identification of the MS peaks as well as high sensitivity. 
Yet such approaches do not allow unbiased analyses of the metabolic response. 
Moreover, the explorative study of the effects of a FR mixture, described in 
Chapter 5, was focusing on a simple mixture of four FRs. To fully understand the 
potential effects of exposure to mixtures of FRs, further evaluation of more FRs 
or other groups of chemicals are necessary due to the complexity and variability 
of multiple chemicals which humans are exposed to in real life scenarios. 
 
In conclusion, the work presented in this thesis has assessed the molecular 
responses of human cell lines to several FRs using high-throughput omics 
approaches. Unbiased analyses of gene expression and metabolic profiles 
provide more insights of human exposure to FRs investigated in this project, 
which would be beneficial for both understanding the potential mechanisms of 
effects of FRs investigated here and future risk assessment. 
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